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1  Introduction 
1.1  Lysophosphatidic acid (LPA) 
Lysophosphatidic acid (LPA) is a lipid mediator which is found in different biological samples 
such as serum and plasma [1]. The structure of LPA consists of a glycerol backbone, a fatty acid 
chain and a phosphate group. Depending on variability in the fatty acid chain length, the 
saturation, and the type of linkage to the glycerol backbone, it has various biological functions [1, 
2]. LPA is produced following platelet activation and exerts many functions such as SMC 
contraction, platelet aggregation, wound healing, induces changes in blood pressure, Ca2+ 
mobilisation, chemotaxis, neurite regeneration and differentiation [1].  
Two pathways have been described for LPA synthesis [1]. In the first pathway, 
lysophospholipids (LPL) such as lysophosphatidylcholine (LPC), lysophosphatidylethanolamine 
(LPE) and lysophosphatidylserine (LPS) are produced via the enzymes secretory-type 
phospholipase (PL)-A2 and phosphatidylserine (PS)-specific PLA1 (Fig. 1) [1]. LPC can also be 
produced in the plasma from lipoprotein-derived phosphatidylcholine by the action of the enzymes 
lecithin-cholesterol acyltransferase (LCAT) and PLA1-like enzymes (Fig. 1) [1]. The LPLs which 
are produced by these various mechanisms are then converted to LPA by the lysophospholipase D 
(PLD) activity of the enzyme autotaxin (ATX) (Fig. 1). High levels of ATX are present in the 
blood [1]. The depletion of ATX in serum or plasma leads to the complete absence of LPA. ATX 
is considered to be the major LPA producing enzyme in the blood [1].  
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Figure 1: LPA synthesis by ATX  
LPL such as LPC, LPE and LPS are produced from activated platelets and from lipoproteins by the 
action of various enzymes. These LPLs are then converted to LPA via the enzyme ATX [1]. 
 
In the second pathway of LPA synthesis, phosphatidic acid (PA) is produced from 
phospholipids or diacylglycerol (DAG) by the action of the enzymes PLD or diacylglycerol kinase 
(DGK) (Fig. 2). PA is further converted to LPA by PLA1- or PLA2-type enzymes (Fig. 2) [1]. 
Since the occurrence of PA can be found in the cell membrane, this reaction mostly occurs in the 
cell or in the plasma membrane. 
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Figure 2: LPA synthesis from PA 
PA is produced from phospholipids and DAG by the enzymes PLD and DGK. Then, PA is 
converted to LPA by the action of PLA1 and PLA2 [1]. 
 
LPA elicits its functions via seven G-protein coupled receptors namely LPA1/EDG2, 
LPA2/EDG4, LPA3/EDG7, LPA4/GPR23/P2Y9, LPA5/GPR92, GPR87, and P2Y5/P2RY5 [1, 3, 
4]. In addition, LPA also activates the nuclear receptor, peroxisome proliferator activated receptor 
(PPAR)-[5, 6].Out of these receptors, LPA receptor 1 (LPA1), LPA2, and LPA3 belong to the 
endothelial differentiation gene (EDG) family [7] and show 50% similarity at the amino acid level 
[1]. LPA1, LPA2, and LPA3 play a role in physiological and pathological conditions as revealed by 
genetically null mice [1, 4, 8]. LPA4, LPA5, GPR87, and P2Y5 belong to the group of purinergic 
receptors and are approximately 35% homologous at amino acid level [1]. The pathological 
importance of these receptors are unknown [1]. Another orphan receptor named P2Y10 has also 
been identified that can be activated by LPA [9].  
The first receptor identified for LPA was LPA1 [8]. In adult mice LPA1 is expressed in the 
brain, heart, lung, stomach, small intestine, spleen, thymus, testis and skeletal muscle [8]. 
Activation of LPA1 leads to cell proliferation, MAP kinase activation, activation of serum response 
element (SRE), AKT activation, adenylyl cyclase (AC) inhibition, protein kinase (PK) C 
activation, and Rho activation through three types of G proteins namely Gi/o, Gq, G12/13 [8]. LPA2 
expression in mice can be seen in the embryonic brain, testis, kidney, lung, thymus, spleen, and 
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stomach [8]. Similar to LPA1, the signalling events induced by LPA2 also occur via the three G 
proteins, Gi/o, Gq, and G12/13. LPA3 expression is present in the testis, kidney, lung, small intestine, 
heart, thymus, brain, oviduct, placenta, and uterus in adult mice [8]. Following activation of LPA3 
the downstream signalling events occur only via two G proteins, Gi/o and Gq [8]. 
LPA has been demonstrated to be involved in many biological processes associated with 
atherosclerosis. LPA is generated during mild oxidation of LDL [10]. It is the active component of 
mildly oxidised LDL (moxLDL) which induces platelet activation, endothelial stress fibre 
formation and endothelial gap junction formation [10]. LPA accumulation in human carotid 
atherosclerotic lesions has been identified, with the highest amounts present in the lipid rich core 
of the plaque [10, 11]. LPA has also been shown to be the major platelet activating lipid in the 
plaque [10]. In vitro, LPA stimulates endothelial-monocyte adhesion by increasing the endothelial 
expression of adhesion molecules and chemokines such as inter-cellular adhesion molecule-1 
(ICAM-1), IL-1, IL-8, MCP-1, E-selectin, and vascular cell adhesion molecule-1 (VCAM-1) [12, 
13]. In addition, increased levels of serum LPA has been detected in hypercholesterolemic rabbits 
due to increased ATX activity [14]. Although there are many studies which show that LPA is 
involved in atherosclerosis, there is no direct evidence for this association. 
Short term intraluminal incubation of uninjured carotid arteries with unsaturated LPAs but not 
saturated LPAs induces the formation of neointimal hyperplasia containing mostly SMCs [5]. Out 
of these unsaturated LPAs, LPA20:4 (1-arachidonoyl-2-lyso-sn-glycero-3-phosphate) and the LPA 
analogue, 1-AGP18:1 (1-oleyl-2-lyso-sn-glycero-3-phosphate) were the most efficient in inducing 
neointima formation in rats [5].  
LPA has been shown to up-regulate the chemokine CXCL12 in human adipose tissue derived 
mesenchymal stem cells which can be inhibited by blocking LPA1 and LPA3 using the antagonist 
Ki16425 [15]. Although LPA induces in vitro the proliferation of rat VSMC [16], the exact 
mechanism by which LPA induces neointima formation is unknown. 
 
1.2  Chemokines  
Chemokines are a family of heparin binding proteins that direct leukocyte migration [17-19]. 
They can be presented on the cell surface by binding to glycosaminoglycans (GAGs), hence 
producing an immobilised chemokine gradient under flow conditions [20]. Approximately 50 
human chemokines and 20 chemokine receptors have been discovered (Table.1) [18, 19, 21]. 
Most of the chemokines have four cysteine residues and based on the amino acid sequence 
which is present between the first two cysteine residues they are further classified into chemokine 
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subfamilies [17, 18, 22]. Chemokines with one amino acid present in between the first two 
cysteine residues are known as CXC or -chemokines [17, 19, 22]. These CXC chemokines can be 
further divided into ELR+ and ELR- chemokines [17]. The ELR+ chemokines, such as CXCL1, 
have a glutamate-leucine-arginine (ELR) residue preceding the first cysteine residue of the CXC 
motif. The ELR+ chemokines are chemotactic for neutrophils and have angiogenic properties, 
whereas the ELR- chemokines are chemotactic for lymphocytes and are mostly angiostatic in 
nature except for CXCL12 [18, 23]. Inflammatory mediators such as interleukin-1, tumour 
necrosis factor (TNF)- or bacterial antigens such as lipopolysaccharide induce the synthesis of 
ELR+ chemokines [17].  
If the first two cysteines are adjacent to each other, chemokines are classified as CC- or -
chemokines (examples- CCL1, CCL2, CCL3, and CCL4) which are the largest family of 
chemokines. The third subfamily includes only one member (CX3CL1) and is characterised by 
three amino acid molecules in between the first two cysteine residues (CX3C or the -chemokine) 
[19]. The fourth chemokine subtype, called C or -chemokines (examples- XCL1, XCL2), contain 
only two of the four cysteine residues [17, 19, 22].  
Initially, chemokines were broadly classified based on their function as homeostatic and 
inflammatory chemokines [19, 22]. The homeostatic chemokines are continuously produced and 
secreted and they have many functions, such as immune surveillance and localisation of 
lymphocytes with the antigens in the lymphatic system [19, 22]. The inflammatory chemokines are 
induced only during infection or by non-infectious pro-inflammatory stimuli. Here, they guide the 
migration of leukocytes to the area of infection and inflammation. Later it became clear that some 
chemokines cannot be designated to either of these functional groups and are therefore referred to 
as dual function chemokines [24].  
Chemokines act via G protein-coupled chemokine receptors [17, 19, 23, 25], which are named 
according to their chemokine ligands (e.g., chemokine receptors that bind to CXC chemokines are 
called CXC receptors) (Table.1) [18]. Notably, many chemokines can bind the same chemokine 
receptor and a single chemokine can bind multiple receptors [23].  
Upon binding to the receptor, the N-terminal domain of the chemokine is of crucial importance 
for receptor activation [18, 22, 26]. Following activation of the chemokine receptor, the guanosine 
diphosphate (GDP) bound to the  subunit of the G proteins is replaced by guanosine triphosphate 
(GTP). Then the G proteins disassociate from the receptor and activate downstream molecules 
resulting in a cascade of signalling events which can lead for example to actin re-arrangement, 
shape change and cell movement [27]. 
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Table 1: Chemokines and chemokine receptors [18] 
 
1.3  Atherosclerosis 
Cardiovascular diseases are the main cause of mortality worldwide [28, 29]. One of the most 
common type of cardiovascular disease is coronary artery disease (CAD) which is mainly caused 
by atherosclerosis [28, 30]. Atherosclerosis is a chronic inflammatory disease of large- and 
medium-sized vessels which forms lesions in the vessel wall [28, 31-34]. These lesions are known 
as atherosclerotic plaques. Over time these plaques gradually increase in size and may cause 
complications such as a reduction in the lumen size making the vessel stenotic [31, 35, 36]. This 
stenosis may impair blood flow and thus limit the oxygen supply to tissues like the myocardium. 
Moreover, plaque rupture may occur resulting in acute obliteration of the vascular lumen due to 
thrombus formation when pro-thrombotic components of the plaque come into contact with the 
blood [34-37]. This acute vascular occlusion may cause ischemia and tissue necrosis with 
devastating clinical consequences, such as myocardial infarction or stroke [32, 34-37].  
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The development of atherosclerosis is initiated by pro-atherogenic factors such as diabetes or 
smoking leading to the activation and dysfunction of endothelial cells [32, 35, 37-39]. This results 
in increased adhesion of circulating leukocytes to the endothelium and increases the permeability 
of the vessel wall for plasma components, such as low density lipoprotein (LDL) [35, 37-39].  
Although LDL is protected from oxidation in the plasma, it is susceptible to enzymatic and non-
enzymatic modifications while present within the vessel wall [28, 40, 41]. Within the intima, the 
LDL particles are oxidised by myeloperoxidase and lipoxygenases or by reactive oxygen species 
such as HOCL, phenoxyl radical intermediates, or peroxynitrite which are generated in the intima 
during inflammation [28, 42]. The modified LDL particles further activate the endothelial cells to 
express various adhesion molecules resulting in the adhesion and transmigration of circulating 
monocytes to the sub-endothelial space [32, 34, 35] (Fig. 3). Following transmigration, these 
monocytes differentiate into macrophages which engulf excess of modified LDL particles and 
become foam cells, characteristic for fatty streaks (Fig. 3). This is due to the unrestricted uptake of 
modified LDL by macrophages via the scavenger receptors because these receptors do not have a 
negative feedback regulation system like the LDL receptor. Although many scavenger receptors 
are involved in this process, the scavenger receptor A (SR-A) and CD36 have been shown to play 
a significant role [34]. The formation of fatty streaks is the first stage in the development of 
atherosclerosis [32, 34-36].  
 
 
Figure 3: Initiation of atherosclerosis 
Activated endothelial cells express various cell surface adhesion molecules leading to monocyte 
recruitment. The monocytes differentiate into macrophages and take up modified LDL particles to 
become foam cells [34]. 
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The progression of fatty streaks to atherosclerotic plaque is caused by secretion of cytokines 
and growth factors by the plaque cells and involves the further accumulation of other inflammatory 
cell types, smooth muscle cells (SMC), and the deposition of extracellular matrix proteins [34, 37, 
38] (Fig. 4).  
 
 
Figure 4: Atherosclerotic lesion progression 
Further accumulation of immune cells, secretion of growth factors and formation of fibrous cap 
leads to plaque progression [34]. 
 
Necrosis of the lipid-laden foam cells results in the accumulation of extracellular cholesterol 
and the formation of a necrotic core which is surrounded by a fibrous cap (Fig. 5). Matrix 
degrading proteases released from the cells within the plaque can cause thinning of the fibrous cap 
and promote plaque rupture [32, 34-36] (Fig. 5). This releases the plaque lipids and tissue factor 
into the blood causing thrombus formation (Fig. 5) [32, 34-36]. 
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Figure 5: Plaque rupture and thrombosis 
Proteases and cytokines produced from the plaque cells degrade the fibrous cap resulting in plaque 
rupture and thrombus formation [34]. 
 
1.3.1 Leukocyte adhesion cascade 
The leukocyte adhesion cascade includes the following steps: tethering, rolling, slow 
rolling, arrest, adhesion strengthening, intravascular crawling, and paracellular or transcellular 
transmigration [43]. Leukocyte rolling and tethering is mediated by a family of three-carbohydrate 
recognising molecules named selectins [43-45]. P-selectin and E-selectin are expressed by 
inflamed ECs whereas L-selectin is expressed by leukocytes. P-selectin is also expressed by 
platelets [43, 45]. The ligands for selectins are highly glycosylated-glycoproteins, such as P-
selectin glycoprotein ligand 1 (PSGL1), which is the primary ligand for all three selectins [43, 46]. 
PSGL1 is expressed on almost all leukocyte-subtypes. Binding of PSGL1 to L-selectin mediates 
leukocyte-leukocyte interactions which lead to secondary leukocyte tethering [43]. L-selectin and 
P-selectin require shear stress to support adhesion of leukocytes which is due to the catch bond 
character of selectins [47-49]. Binding of selectin to its ligand activates signalling pathways in the 
selectin-expressing and ligand-expressing cells [43].  
Integrins are heterodimeric cell surface cell surface receptors that participate in inducing 
leukocyte rolling and firm adhesion [43, 44, 46]. Rolling by lymphocytes is due to interactions 
between very late antigen 4 (VLA4; also called 41-integrin) present on lymphocytes and its 
ligand VCAM1 present on ECs. VLA4-induced rolling is mostly seen in monocytes and T-cells 
[43, 46]. The leukocyte functional antigen 1 (LFA1; also calledL2-integrin) is a 2 integrin that 
supports rolling by binding to its ligand ICAM1 [43].  
Endothelial-leukocyte arrest is triggered by chemokines and is mediated by the binding of 
leukocyte-specific integrins to their endothelial ligands [43, 46]. The ligand binding capacity of the 
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integrins, also known as avidity, mainly depends on the integrin affinity and valency. Integrin 
affinity is increased by inducing a conformational change in each of the integrin heterodimers 
which increases ligand-binding energy and reduces the rate of ligand-dissociation [43]. Integrin 
valency corresponds to the density of integrin heterodimers per area of the plasma membrane and 
is dependent on the mobility and the expression level of the integrin on the cell-surface [43]. 
 During inflammation, inflammatory cytokines induce the expression of chemokines in ECs [43, 
45]. Chemokines are immobilised on the endothelial surface through GAGs [43, 45], which 
facilitates the chemokine binding to their GPCR expressed on leukocytes under flow conditions 
and activates integrin-mediated adhesion [43, 45]. Chemokines can rapidly regulate the avidity of 
integrins by increasing both the affinity and valency, also known as inside-out signalling [45, 50, 
51]. In contrast, outside-in signalling occurs following binding of the activated integrins to its 
ligand and regulates many cellular functions such as proliferation, apoptosis and motility [52, 53].  
Following firm adhesion, leukocytes transmigrate through the vascular endothelium via either a 
transcellular or paracellular route [45]. Leukocytes crawl on the endothelial surface in a MAC1- 
and ICAM1-dependent manner promotes transmigration, indicating that leukocyte crawling assists 
in the identification of a suitable site for transmigration [43]. In paracellular transmigration, 
interaction between the endothelial cell-specific adhesion molecules and the leukocytes can reduce 
the inter-endothelial contacts and induce leukocyte migration through the endothelial-cell junctions 
[43]. An increased intracellular level of calcium results in contraction of ECs via activation of the 
myosin light chain kinase and opens up the endothelial-cell contacts [43]. Some endothelial 
junctional molecules such as platelet/EC adhesion molecule 1 (PECAM1), junctional adhesion 
molecule A (JAM-A), JAM-B, JAM-C ICAM1, ICAM2, and EC-selective adhesion molecule 
(ESAM) mediate leukocyte trans-endothelial migration [43]. 
The rather infrequent transcellular leukocyte migration occurs at thin regions of the 
endothelium and has been described in the central nervous system and at various sites of 
inflammation [54]. Leukocyte binding to ICAM1 translocates ICAM1 to actin- and caveolae-dense 
regions of the plasma membrane, which results in the formation of channels within the ECs 
through which leukocytes can migrate [43]. 
 
1.3.2 Keratinocyte-derived chemokine (KC)/CXCL1 
CXCL1/KC is a 73 amino acid peptide that was initially isolated and characterised from 
malignant melanoma cells for its growth stimulatory activity [55, 56]. CXCL1 is a CXC 
chemokine containing the N-terminal ELR motif [18]. It has a human ortholog known as GRO 
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(growth-regulated oncogene)-CXCL1 functions via its receptor, CXCR2 [57]. CXCL1 
induces the chemotaxis of neutrophils and T lymphocytes [58, 59]. 
Arterial CXCL1 is important for macrophage accumulation during atherosclerosis via its 
receptor CXCR2 present on leukocytes [60]. Only CXCL1 but not the other CXCR2 ligand, 
macrophage inflammatory protein-2 (MIP-2) has been shown to induce monocyte arrest on 
isolated carotid arteries of atherosclerotic Apolipoprotein (Apo)E-/- mice [61]. In addition, mice 
with CXCR2-/- BM cells developed significantly less plaque with reduced macrophage 
accumulation indicating the importance of this receptor in macrophage localisation during 
atherosclerosis. The loss of CXCR2 does not affect the fatty streak formation but inhibits the 
development of plaque at later stages of atherosclerosis [60]. Moreover, it has been shown in vitro 
that minimally modified (MM) LDL induces the binding of monocytes to endothelial cells by up-
regulating the chemokine CXCL1 on the endothelial surface [62]. In an activated endothelium, 
CXCL1 is immobilised on the cell surface by binding to heparin sulphate proteoglycans and 
induces rolling and firm arrest of monocytes to the endothelium via CXCR2 [63]. In contrast, 
CCL2/monocyte chemotactic protein (MCP)-1 is secreted following endothelial activation [63]. 
CCL2 via its receptor CCR2 induces monocyte shape change and transmigration when present as a 
gradient across the endothelial monolayer [63, 64]. 
 
1.4  Restenosis 
Percutaneous interventions (PI) such as balloon angioplasty and stent implantation are most 
commonly used techniques to treat CAD [65-67]. Initially when bare metal stents were used, 
subacute thrombotic coronary artery occlusion (STCAO) occurred in 18% of the patients within 2 
weeks of stent implantation [68]. To reduce the occurrence of STCAO following stent 
implantation, anti-coagulation therapy was used [68]. But this lead to increased bleeding and 
lengthened hospitalization time of the patients [68]. Following studies showed that stenting was 
safe when anti-platelet therapy was used instead of anti-coagulant therapy [69-71]. The use of 
stents became widely accepted following these studies. But another problem that was encountered 
following stent implantation was the development of in-stent neointimal hyperplasia. The 
mechanical injury to the vessel wall by PI induces the formation of neointimal thickening which is 
clinically known as restenosis [65, 72, 73] (Fig. 6). The neointimal tissue primarily consists of 
SMCs and leukocytes [74, 75]. Following implantation of bare metal stents, a restenosis rate of 10-
30% was observed [65, 68]. The development of drug eluting stents reduced the risk for restenosis 
after PI [66, 76, 77]. These stents slowly release a drug, such as sirolimus or paclitaxel, which 
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inhibits cell proliferation and migration. In 2003, the approval for the use of drug eluting stents 
(Cordis’s sirolimus-eluting cypher stent) was given by the Food and Drug Administration (FDA) 
and by the end of 2004, these stents were used in almost 80% of the PI in the United States [78].  
Drug eluting stents have reduced the need for revascularisation of the target vessel following 
stent implantation substantially [66, 76, 77], however, a significant constrain is the requirement of 
long term treatment with drugs that inhibit platelet aggregation to avoid late stent thrombosis [79]. 
Drug eluting stents cause impaired endothelial recovery due to non-specific anti-migratory and 
anti-proliferative activities of the drugs such as rapamycin and paclitaxel. This is a major risk 
factor for late stent thrombosis [80-82]. Therefore, development of drugs that specifically inhibit 
the neointimal SMC accumulation without affecting the re-endothelialisation would be desirable.  
 
 
Figure 6: Restenosis 
PI such as stent implantation injures the vessel wall leading to neointima formation also known as 
restenosis [83]. 
 
1.4.1 Stromal cell derived factor (SDF)-1/CXCL12 
SDF-1/CXCL12 also known as pre B-cell stimulatory factor belongs to the non-ELR CXC 
family of chemokines and was initially cloned from supernatant of BM-derived stromal cells [84-
86]. CXCL12 is an exception in the CXC chemokine family because even though it is an ELR 
negative chemokine, it still has angiogenic activity [18]. CXCL12 induces the chemotaxis of 
CD34+ cells, pre B-cells and hematopoietic progenitor cells [85, 87]. It was thought that CXCL12 
induces its biological functions exclusively by binding to CXCR4. until the orphan receptor RDC1, 
designated now as CXCR7, has been characterised as an alternative CXCL12 receptor [88]. 
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In mice, two CXCL12 isoforms, CXCL12 and CXCL12exist which are splicing variants 
encoded by the same gene [89, 90]. Both have identical amino acid sequences except for the four 
additional amino acids at the carboxy terminal of CXCL12[86, 90]The importance of the 
existence of two variants is unknown [90]. Four additional human CXCL12 isoforms have also 
been identified, namely CXCL12, CXCL12, CXCL12 and CXCL12 but their physiological 
and pathological relevance is unknown [91]. CXCL12 is chemotactic for hematopoietic 
progenitor cells [85]. CXCL12 is highly conserved between different species, for example, the 
human and murine CXCL12 differ only in one amino acid [85]. Hereafter, CXCL12 will refer to 
CXCL12.  
The gene encoding CXCL12 is located in chromosome 10 whereas all the other human  and  
chemokines are encoded in chromosomes 4 and 17, respectively [92]. All other chemokines are 
usually expressed during inflammation, whereas CXCL12mRNA is constitutively present in 
different organs [86]. The knock down of CXCR4 or CXCL12 genes in mice causes embryonic 
death due to deficiency in B-lymphopoiesis, myelopoiesis, vasculogenesis, and defective heart 
development [93, 94]. The retention of hematopoietic stem cells in the bone marrow (BM) requires 
high concentration of CXCL12in the BM compared to the circulation [95]. Overexpression of 
CXCL12 in the circulation by an adenoviral vector resulted in the mobilisation of hematopoietic 
progenitor cells to the peripheral circulation [95]. CXCR4 antagonists such as plerixafor are used 
as drugs to mobilise stem cells from the BM to the circulation, so that these stem cells can be 
collected for transplantation to patients suffering from non-Hodgkin’s lymphoma or multiple 
myeloma [96]. 
 
1.4.2 CXCL12-induced stem cell mediated vascular repair 
The CXCL12/CXCR4 axis plays a crucial role in neointima formation following vascular injury 
in mice by inducing the stem cell-mediated vascular repair [97, 98]. Immediately after vascular 
injury, approximately 70% of the medial SMCs are apoptotic [99]. The repair of the vessel wall by 
resident SMCs is not adequate resulting in the recruitment of smooth muscle progenitor cells 
(SPCs) from the BM [99]. High concentration of CXCL12 in the circulation mobilises progenitor 
cells from the BM to the circulation. Therefore it is assumed that progenitor cells are retained 
within the BM due to the high CXCL12 concentration in the BM compared to the circulation [95]. 
As early as 1 day following wire-induced vascular injury in mice, CXCL12 protein is up-regulated 
in the vascular smooth muscle cells (VSMC) and in the circulation [98]. It is assumed that there is 
a change in the CXCL12 concentration gradient between the circulation and the BM, which 
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triggers the mobilisation of the SPCs (these SPCs express the stem cell antigen-1 (Sca-1), PDGFR-
 and CXCR4 but not hematopoietic lineage markers) to the circulation (Fig. 7). Blocking the 
CXCL12 receptor, CXCR4 following injury inhibited the mobilisation of SPCs and neointima 
formation [100]. This indicates that, the SPCs which are mobilised following injury are further 
recruited to the site of injury via CXCR4 resulting in the formation of neointimal hyperplasia (Fig. 
7). But the molecule produced following injury which induces this stem cell-mediated vascular 
repair is unknown. Following vascular injury, a majority of the medial SMCs are apoptotic [97]. 
When cultured SMCs were exposed to apoptotic bodies generated from injured SMCs, it induced 
the expression of CXCL12Following injury, apoptosis could be the signal which induces the 
expression of CXCL12in the vessel wall. 
 
   
 
 
Figure 7: Model of CXCL12 mediated vascular repair 
Following vascular injury, the concentration of CXCL12 is upregulated in the circulation 
disrupting the CXCL12 gradient between the BM and the circulation. This induces the 
mobilisation of SPCs to the circulation which are then recruited to the site of injury resulting in 
neointima formation. (Modified according to Schober 2008) 
 
Hypoxia inducible factor (HIF)-1is a transcription factor which regulates oxygen and energy 
haemostasis [101]. It is a multi-subunit protein which is made of two basic helix loop helix 
proteins namely, HIF-1 and HIF-1or aryl hydrocarbon receptor nuclear translocator (ARNT) 
[102]. HIF-1 is a constitutively produced transcription factor. Under normoxia, HIF-1 is unstable 
and is targeted to proteosomal degradation, whereas HIF-1 is stably expressed in the nucleus 
irrespective of the oxygen level [103]. 
 Under normoxia, the HIF-1 subunit is hydroxylated in the proline and asparaginyl residues by 
the enzymes proline hydroxylase and factor inhibiting HIF-1 (FIH), respectively (Fig. 8A). 
Following hydroxylation, the von Hippel-Lindau tumour suppressor protein (vHL) binds to HIF-
1and ubiquitinylates it, thereby targeting HIF-1 for proteosomal degradation (Fig. 8A) [102]. 
MOBILISATION 
disrupted CXCL12 gradient 
macrophage 
CXCL12 
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Under hypoxia, the oxygen dependent hydroxylation of HIF-1 is downregulated; hence HIF-1 is 
protected from poly-ubiquitinylation and degradation by the proteosomal complex (Fig. 8B). Then, 
HIF-1 is transferred to the nucleus where it binds to HIF-1andthe transcriptional co-activator 
proteins such as p300/CBP and regulates gene transcription at the HIF response elements (HRE) 
of the target gene (Fig. 8B). 
HIF-1 plays an important role in neointima formation following vascular injury [104]. In 
mice, transcriptional upregulation of HIF-1 is evident following carotid injury. This in turn 
induces the expression of CXCL12 in the neointimal tissue [104]. CXCL12 has been shown to 
induce neointima formation following vascular injury by the recruitment of BM-derived SPCs [97, 
98]. Following carotid injury, HIF-1 regulates the stem cell based repair of arteries by 
upregulating CXCL12 expression. But the upstream molecule produced following vascular injury 
which activates this HIF-1-dependent stem cell repair mechanism remains to be determined. 
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Figure 8: Regulation of HIF-1 subunit under hypoxia and normoxia 
a) Under normoxia, HIF-1 protein is hydroxylated by proline hydroxylase at the proline residues 
and by FIH at the asparaginyl residues. FIH also inhibits the interaction of HIF-1 with P300/CBP 
transcriptional co-activator proteins. Then, HIF-1 is bound and ubiquitinylated by vHL, and 
finally degraded by the proteosomal complex. b) Oxygen, the co-factor for proline hydroxylase is 
absent during hypoxia. HIF-1 is protected from hydroxylation and degradation by the 
proteosomal complex under hypoxia. So, it binds to HIF-1 and regulates gene expression at the 
HRE sites of the target gene [102]. 
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1.5   Aim of the study 
The CXCL12/CXCR4 axis has been shown to play an important role in neointima formation 
following vascular injury by inducing the mobilisation and recruitment of SPCs from the BM [97-
99]. Unsaturated LPAs which can upregulate CXCL12 in vitro, can induce neointimal hyperplasia 
containing mainly SMCs even in the absence of injury [15, 105]. Following vascular injury, HIF-
1is upregulated and regulates the neointimal expression of CXCL12 [104]. MmLDL induces 
monocyte adhesion to the endothelium by upregulating the endothelial expression of CXCL1 [62]. 
Furthermore, LPA which can be produced during mild oxidation of LDL induces monocyte 
adhesion to the endothelium by upregulating various adhesion molecules and chemokines [10, 12, 
13].  
The hypothesis of this study is that LPA induces different chemokine axes depending on the 
vascular cell type and this in turn triggers different types of atherosclerotic diseases. LPA acts on 
SMCs to induce the CXCL12-mediated SPC recruitment during neointima formation and it acts on 
endothelial cells to induce CXCL1-mediated monocyte adhesion during hyperlipidemia-induced 
atherosclerosis. Following are the objectives of this study: 
 To identify the molecular mechanism of LPA-induced neointima formation and the role of 
the individual LPA receptors, LPA1 and LPA3 in mediating this effect. 
 To determine if LPA can recruit BM-derived SPCs to the neointima and to define the role 
of LPA receptors in this process. 
 To find out if LPA is the active component of moxLDL that induces monocyte adhesion to 
the endothelium and to identify the role of CXCL1 in mediating this effect. In addition, to 
determine the role of the individual LPA receptors, LPA1 and LPA3 in mediating LPA-
induced monocyte recruitment. 
 To find out the role of different LPA species in promoting atherogenesis and the role of the 
LPA receptors in mediating atherosclerotic plaque development. 
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2  Materials and methods 
All solutions were prepared with Millipore water (Milli-Q Plus ultrapure purification, Millipore, 
Billerica, USA). The reagents were purchased from Sigma-Aldrich (Steinheim, Germany), Carl 
Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany) and Fluka (Buchs, Switzerland) unless 
stated otherwise in the text. 
 
2.1  General equipment 
 
Balance -    Sartorius CPA64 (Sartorius mechatronics, Germany) 
Centrifuge -  Heraeus multifuge 3S-R (Heraeus, Osterode, Germany) Hettich 
mikro 200R (Hettich laborapparate, Germany) 
Flow cytometer -   FACSCantoII (BD Biosciences, San Jose, CA, USA) 
Microscopes -  Leica DMLB (Leica, Wetzlar, Germany) and Olympus SZX10 
(Olympus optical, Germany) 
Laminar flow hood -  Herasafe (Heraeus, Osterode, Germany) 
pH-meter -  SCHOTT Instruments Lab 850 (SI Analytics GmbH, Mainz, 
Germany) 
Spectrophotometer -  nanoVue plus (GE Healthcare, Uppsala, Sweden) and nanodrop 1000 
(PeqLab, Erlangen, Germany) 
PCR thermocyclers -  MyCycler (Bio-Rad, Hercules, USA) and 7900HT fast real-time PCR 
system (Applied Biosystems, Darmstadt, Germany) 
Tissue homogenizer -  TissueLyserLT (Qiagen, Hilden, Germany) 
Autoclave -    systec 2540EL (systec, Wettenberg, Germany) 
Microtome -    Cut 6062 (SLEE medical GmBH, Mainz, Germany) 
Plate reader -   microplate reader SpectraFluor Plus  
(Tecan, Crailsheim, Germany)  
Image reader -   LAS 3000 (Fujifilm, Dusseldorf, Germany) 
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2.2  Antibodies 
2.2.1  Primary antibodies 
 
Antigen Details Supplier 
-SMA monoclonal mouse anti-human alpha smooth muscle actin antibody (clone 1A4) Dako 
Mac-2 anti-mouse monoclonal Mac-2 antibody (clone M3/38) Cedarlane 
CXCL12 human/mouse CXCL12/SDF-1 antibody (clone 79018) R&D systems 
HIF-1 rabbit polyclonal hypoxia inducible factor-1 alpha antibody 
Santa cruz 
biotechnology 
SM22 alpha rabbit polyclonal SM22 alpha antibody Abcam 
Calponin rabbit monoclonal calponin antibody (clone EP798Y) Abcam 
von Willebrand 
factor (vWF) rabbit polyclonal von Willebrand Factor antibody Abcam 
CD3 rabbit polyclonal CD3 antibody Dako 
CXCR4 rat polyclonal CXCR4 antibody Santa Cruz biotechnology 
Sca-1 goat polyclonal stem cell antigen-1 antibody R&D systems 
LPA1 receptor 
rabbit polyclonal lysophosphatidic acid receptor 1 
antibody Imgenex 
LPA3 receptor 
rabbit polyclonal lysophosphatidic acid receptor 3 
antibody Imgenex 
-galactosidase rabbit polyclonal -galactosidase antibody Abcam 
CXCL1 rabbit polyclonal CXCL1 antibody peprotech 
CXCL1 monoclonal rat anti-mouse CXCL1/KC antibody (clone 124014) R&D systems 
IgG monoclonal rat anti-rat IgG antibody (clone 54447) R&D systems 
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2.2.2  Fluorescent antibody and streptavidin conjugates 
 
goat-anti-rabbit IgG Dylight549-conjugated (KPL) 
anti-rabbit IgG biotinylated (Serotec) 
streptavidin Dylight549-conjugated (KPL) 
donkey-anti-mouse IgG FITC-conjugated (Jackson immunoResearch) 
donkey-anti-rat IgG FITC-conjugated (Jackson immunoResearch) 
goat-anti-mouse IgG Dylight488-conjugated (KPL) 
donkey-anti-rabbit IgG FITC-conjugated (Jackson immunoResearch) 
donkey-anti-goat IgG FITC-conjugated (Jackson immunoResearch) 
donkey-anti-mouse IgG cy3-conjugated (Jackson immunoResearch) 
 
2.3 Buffers 
 
Hanks´ complete solution: 
1 x HBSS, 0.1% BSA and 5 mM EDTA 
 
FACS staining buffer: 
Phosphate buffered saline (PBS), 2% BSA, 2% mouse serum, 2% rabbit serum, 2% human serum 
 
Flow cytometry lysis buffer: 
150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA, pH 7.4  
 
MOPS buffer: 
145 mmol/L NaCl, 4.7 mmol/L KCL, 2.0 mmol/L CaCl2 2H2O, 1.2 mmol/L MgSO4 7H2O, 5.0 
mmol/ glucose, 2.0 mmol/L sodium pyruvate, 1.2 mmol/L NaH2PO4 H2O and 2.0 mmol/L MOPS, 
pH 7.4 
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ELISA lysis buffer: 
100mM NaCl, 0.1mM EDTA, 20mM Tris (pH-7.4), 10% glycerol, 0.2% NP-40 and 0.1% Triton-
100 containing protease inhibitors (1 tablet in 10 ml of lysis buffer, Roche). 
 
Blotting buffer (1X)):  
25mM Tris base, 192mM Glycine, 10% methanol, 0.005% SDS 
 
TBS (1X): 
25mM Tris-HCL, pH 7.4, 2.7 mM KCl, 137 mM NaCl      
 
Hanks Balanced Salt Solution (HBSS): 
144mM NaCl, 14.9mM HEPES, 5.5mM glucose, 4.7mM KCl, 2.5mM CaCl2, 1.2mM KH2PO4 and 
1.2mM MgSO4, pH 7.4 
 
Citrate buffer: 
630ml millipore water, 12.6ml solution A (2.101g citric acid in 100ml millipore water), 57.4ml 
solution B(14.70g nitrium citrate in 500ml of millipore water), 320µl Tween 20, pH 6. 
 
Western blot lysis buffers: 
 
Lysis buffer A: 100mM NaCl, 20mM KCL, 0.5mM Na2HPO4, 20mM Tris (pH-7.4) with protease 
inhibitors (1 tablet in 10 ml of lysis buffer, Roche). 
Lysis buffer B: 100mM NaCl, 0.1mM EDTA, 20mM Tris (pH-7.4), 10% glycerol, 0.2% NP-40 and 
0.1% Triton-100 with protease inhibitors (1 tablet in 10 ml of lysis buffer, Roche). 
 
Movat’s staining solutions: 
 
a) Alcian blue solution (1%): 1g Alcian blue 8 GX (Sigma A5268) was dissolved in 100ml of 
millipore water, filtered and 1ml of acetic acid was added. 
b) Alkaline ethanol: 5ml ammonium hydroxide was mixed with 95ml of 96% ethanol.  
c) Orcein-Verhoeffschem Hematoxylin solution (stock solution):  
Solution A- 1g Orcein (Merck, 1071000025), 98ml 70% ethanol, 1ml 25% HCL 
Solution B- 8g Hematoxylin (Sigma, H3136), 160ml 100% ethanol 
Solution C- 9.6g Iron(III)-Chloride (Merck, 8039450500), 90ml Millipore water 
Solution D- 1g Iodine, 2g Potassium iodide, 97ml Millipore water 
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d) Orcein-Verhoeffschem Hematoxylin solution (working solution): freshly prepared. 
Solution A- 25ml 
Solution B- 20ml 
Solution C- 8ml 
Solution D- 8ml 
e) Acidic alcohol:  
1ml of 25% HCL was added to 100ml of 95% ethanol. 
f) Brilliant Crocein Scarlet MOO (Stock solution): 
Solution A- 0.1g Brilliant Crocein Scarlet, 0.5ml Acetic acid, 99.5ml Millipore water 
Solution B- 0.1g Acid fuchsin (Merck, 105231), 0.5ml Acetic acid, 99.5ml Millipore water 
g) Brilliant Crocein Scarlet MOO (working solution): 
Solution A- 40ml 
Solution B- 10ml 
h) 0.5% acetic acid: 
1ml of acetic acid was added to 200ml of millipore water. 
i) 6% alcoholic saffron: 
6g of saffron was dissolved in 94ml of absolute ethanol and stored at 56ºC for 48 hours before use.  
 
Elastica van Gieson (EVG) staining solutions: 
 
Solution A: 
10g of hematoxylin was dissolved in 100ml of 96% ethanol 
Solution B: 
29% Iron(III)-Chloride solution (145g of Iron(III)-Chloride was dissolved in 500ml of millipore 
water) and 7.5ml of 37% HCL was added to 950ml of millipore water.  
 
4% paraformaldehyde (PFA): 
16g of PFA was added to 184ml of millipore water and dissolved by adding 5ml of 10M NaOH in 
addition to heating at 100°C. The pH was increased to 7.4-8 by adding 25% HCL. This was 
followed by adding equal volume of 2X PBS and filtering the solution with a filter paper. 
 
Immunofluorescence staining: 
 
Blocking solution A: 
5.4ml PBS, 600µl 10%BSA, 3 drops horse serum  
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LPA18:0 (50M) stock solution: 
11.5mg of LPA18:0 was added to 500ml of PBS and was continuously stirred overnight.  
 
Ki16425 stock solution:  
10mg of Ki16425 was dissolved in 1ml of dimethyl sulfoxide (DMSO).  
Ki16425 working solution: 
10µl of the stock solution was dissolved in 90µl of PBS.  
 
2.4  Animal experiments 
Mice were housed 4 per cage, had free access to water and mouse chow and were maintained on 
a 12 hour light-dark schedule. The animal experiments were reviewed and approved by local 
authorities (LANUV NRW) in accordance with the German animal protection law.  
 
2.4.1  Endoluminal injury to the carotid artery 
Female ApoE-/- mice (Jackson Laboratory, female, 8-12 weeks old, n=11) on high fat diet 
(HFD, 21% crude fat, 0.15% cholesterol and 19.5% casein, Altromin, Germany) were subjected to 
wire-induced endothelial denudation of the left carotid artery using an angioplasty guide wire (0.36 
mm diameter). The mice were anesthetised with ketamine hydrochloride (80 mg/kg, IP) and 
xylazine (5 mg/kg, IP) and the left carotid artery was exposed. The common, external, and internal 
carotid arteries were temporarily ligated to interrupt the blood flow. The angioplasty guide wire 
was inserted into the common carotid artery (CCA) via a transverse arteriotomy made in the 
external carotid artery (ECA). The wire was moved 3 times back and forth in the artery in rotations 
resulting in endothelial denudation of the CCA. After removal of the wire, the ECA was ligated 
and the blood flow restored through the common and the internal carotid arteries (ICA) [98]. The 
mice were injected (IP) with Ki16425 (5 mg/kg/day, Sigma, filter sterilised using a syringe filter, 
pore size of 0.20 µm, Corning) [106] or control buffer (10% DMSO made in PBS, daily, filter 
sterilised using a syringe filter, pore size of 0.20 µm, Corning) every day for 3 weeks following 
injury. Ki16425 selectively inhibits LPA1 and LPA3 with a Ki value of 0.34 µM and 0.93 µM 
respectively. The first injection was given to the anesthetised mice before injury. Perfusion fixation 
with 4% PFA was performed 28 days after injury. The mice were anesthetised with ketamine 
hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, IP), a cut was made in the right atrium and an 
incision was made in the left ventricle through which a catheter was inserted. 4% PFA was 
perfused using a syringe pump (Aladdin-1000, World Precision Instruments, Inc, 336 µl/min) for 
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10 minutes through the left ventricle and the solution was allowed to flow out through the right 
atrium. The carotid arteries were harvested and kept in formalin over night at 4ºC and the next day 
the samples were dehydrated and paraffin embedded (see also section 2.5.4). Blood was taken 
intracardially for serum cholesterol measurements.  
 
2.4.2  LPA-incubation of the carotid artery 
C57BL/6 mice (Charles River, Sulzfeld, female, 8-12 weeks old, n=13-17) were used to 
perform endoluminal incubation of the carotid artery with LPA. 
 
 
 
Figure 9: Schematic representation of intraluminal treatment of mouse carotid arteries 
The CCA, the ECA and the ICA were ligated to temporarily interrupt the blood flow. Then, a 
transverse arteriotomy was made in the ECA through which a catheter was advanced into the ECA 
without touching the bifurcation. The treatment solution was injected into the CCA via the 
catheter. Following incubation, the catheter and the treatment solution were removed. The second 
caudal ligature of the ECA was closed and the blood flow was restored through the CCA and the 
ICA. 
 
The mice were anesthetised with ketamine hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, 
IP) and the left carotid artery was exposed. The blood flow was temporarily interrupted by ligation 
of the common and the internal carotid arteries (Fig. 9). A transverse arteriotomy was made in the 
ECA through which a catheter (Rat intrathecal catheter, Alzet Inc) was inserted without touching 
the bifurcation (Fig. 9). The treatment solution (Table.2) was administered via the catheter to the 
lumen of the CCA and incubated for 30 minutes. After removal of the treatment solution and the 
catheter, the ECA was ligated and the blood flow through the CCA and ICA was re-established. 
All treatment solutions were filter sterilised using a syringe filter (pore size 0.20 µm, Corning). 
Perfusion fixation with 4% PFA was performed after 28 days as stated in section 2.4.1. The carotid 
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arteries were harvested and kept in formalin over night at 4ºC and the next day the samples were 
dehydrated and paraffin embedded (see also section 2.5.4). For protein isolation, the mice were 
perfused with ice cold PBS at 1, 9 or 28 days following LPA20:4-incubation and the carotid 
arteries were harvested and stored at -80ºC until protein isolation. The mobilisation of SPCs into 
the circulation was measured before, 1 day and 9 days following incubation by flow cytometry 
(see also section 2.5.1). The mice were anesthetised using isoflurane and the blood was taken at 
different time points by retro-orbital bleeding.  
 
Treatment 
solution Concentration Ki16425 (100 m) Supplier 
LPA20:4, D(+)-
sn-O-arachidonoyl-
glyceryl-3-phosphate 
40 M without Avanti Polar Lipids 
LPA20:4, D(+)-
sn-O-arachidonoyl-
glyceryl-3-phosphate 
40 M with Avanti Polar Lipids 
1-APG18:1 L-sn-
1-O-oleyl-glyceryl-
3-phosphate 
40 M without Echelon Biosciences 
1-APG18:1 L-sn-
1-O-oleyl-glyceryl-
3-phosphate 
40 M with Echelon Biosciences 
PBS - without Dulbecco 
 
Table 2: Treatment solutions used for intraluminal incubation of carotid artery 
 
2.4.3  Diet-induced atherosclerosis 
ApoE-/- mice (female, 6 weeks old, n=8) were fed a HFD for 12 weeks. During these 12 weeks 
they were injected (IP) everyday with Ki16425 (5 mg/kg/day) or control buffer (10% DMSO made 
in PBS, daily). All the treatment solutions were filter sterilised using a syringe filter (pore size 0.20 
µm, Corning). At the end of 12 weeks, perfusion fixation with 4% PFA was performed as stated in 
section 2.4.1. The aortic roots were harvested and kept in formalin over night at 4ºC and the next 
day the samples were dehydrated and paraffin embedded (see also section 2.5.4). Blood was taken 
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intracardially for serum cholesterol measurements. The aortas were taken for quantification of lipid 
deposition in the aortic wall by Oil red O staining (see also section 2.5.4).  
 
2.4.4  LPA injection 
ApoE-/- mice (female and 6-7 weeks old, n=18) were fed a HFD for 4 weeks prior to and 
throughout the duration of treatment. They were treated (IP) with LPA20:4, LPA18:0 (1-stearoyl-
2-lyso-sn-glycero-3-phosphate, Avanti Polar Lipids, 2 nmol each injection), or PBS for 4 weeks 
(twice weekly). All the treatment solutions were filter sterilised using a syringe filter (pore size 
0.20 µm, Corning). Following treatment, perfusion fixation with 4% PFA was performed as stated 
in section 2.4.1. The aortic roots were harvested and kept in formalin over night at 4ºC and the 
next day the samples were dehydrated and paraffin embedded (see also section 2.5.4). The aorta 
was harvested for Oil red O staining (see also section 2.5.4). Blood was taken intracardially for 
serum lipid measurements.  
 
2.4.5  Partial ligation of the carotid artery 
ApoE-/- mice (female, 7-10 weeks old, n=7) on HFD were anesthetised by ketamine 
hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, IP), and then the left carotid artery was 
exposed. The external carotid, internal carotid, and occipital arteries were ligated; thus outflow of 
blood was only possible via the superior thyroid artery (Fig. 10). This procedure acutely reduced 
the blood flow velocity and in turn, the shear stress in the CCA. This reduced blood flow in 
addition to diet-induced hyperlipidemia forms atherosclerotic plaques in the CCA [107]. Following 
ligation, the left carotid artery was perivascularly treated with LPA20:4 (2 nmol, once weekly for 4 
weeks) or PBS (once weekly for 4 weeks) dissolved in pluronic gel (37%, Sigma). All the 
treatment solutions were filter sterilised using a syringe filter (pore size 0.20 µm, Corning). 4 
weeks after ligation, perfusion fixation with 4% PFA was performed as stated in section 2.4.1. The 
carotid arteries were harvested and kept in formalin over night at 4ºC and the next day the samples 
were dehydrated and paraffin embedded (see also section 2.5.4).  
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Figure 10: Schematic representation of partial ligation of the left carotid artery  
ICA – internal carotid artery, ECA – external carotid artery, OA – occipital artery, STA – superior 
thyroid artery, RCA – right carotid artery, LCA – left carotid artery, RSA – right subclavian artery, 
LSA – left subclavian artery [107]. 
 
2.4.6  Bone marrow transplantation 
To study the role of BM-derived SPCs in LPA-induced neointima formation, BM cells from 
SM22-LacZ mice which express LacZ under the SM22 promoter [108], were transplanted into 
C57BL/6 mice (female 6-8 weeks, n=6). C57BL/6 mice were subjected to whole body irradiation 
(2x6.5 Gy, 4h apart, Faxitron CP-160). The next day, femurs and tibias were removed aseptically 
from donor SM22-LacZ mice, the marrow cavities were flushed with sterile PBS and a single cell 
suspension was prepared by pipetting the cells up and down repeatedly followed by passing the 
cells through a cell strainer (40 µm, BD Falcon) to remove any large pieces of tissue or bone 
which may be present. 24 hours following irradiation, 2 to 3 million BM cells from the donor were 
injected via the tail vein into the recipient mouse which was held in a mouse strainer. 4 weeks 
following BM transplantation, endoluminal incubation of the carotid artery with LPA20:4 (40 µM) 
and Ki16425 (100 µM) or sterile PBS was performed (see also section 2.4.2). All the treatment 
solutions were filter sterilised using a syringe filter (pore size 0.20 µm, Corning). 4 weeks 
following incubation, the carotid arteries were imaged with two photon laser scanning microscopy 
(see also section 2.5.6). Successful repopulation of the BM was studied by quantifying the 
peripheral blood cells for the SM22-LacZ genotype (see also section 2.6.2).  
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2.4.7  SiRNA treatment 
To study the role of LPA1, LPA3, and CXCL12 in LPA-induced neointima formation, carotid 
arteries from C57BL/6 (female, 10-12 weeks n=17) mice were treated perivascularly with the 
respective siRNAs dissolved in pluronic gel. The slow and continuous release of siRNA into the 
tissue is mediated by Pluronic gel. Pluronic F-127 also known as poloxamer 407 is a hydrophilic 
non-ionic surfactant [109]. It consists of a hydrophobic block of polypropylene glycol in the centre 
flanked by two hydrophilic blocks of polyethylene glycol. Due to the presence of both hydrophilic 
and hydrophobic molecules, at low concentrations they form monomolecular micelles and at high 
concentrations they form multimolecular aggregates [109]. Pluronic F-127 is a thermo-reversible 
gel that is liquid at low temperatures (4-5ºC) and becomes a gel upon warming to room 
temperature [109]. At low temperatures in an aqueous solution, the pluronic F-127 molecules are 
surrounded by a hydration layer. But when the temperature is increased, the hydrogen bonds 
between the solvent and the hydrophilic chains of the pluronic F-127 molecules are broken which 
results in hydrophobic interactions between the polypropylene domains leading to gel formation 
[109].  
50% pluronic gel (Sigma Aldrich) was made by dissolving 10 g of pluronic F-127 powder in 20 
ml of millipore water with continuous stirring on ice and filter sterilised with a sterile syringe filter 
(pore size of 0.20 µm, Corning). The transfection reagent (DharmaFECT4, Thermo scientific) was 
diluted 50 times with PBS (Dulbecco) and kept on ice until use. The siRNA (Accell SMART pool, 
Dharmacon) was dissolved in PBS (Dulbecco). 4 nmol of LPA1-specific siRNA, 3 nmol of LPA3-
specific siRNA, 4 nmol of CXCL12-specific siRNA or 4 nmol of non-targeting siRNA was taken 
in a volume of 5 µl and mixed with 0.5 µl of the diluted transfection reagent and kept on ice for 10 
min. Then 14.5 µl of the 50% pluronic gel was mixed with the 5.5 µl of the siRNA solution 
containing transfection reagent to get a final gel concentration of 35%. This was used to treat the 
carotid artery perivascularly. After four days, arteries were intraluminally incubated with LPA20:4 
as described previously (see also section 2.4.2). Following 28 days, perfusion fixation with 4% 
PFA was performed as stated in section 2.4.1. The carotid arteries were harvested and kept in 
formalin over night at 4ºC and the next day the samples were dehydrated and paraffin embedded 
(see also section 2.5.4). The mobilisation of Sca1+/lin- cells was analysed one day before and one 
day following LPA20:4-incubation (see also section 2.5.1). The mice were anesthetized using 
isoflurane and the blood was taken at different time points by retro-orbital bleeding. 
In a separate study, ApoE-/- mice (female, 8-10 weeks, n=10) were put on a HFD for 4 weeks. 
Then non-targeting siRNA, LPA1-, LPA2-, or LPA3-specific siRNA (4 nmol of LPA1, 3 nmol of 
LPA3, 4 nmol of LPA2 and 4 nmol of non-targeting siRNA, Accell SMART pool, Dharmacon) 
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dissolved in 35% pluronic gel was applied around the carotid artery. Intravital microscopy (see 
also section 2.4.8) was performed 4 days or 14 days after siRNA treatment.  
 
2.4.8  Intravital microscopy (IVM) 
The role of LPA receptors in hyperlipidemia-induced endothelial-leukocyte interaction was 
studied by IVM. ApoE-/- (female, age, n=10) mice were fed a HFD for 4 weeks before the carotid 
arteries were treated perivascularly with non-targeting siRNA, LPA1-, LPA2- or LPA3-specific 
siRNA dissolved in pluronic gel (see also section 2.4.7). All the treatment solutions were filter 
sterilised using a syringe filter (pore size 0.20 µm, Corning). IVM was performed 4 days or 14 
days after siRNA treatment. The mice were anaesthetised (ketamine, 80 mg/kg and xylazine 0.3 
mg/kg, IP) and the left carotid artery was exposed. The circulating leukocytes were labelled with 
Rhodamine6G (0.03 mg/kg) by intravenous injection (IV). Leukocyte-endothelial adhesion at the 
carotid bifurcation area was recorded with a microscope (BX51, saline-immersion 10x objective, 
Olympus) equipped with a CCD camera (EM-CCD camera C9100, Hamamatsu). Quantification of 
leukocyte adhesion was performed by digital image analysis (ImageJ) [110]. Cells adherent to the 
endothelium for 30 seconds were counted as adherent cells. 
 
2.4.9  Ex vivo perfusion of carotid artery 
Ex vivo perfusion of carotid arteries can be used as a model to study the mononuclear cell 
adhesion to the vessel wall [111]. Human Mono Mac 6 (MM6) cells were used in the study. MM6 
cells belong to a monocytic cell line that was established from the peripheral blood of a 
monoblastic leukemia patient [112]. These cells react with a panel of monoclonal antibodies that 
are specific for mature monocytes such as M42, 63D3, LeuM3, Mo2, and UCHMI [112]. They 
exhibit functional and phenotypic characters of mature monocytes [112]. To label the MM6 cells 
with calcein AM (Invitrogen), the cells were incubated with 1 µM calcein at 37°C for 30 minutes. 
This was followed by washing with PBS 2 times.  
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Figure 11: Schematic representation of Ex vivo perfusion of carotid artery 
The figure depicts an excised carotid artery placed in an intravital microscope stage. The catheter 
is inserted into the CCA and using a syringe pump the CCA is perfused with the perfusion 
solution. There is a puncture hole at the end of the external and internal carotid arteries which 
serves as an outlet [111].  
 
Mice were anaesthetised (ketamine, 80 mg/kg and xylazine 0.3 mg/kg, IP) and the LCA was 
exposed. The ICA and ECA were cleaned thoroughly such that the connective tissue, vagus nerve, 
bone, and fat tissue surrounding the artery were removed. This was followed by ligation of the 
ICA, ECA, and the CCA. A puncture was made in the ICA and ECA using a 30-gauge needle such 
that the puncture site was not too close to the bifurcation. An incision was made in the CCA 
through which a catheter was inserted and the artery was perfused with MOPS buffer solution (see 
also section 2.3) using a syringe pump (Aladdin-1000, World Precision Instruments, Inc.). The 
solution was allowed to flow out through the puncture holes made in the ICA and the ECA. The 
artery was then transferred to an intravital microscopic stage [111] (Fig. 11) and perfused with the 
treatment solutions (Table.3) for 1 or 3 hours at 37°C. This was immediately followed by perfusion 
with calcein-AM labeled monocytic MonoMac6 (106/ml) cells at a speed of 4 µl/min. The 
adhesive interactions between the MM6 cells and the vessel wall were recorded using stroboscopic 
epifluorescence illumination (Drelloscop 255-01; Drello, Monchengladbach, Germany) and an 
intensified camera system (DAGE-MTI SIT-68). The firm adhesion (>30 seconds) and rolling (<1 
second) of monocytes at the bifurcation area were quantified visually during a time interval of 5 
minutes. All the treatment solutions were filter sterilised using a syringe filter (pore size 0.20 µm, 
Corning). 
 
2 Materials and methods 
 40
Genotype and 
number of 
mice/experiment 
Age/sex Carotid artery treatment solution 
Duration of 
treatment 
MM6 cell 
treatment 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
MOPS buffer 
solution 3 h none 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, Echelon 
Biosciences Inc, 40 
M 
3 h 
isotype control 
IgG, 10 µg/ml, 
clone 20102, 
R&D systems, 
20 min 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, Echelon 
Biosciences Inc, 40 
M 
3 h 
CXCR4 Ab, 10 
µg/ml, clone 
12G5, R&D 
systems, 20 
min 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, Echelon 
Biosciences Inc, 40 
M 
3 h 
CXCR2 Ab, 10 
µg/ml, clone 
48311, R&D 
systems, 20 
min 
C57BL/6 mice, 
n=11 
8-10 weeks, 
female 
MOPS buffer 
solution 1 h none 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
nLDL, Calbiochem, 
200 µg/ml 1 h none 
C57BL/6 mice, 
n=5 
8-10 weeks, 
female 
moxLDL, 200 
µg/ml 1 h none 
C57BL/6 mice, 
n=5 
8-10 weeks, 
female 
moxLDL, 200 
µg/ml 1 h 
CXCR2 Ab, 10 
µg/ml, clone 
48311, 20 min 
C57BL/6 mice, 
n=5 
8-10 weeks, 
female 
Pre-treatment by 
perfusion with 
CXCL1 Ab (20 
min, 50 µg/ml, 
clone 48415, R&D 
systems) followed 
by perfusion with 
moxLDL, 200 
µg/ml 
1 h none 
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C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
moxLDL, 200 
µg/ml and 
Ki16425, 100 µM, 
Sigma 
1 h none 
C57BL/6 mice, 
n=5 
8-10 weeks, 
female 
moxLDL, 200 
µg/ml 1 h 
isotype control 
IgG, 10 µg/ml, 
clone 20102, 
R&D systems, 
20 min 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
moxLDL, 200 
µg/ml and S32826, 
5 µM, Cayman 
Chemicals 
1 h none 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, 10 µM, 
Echelon 
Biosciences Inc 
1 h none 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, 10 µM, 
Echelon 
Biosciences Inc 
1 h 
CXCR2, 10 
µg/ml, clone 
48311, 20 min 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
Pre-treatment by 
perfusion with 
CXCL1 Ab (20 
min, 50 µg/ml, 
clone 48415, R&D 
systems) followed 
by perfusion with 
LPA20:4, 10 µM, 
Echelon 
Biosciences Inc 
1 h none 
C57BL/6 mice, 
n=3 
8-10 weeks, 
female 
LPA20:4, 10 µM, 
Echelon 
Biosciences Inc 
1 h 
isotype control 
IgG, 10 µg/ml, 
clone 20102, 
R&D systems, 
20 min 
 
Table 3: Various treatment conditions used for ex vivo perfusion of the carotid artery  
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2.5   Cell characterisation and protein assays 
2.5.1  Flow cytometry 
Flow cytometry is a technique used to analyse many characteristics of cells as they pass through 
a fluid stream. These characters include size, granularity, and fluorescence intensity (e.g. by 
fluorescently conjugated antibody detection). Individual cells are passed through a laser beam 
during which the scattering of laser light and fluorescence emission are measured. The 
mobilisation of Sca1+/lin- SPC population in the circulation was measured using antibodies against 
Sca-1 and for the hematopoietic lineage markers. The Sca1+/lin- cell population was measured in a 
mononuclear gate [104].  
To stain the cells, first 8-10 drops of venous blood was taken by retro-orbital bleeding and 
anticoagulated with EDTA. The blood was incubated with 3 ml of lysis buffer (see also section 
2.3) for 10 minutes at room temperature to lyse the red blood cells. It was then washed with 2ml of 
Hanks’ complete solution (see also section 2.3) and approximately 106 cells were taken for the 
staining. 1 µl of the phycoerythrin (PE)-conjugated Sca-1 antibody (E-Bioscience, clone-Ly-6A/E) 
and 2 µl of each biotinylated lineage antibody (E-Bioscience, CD3 clone- 145-2C11, CD45R 
clone- RA3-6B2, CD11b clone- M1/70, erythroid marker clone- TER-119, LY-6G clone- RB6-
8C5) were resuspended in 50 µl of a 1:1 solution of FACS staining buffer (see also section 2.3) 
and Hanks’ complete solution (see also section 2.3). The antibody solution was added and 
incubated in the dark on ice for 30 minutes. The cells were then washed with Hanks’ complete 
solution (see also section 2.3). 0.75 µl of biotinylated FITC (Vector labs) was resuspended in 50 µl 
of a 1:1 solution of FACS staining buffer (see also section 2.3) and Hanks’ complete solution (see 
also section 2.3) and added to the tubes which were then incubated on ice in the dark for 30 min. 
The samples were measured using a FACSCantoII (BD Bioscience) flow cytometer. In the control 
tubes, the primary antibodies were omitted and only the biotinylated FITC was added. To 
determine the CXCR4 expression on Sca-1+/lin- cells, a FITC conjugated rat anti-CXCR4 antibody 
was used. Raw data were analysed with FlowJo software (Tree star, Inc, Ashland, OR, USA). To 
determine the Sca-1+/lin- cell population, first the dot plot containing the forward scatter (FSC) and 
side scatter (SSC) was taken. The FSC value is proportional to the diameter of the cell and the SSC 
value is proportional to the granularity of the cell. The mononuclear cells were identified based on 
their size and granularity and a mononuclear cell gate was made (Fig. 12A). The fluorescence 
intensities of these cells for PE (expressed on the Y axis) and FITC (expressed on the X axis) (Fig. 
12B) was analysed. The quadrants were set based on the negative control such that more than 95% 
of the events from the negative control lie in the Sca-1-/lin- quadrant. For each quadrant, the 
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percentage of cells was derived from the quadrant statistics determined by the FlowJo software. 
The percentage of Sca-1+/lin- cells was calculated by subtracting the percentage of Sca-1+/lin- cells 
in the sample from the percentage of Sca-1+/lin- cells in the negative control.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Quantification of Sca-1+/lin- cell population using flow cytometry 
(A) The measured cells are shown in the dot plot and the gate discerns the mononuclear cell 
population. (B) The fluorescence intensities of the mononuclear cells for PE and FITC are shown. 
The FITC fluorescence is in the X axis (lineage, hematopoietic marker) and PE fluorescence (Sca-
1, stem cell marker) on the Y axis. The percentage of Sca-1+/lin- cells is shown in the upper left 
quadrant. 
 
2.5.2  Enzyme-linked immunosorbant assay (ELISA) 
a) Following LPA20:4-incubation, the CXCL12 protein in the carotid artery was measured after 
1 day, 9 days and 28 days by ELISA. Untreated carotid arteries were used as controls. The carotid 
arteries were harvested after perfusion with ice cold PBS and were mechanically disrupted (Tissue 
lyser LT, Qiagen) in ice cold ELISA lysis buffer (see also section 2.3). The lysate was then 
incubated on ice for 10 minutes and centrifuged at 3500 g for 10 minutes at 4ºC. The CXCL12 
protein concentration was determined in the supernatant using 96-well plates pre-coated with a 
CXCL12 capture Ab (Ray Biotech, INC). Standard and carotid artery samples (100 µl each) were 
added to the appropriate wells and incubated for 2.5 h at room temperature. Then, the wells were 
washed four times with the wash solution followed by the addition of an anti-mouse biotinylated 
CXCL12 detection Ab for 1 h under shaking conditions. After a further washing step, horseradish 
peroxidase (HRP)-conjugated streptavidin (100 µl per well) was added and incubated for 45 
minutes at room temperature. 100 µl of TMB one-step substrate solution (3,3,5,5-
tetramethylbenzidine) was then added, following a washing step, and the reaction was stopped 
after 30 minutes (room temperature, in the dark) by the addition of 50 µl of stop solution (2 M 
A B 
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sulphuric acid). The addition of TMB substrate solution results in one electron oxidation of TMB 
by HRP. This one electron oxidation product is a cation free radical which is blue in colour and has 
an absorption maximum of 653 nm. Further acidification of this radical with sulphuric acid yields 
the completely oxidised product (diimine) which is formed by two electron oxidation. This product 
yields a yellow colour and has an absorption of 450 nm. The absorbance was measured at 450 nm 
with a microplate reader (see also section 2.1). A graph was plotted for the values obtained from 
the standards and this was used to determine the concentration of CXCL12 protein in the samples.  
b) The concentration of CXCL1 protein in the medium of cultured ECs was determined using 
ELISA. Following treatment of ECs with LPA20:4, native LDL (nLDL) or moxLDL with or 
without the different inhibitors (see also section 2.7), the secreted CXCL1 protein in the medium 
was determined using a mouse CXCL1 ELISA kit (R&D System). 
Cell surface ELISA for CXCL1 was performed on cultured ECs to identify the CXCL1 protein 
immobilised on the cell surface. ECs were cultured in a 96-well plate (see also section 2.7) and 
treated with LPA20:4, moxLDL or nLDL in the presence or absence of the various inhibitors for 1 
hour. Then, the cells were fixed with 4% PFA followed by incubation with a CXCL1 Ab (clone 
48415, R&D system; 1 µg/ml in PBS/1% skim milk) [113]. Then, the secondary Ab (HRP 
conjugated goat anti-rat IgG, Santa Cruz Biotechnology) was added. This was followed by the 
addition of the substrate for HRP, 3,3,5,5-tetramethylbenzidine (TMB, 1-step ultra TMB-ELISA 
solution, Thermo Fisher Scientific Inc., Rockford, IL) which results in colour development. The 
reaction was stopped by adding 2 M H2SO4. The absorbance of the coloured solution was 
measured at 450nm with a microplate reader (see also section 2.1). 
 
2.5.3  Western Blot analysis  
HIF-1 protein in the carotid arteries was studied following LPA20:4 incubation by western 
blot analysis. Following LPA20:4-incubation, carotid arteries were harvested after 1 day, 9 days 
and 28 days. Untreated right carotid arteries were used as controls. The carotid arteries were 
harvested after perfusion with ice cold PBS. The arteries were mechanically disrupted (Tissue 
lyser LT, Qiagen) in ice cold lysis buffer A (80 µl per sample) (see also section 2.3). Then the 
whole lysate was transferred to a new tube and centrifuged at 3000 g for 10 minutes at 4ºC. The 
supernatant was then removed and the pellet was dissolved in 80 µl of lysis buffer B (see also 
section 2.3) and incubated on ice for 10 minutes. Then it was centrifuged at 3000 g for 10 minutes 
at 4ºC. The supernatant containing the nuclear protein was taken and stored in -80ºC till use. 30 µg 
of protein was taken from each sample and separated by SDS-PAGE (Sodiumdocecylsulfate-
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polyacrylamide-gelelectrophoresis). A 7.5% gel was used for the separation. SDS binds to the 
polypeptides resulting in a negative charge and seperates the protein by size. Electrophoresis was 
carried out in a Mini-PROTEAN® 3 cell system (Bio-Rad, Hercules, USA) at 120 V. The 
separated proteins were transferred onto a nitrocellulose membrane (Amersham/GE Healthcare, 
Uppsala, Sweden) at 100V for 1 h in ice cold blotting buffer (see also section 2.3). The non-
specific binding regions in the membrane were blocked by incubating it with 5% milk in TBS for 
1.5 h at room temperature. Then, the membrane was incubated with the primary antibodies, HIF-
1 (1:500 dilution, for 1 h at room temperature, Santa Cruz Biotechnologies) and GAPDH (1:3000 
dilution, at 4°C overnight, Bethyl Laboratories). Following incubation, the membrane was washed 
with TBS/0.05% tween (see also section 2.3) three times. To detect the primary antibodies the 
membrane was incubated with a HRP-conjugated, anti-rabbit secondary Ab for 1 h at room 
temperature. In the presence of hydrogen peroxide (H
2
O
2
) the protein-bound HRP converts 
luminol to an excited intermediate dianion, which emits light on return to its ground state. This 
light can be captured by an image reader (see also section 2.1). 
 
2.5.4  Histochemistry 
The samples (carotid arteries, aortic root) for histological staining were harvested from the mice 
after fixation with 4% PFA. Then the tissue was kept in formalin over night at 4ºC. The next day 
the tissue was dehydrated (SLEE MAIN2, Table.4). This was followed by embedding the tissue in 
liquid paraffin (approximate temperature 60ºC) and the blocks were allowed to harden (Leica 
EG1160). The carotids were embedded such that the bifurcation was facing downwards and care 
was taken that it was embedded vertical and straight. A microtome (see also section 2.1) was used 
to section the paraffin blocks at 5 m thickness. For carotid arteries the sections were collected 
starting from the bifurcation and for the aortic roots the sections were collected starting from the 
first valve that was visible. After sectioning, the slides were kept at 37ºC in an incubator for 5-6 h 
or at room temperature overnight to prevent the detachment of tissue while staining.  
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Reagent Duration Temperature 
Ethanol 70% 30 min 20ºC 
Ethanol 70% 30 min 20ºC 
Ethanol 96% 30 min 20ºC 
Ethanol 96% 30 min 20ºC 
Ethanol 100% 30 min 20ºC 
Ethanol 100% 30 min 20ºC 
Ethanol 100% 30 min 20ºC 
Xylol 30min 45ºC 
Xylol 30 min 45ºC 
Xylol 30 min 45ºC 
Paraffin I 30min 62ºC 
Paraffin II 30min 62ºC 
Paraffin III overnight 62ºC 
 
Table 4: Different steps of paraffin embedding 
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To determine the neointimal area in the carotid arteries of mice following wire injury or LPA 
incubation, Movat’s pentachrome staining was performed. Cross sections of the carotid artery (5 
µm thickness, 4 sections per mouse) were obtained at a standard distance (50 to 300 µm) starting 
from the bifurcation and stained with Movat’s pentachrome.  
1)  For Movat’s staining the sections were first subjected to deparaffinisation and rehydration 
by the following procedure: 
 Incubate in Xylol for 30 minutes. 
 Incubate in 100% isopropanol for 5 minutes. 
 Incubate in 100% isopropanol for 5 minutes. 
 Incubate in 96% isopropanol for 5 minutes. 
 Incubate in 70% isopropanol for 5 minutes. 
 Incubate in millipore water for 5 minutes 
 Incubate in PBS for 5 minutes. 
2) Stained for 20 minutes in alcian blue solution (1%) (see also section 2.3) followed by 5 
minute wash in tap water.  
3) Incubated in alkaline ethanol for 10 minutes at 56ºC (see also section 2.3).  
4) Washed in running tap water for 2 minutes.  
5) Dipped in millipore water and stained in Orcein-Verhoeffschem Hematoxylin solution for 
30 minutes at 37ºC (see also section 2.3) followed by washing in running tap water for 3 
minutes.  
7) Differentiated in 2% Iron (III)-Chloride for 2 minutes. 
8)  Incubated in acidic alcohol for 2 minutes (see also section 2.3) and then dipped in tap 
water for 5 minutes.  
9) Stained in Brilliant Crocein Scarlet MOO solution for 10 minutes (see also section 2.3).  
10) Washed in 0.5% acetic acid for 30 seconds (see also section 2.3) and differentiated in 5% 
phosphor-tungstic acid for maximum 4 minutes. 
11)  Dipped in 0.5% acetic acid for 30 seconds.  
12) Washed in 100% ethanol three times for 1 minute each.  
13) Stained in 6% alcoholic saffron for 8-15 minutes (see also section 2.3) in a closed 
container.  
14) Dehydrated in absolute ethanol two times for 3 minutes each. Finally the tissue was dipped 
in xylol and a cover slip was placed using vitrocloud (langenbrinck).  
The neointimal area in the carotid artery was quantified by computerized image analysis 
(Diskus software, Hilgers, Bonn). First the lumen area was marked and then the internal elastic 
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lamina (IEL) and the external elastic lamina (EEL) were marked. The area of lumen, IEL and EEL 
was automatically calculated by the software (Diskus). The neointimal area was calculated by 
subtracting the area of IEL from the lumen area. The medial area was calculated by subtracting the 
area of EEL from the area of IEL (Fig. 13).  
 
 
Figure 13: Morphometric analysis of the CCA 
EEL- external elastic lamina, IEL- internal elastic lamina. 
 
The atherosclerotic plaques in the aortic root or carotid arteries of mice were analysed in 
Movat’s pentachrome stained or EVG stained sections (4 sections per mouse, 5 µm thick). The 
plaque area was quantified by computerized image analysis (Diskus software, Hilgers, Bonn). The 
circumference of the plaque was marked in each valve and the area of plaque in each valve was 
calculated by the software. The plaque area per valve was calculated by taking the average of the 
plaque area in all three valves. 
EVG staining was performed using the following protocol: 
1) The sections were deparaffinised and rehydrated by the following procedure: 
 Incubate in Xylol for 30 minutes. 
 Incubate in 100% isopropanol for 5 minutes. 
 Incubate in 100% isopropanol for 5 minutes. 
 Incubate in 96% isopropanol for 5 minutes. 
 Incubate in 70% isopropanol for 5 minutes. 
 Incubate in millipore water for 5 minutes 
 Incubate in PBS for 5 minutes 
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2) Stained in resorcein-fuchsin solution (Roth, X877.1) for 15 minutes at 56ºC followed by 
slowly dipping in tap water 1-2 times. 
3) Differentiated in 80% ethanol followed by dipping in tap water and millipore water.  
4) Incubated in solution A+ B (100ml solution A and 100 ml solution B, freshly prepared, see 
also section 2.3) for 5 minutes. 
5) Differentiated with 0.5% HCL-alcohol by dipping in the solution a few times. 
6) Washed in tap water till the colour of the nucleus turned blue. 
7) Incubated in pikrofuchsin (Merck, 1.15974/4) for 1 minute and washed in tap water shortly. 
8) Dipped shortly in 70% ethanol followed by 96% ethanol. 
9)  Incubated in 100% ethanol for 3 minutes followed by 5 minutes in xylol and then the cover 
slip was placed using vitrocloud. 
The lipid area in the aorta was studied by Oil red O staining. The thoracic and abdominal aortas 
were cut longitudinally and prepared en face. The aorta was dipped in 60% isopropanol for 15 to 
20 seconds followed by incubation in 0.3% Oil red solution for 15 minutes. The aorta was then 
washed in 60% isopropanol for 10 to 15 seconds. Finally, the aorta was washed in water and 
mounted on the slide. The stained lipid depositions in the aortic wall were quantified in digitized 
images using ImageJ software. The circumference of the aorta was marked and percentage of 
positively stained area was quantified out of the total area of aorta in each image. 
 
2.5.5  Immunofluorescence  
To determine the composition of the neointimal area following wire injury and LPA incubation, 
quantitative immunostaining was performed in carotid artery sections (5 µm thick) using 
antibodies against -smooth muscle actin (SMA), Mac-2, SM22, calponin, vWF, -galactosidase, 
and CD3 (Table.5, see also section 2.2.1). Appropriate isotype matched IgG antibodies were used 
as negative controls (Santa Cruz biotechnology). For detection of the primary Ab, a FITC-, 
Dylight549-, Dylight488 or cy3-conjugated secondary Ab was used (see also section 2.2.2). The 
nuclei were counterstained with 4',6-Diamidino-2-phenylindol (DAPI). The percentage of 
positively stained area was quantified per neointimal area using image analysis software (ImageJ). 
The analysis was performed by setting the threshold according to the background of the negative 
control stainings. The CD3 staining, however, was analysed by counting the number of CD3+ 
cells. Briefly, the CD3+ cells were identified by the co-localisation of the CD3 and the DAPI 
staining and expressed as the percentage of CD3+ cells out of the total number of DAPI+ nuclei in 
the neointima. In sections stained for -SMA and Sca-1, the double positive cells were counted 
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and expressed as the percentage of -SMA+/Sca-1+ cells out of the total number of cells in the 
neointima (Table.6). In addition, double immunostaining was performed for HIF-1and CXCL12 
(Table.6, see also section 2.2.1). LPA1 and LPA3 stainings were performed with the appropriate 
primary antibodies (see also section 2.2.1). The bound primary antibodies were visualized by a 
biotinylated secondary Ab followed by a streptavidin-Dylight549 conjugate (Table.5, see also 
section 2.2.1 and 2.2.2). The images were recorded with a fluorescence microscope (see also 
section 2.1) connected to a CCD camera (JVC). The analysis was performed by setting the 
threshold according to the background of the negative control stainings. The specificity of the 
LPA1 and LPA3 antibodies were checked using sections from LPA1-/- and LPA3-/- mouse carotid 
arteries respectively (obtained from Jerold Chun, Department of Molecular Biology, Dorris 
Neuroscience Center, The Scripps Research Institute, La Jolla, CA, USA). 
 
Antigen Antigen retrieval Blocking Primary Ab Detection system 
-SMA none 
Blocking solution A 
(see section 2.3), 30 
min 
mouse 
monoclonal (MC) 
-SMA Ab, 
1:200, 4ºC, 
overnight (ON) 
donkey-anti-
mouse IgG-FITC-
conjugated Ab, 
1:100, 30 min 
Mac-2 none 
Blocking solution A 
(see section 2.3), 30 
min 
rat MC Mac-2 
Ab, 1:400, 4ºC, 
ON 
donkey-anti-rat 
IgG-FITC-
conjugated Ab, 
1:100, 30 min 
CD3 Citrate buffer, 20 min (100ºC) 
10% goat serum, 30 
min 
rabbit polyclonal 
(PC) CD3 Ab, 
1:100, 4ºC, ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:400, 30 min 
CXCL1 
Citrate buffer, 
20 min 
(100ºC) 
Blocking solution A 
(see section 2.3), 30 
min 
rabbit PC CXCL1 
Ab, 1:50, 4ºC, 
ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:200, 30 min 
LPA1 
Citrate buffer, 
20 min 
(100ºC) 
Blocking solution A 
(see section 2.3), 30 
min followed by 
blocking with 
avidin/biotin solution 
(avidin 15 min and 
subsequently biotin 15 
min) 
rabbit PC LPA1 
Ab, 1:500, 4ºC, 
ON 
anti-rabbit IgG-
biotinylated Ab, 
1:100, 30 min 
followed by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
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LPA3 
Citrate 
buffer, 20 min 
(100ºC) 
Blocking solution 
A (see section 2.3), 30 
min followed by 
blocking with 
avidin/biotin solution 
(avidin 15 min and 
subsequently biotin 15 
min) 
rabbit PC LPA3 
Ab, 1:250, 4ºC, 
ON 
anti-rabbit IgG-
biotinylated Ab, 
1:100, 30 min 
followed by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
-
galactosida
se 
Citrate 
buffer, 20 min 
(100ºC) 
Blocking solution 
A (see section 2.3), 30 
min 
rabbit PC -
galactosidase Ab, 
1:1000, 4ºC, ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:200, 30 min 
vWF 
Citrate 
buffer, 20 min 
(100ºC) 
Blocking solution A 
(see section 2.3), 30 
min 
rabbit PC vWF 
Ab, 1:1000, 4ºC, 
ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:200, 30 min 
SM22 
alpha none 
10% goat serum, 30 
min 
rabbit PC SM22 
alpha Ab, 1:200, 
4ºC, ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:200, 30 min 
calponin none 10% goat serum, 30 min 
rabbit MC 
calponin Ab, 
1:100, 4ºC, ON 
goat-anti-rabbit 
IgG-Dylight549-
conjugated Ab, 
1:200, 30 min 
 
Table 5: Immunostaining protocols 
Ab details are given in sections 2.2.1 – 2.2.2 
 
The composition of the atherosclerotic lesions in the aortic root was analysed by 
immunostaining (2-3 sections per mouse) using antibodies against -SMA, Mac-2, and CXCL1 
(Table.5, see also section 2.2.1). The atherosclerotic lesions in the carotid arteries were stained for 
the macrophage-specific marker Mac-2 (Table.5, see also section 2.2.1). The primary antibodies 
were detected using appropriate secondary antibodies (see also section 2.2.2). The percentage of 
the positively stained area out of the total plaque area was calculated from the measurements made 
using image analysis software (ImageJ). In addition, the Mac-2+ cell number in the plaques was 
determined by counting the Mac-2 and DAPI positive cells and expressed as the percentage of 
Mac-2+ cells out of the total number of plaque cells. Double immunostaining was performed using 
antibodies against LPA1, LPA3, or CXCL1 with a Mac-2 or vWF Ab (Table.6, see also section 
2.2.1).  
2 Materials and methods 
 52
Formalin-fixed and paraffin-embedded human carotid plaque sections were obtained from 
atherectomy specimens. They were used for double immunostaining for LPA1 or LPA3 with Mac-2 
or vWF (Table.6, see also section 2.2.1). Appropriate unspecific primary antibodies were used as 
negative controls. 
 
Antigen 
retrieval Blocking 
1st primary 
Ab 
1st secondary 
Ab 
2nd 
primary Ab 
2nd secondary 
Ab 
Citrate 
buffer, 20 
min 
(100ºC) 
10% goat 
serum, 30 min 
mouse MC 
CXCL12 
Ab, 1:50, 
4ºC, ON 
goat-anti-
mouse IgG-
Dylight488-
conjugated, 
1:400, 30 min 
rabbit PC 
HIF-1 alpha 
Ab, 1:50, 1 h 
at room 
temperature 
goat-anti-rabbit 
IgG-Dylight549-
conjugated, 
1:400, 30 min 
Citrate 
buffer, 20 
min 
(100ºC) 
Blocking 
solution A (see 
section 2.3), 30 
min 
rabbit PC 
CXCL1 Ab, 
1:50, 4ºC, 
ON 
goat-anti-
rabbit IgG-
Dylight549-
conjugated, 
1:200, 30 min 
rabbit PC 
vWF Ab, 
1:1000, 4ºC, 
ON 
donkey-anti-
rabbit IgG-
FITC-
conjugated, 
1:100, 30 min 
Citrate 
buffer, 20 
min 
(100ºC) 
Blocking 
solution A (see 
section 2.3), 30 
min followed 
by blocking 
with 
avidin/biotin 
solution 
(avidin 15 min 
and 
subsequently 
biotin 15 min) 
rabbit PC 
LPA1 Ab, 
1:500, 4ºC, 
ON 
anti-rabbit 
IgG-
biotinylated 
Ab, 1:100, 30 
min, followed 
by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
rabbit PC 
vWF Ab, 
1:1000, 4ºC, 
ON 
donkey-anti-
rabbit IgG-
FITC-
conjugated, 
1:100, 30 min 
Citrate 
buffer, 20 
min 
(100ºC) 
Blocking 
solution A (see 
section 2.3), 30 
min followed 
by blocking 
with 
avidin/biotin 
solution 
(avidin 15 min 
and 
subsequently 
biotin 15 min) 
rabbit PC 
LPA1 Ab, 
1:500, 4ºC, 
ON 
anti-rabbit 
IgG-
biotinylated 
Ab, 1:100, 30 
min, followed 
by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
rat MC Mac-
2 Ab, 1:400, 
1 h at room 
temperature 
donkey-anti-rat 
IgG-FITC-
conjugated Ab, 
1:100, 30 min 
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Citrate 
buffer, 20 
min 
(100ºC) 
Blocking 
solution A (see 
section 2.3), 30 
min followed 
by blocking 
with 
avidin/biotin 
solution 
(avidin 15 min 
and 
subsequently 
biotin 15 min) 
rabbit PC 
LPA3 Ab, 
1:250, 4ºC, 
ON 
anti-rabbit 
IgG-
biotinylated 
Ab, 1:100, 30 
min followed 
by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
rabbit PC 
vWF Ab, 
1:1000, 4ºC, 
ON 
donkey-anti-
rabbit IgG-
FITC-
conjugated, 
1:100, 30 min 
Citrate 
buffer, 20 
min 
(100ºC) 
Blocking 
solution A (see 
section 2.3), 30 
min followed 
by blocking 
with 
avidin/biotin 
solution 
(avidin 15 min 
and 
subsequently 
biotin 15 min) 
rabbit 
polyclonal 
LPA3 Ab, 
1:250, 4ºC, 
ON 
anti-rabbit 
IgG-
biotinylated 
Ab, 1:100, 30 
min followed 
by 
Streptavidin-
Dylight549-
conjugated, 
1:500, 30 min 
rat MC Mac-
2 Ab, 1:400, 
1 h at room 
temperature 
donkey-anti-rat 
IgG-FITC-
conjugated Ab, 
1:100, 30 min 
- 
Blocking 
solution A (see 
section 2.3), 30 
min 
goat PC 
Sca-1 Ab, 
1:10, 4ºC, 
ON 
donkey-anti-
goat IgG-
FITC-
conjugated, 
1:100, 1 h 
mouse MC 
-SMA Ab, 
1:200, 4ºC, 
ON 
donkey-anti-
mouse IgG-cy3-
conjugated, 
1:300, 1 h 
 
Table 6: Double-immunostaining protocols 
Ab details are given in sections 2.2.1 – 2.2.2 
 
2.5.6  Two-photon laser scanning microscopy (TPLSM) 
To determine, whether LPA20:4-induced neointima formation is due to the recruitment of BM-
derived SPCs, BM cells from mice which express -galactosidase under a SMC-specific promoter 
(SM22-LacZ) were transplanted into C57BL/6 mice (18-20 weeks, female, n=6) (see also section 
2.4.6). Then, the carotid arteries were incubated with LPA20:4 and the neointimal -galactosidase 
expressing cells were studied using TPLSM (see also section 2.5.6).  
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In contrast to the conventional single-photon microscopy methods which use UV or visible light 
to excite fluorescent molecules, TPLSM uses two photons of the infrared light to excite the 
fluorophore [114]. Due to two-photon excitation, out of focus absorption and background 
fluorescence are strongly suppressed. The use of infrared light reduces the scattering in the tissue 
which enhances penetration depth. Other advantages of TPLSM are enhanced resolution and 
optical sectioning [115].  
28 days following LPA20:4-incubation, carotid arteries were excised (including the bifurcation) 
and incubated in chloroquine (300 µm in HBSS, see also section 2.3), ImaGene Green C12 FDG 
lacZ Gene Expression Kit, Invitrogen, Karlsruhe, Germany) for 30 minutes to block the 
endogenous lysosomal -D-galactosidase activity. Then, the arteries were mounted in a perfusion 
chamber (Fig. 14a) which was filled with HBSS (see also section 2.3) and the temperature was 
maintained at 37°C. To study the activity of the -galactosidase, C12 fluorescein di--d-
galactopyranoside (FDG) substrate (ImaGene Green, Invitrogen, 33 µM in HBSS) was perfused 
through the artery at a rate of 12 µl/min for 30 minutes. Phenylethyl -D-thiogalactopyranoside 
(PETG) reagent (ImaGene Green, 1 mM in HBSS) was used to stop the -galactosidase reaction. 
SYTO41 and propidium were used to perform a live-dead-cell staining, which identified that the 
lacZ signal was derived only from live cells. The intraluminal pressure was restored prior to 
imaging. A multiphoton system (TriM Scope, LaVision Biotec GMBH, Bielefeld, Germany) in 
single beam mode coupled to a motorised up-right microscope (Olympus BX61WI with a 20X NA 
0.95 water immersion objective; Olympus GMBH, Hamburg, Germany) was used to image the 
arteries. For two-photon excitation, the pulsed Ti-Sapphire laser (MaiTai HP, Spectra Physics, 
Mountain View, US) was tuned to 830 nm. This was used to visualise the second harmonic 
generation (SHG) signal of collagen, C12 FDG (ImaGene Green), and the autofluorescent signal 
originating from the elastic laminae. Detection of the emitted fluorescent signals was achieved 
with two photomultiplier tubes (PTMs) tuned to corresponding parts of the emission spectra: SHG, 
453-497 nm (PMT 1); C12 FDG, 500-550 nm (PMT 2); autofluorescence signal of elastin was 
detected in both PMT 1 and PMT 2. ImSpector Pro 4.0.43 acquisition software (LaVision Biotec 
GMBH) was used to obtain series of xy images at successive depth (z-stack) (Fig. 14b). Further 
image processing was performed with Image-Pro 3D analyser 7.0 software (Media Cybernetics, 
Silver Spring, USA). 
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Figure 14: TPLSM-perfusion chamber and 3D reconstruction of an artery 
a) The image shows a mouse uterine artery mounted on two glass pipettes. The distance between 
the two pipettes is adjustable. b) The image shows the 3D re-construction of a uterine artery and 
the z-stack of optical xy-slices [115]. 
 
LPA20:4-induced endothelial-surface deposition of CXCL1 was studied using TPLSM. Carotid 
arteries from C57BL/6 mice were isolated and mounted in a perfusion chamber (Fig. 14a). The 
arteries were then perfused ex vivo with LPA20:4 (10 µM, Echelon Biosciences Inc.) or a control 
buffer for 1 hour at 37°C. This was immediately followed by perfusion with a Cy3-labelled 
CXCL1 Ab (50 µg/ml, clone 48415, R&D Systems) for 15 minutes at a rate of 2 µl/min and by 
washing with HBSS (see also section 2.3) for 15 minutes. The endothelial surface deposition of 
CXCL1 was imaged by detecting the Cy3-derived fluorescence. Imaging was performed using an 
Olympus FV1000MPE multi-photon system that was coupled to an upright microscope (Olympus 
BX61WI) with a 25X NA 1.05 water immersion objective (Olympus GMBH, Hamburg, 
Germany). For two-photon excitation, the pulsed Ti-sapphire laser (MaiTai DeepSee, Spectra 
Physics, Mountain View, US) was set to 800 nm. The detection of the fluorescent signal was 
achieved with three PMTs, which were each set to detect a separate range of the emission 
spectrum: intrinsic fluorescent signals of SHG, 400-490 nm (PMT 1); calcein labeled MM6 cells, 
510-525 nm (PMT 2); autofluorescent signal from elastin, 505-560 nm (PMT 2); anti PE-labeled 
CD31, 560-660 nm (PMT 3); and Cy3-labeled CXCL1, 560-660 nm (PMT 3). The Fluoview 
FV10-ASW 2.0 acquisition software (Olympus GMBH, Hamburg, Germany) was used to obtain a 
series of xy-images (Fig. 14b) at varying depths (z-stack) and Image-Pro 3D analyser 7.0 (Media 
Cybernetics, Silver Spring, USA) was used for further image processing.  
The CXCL1 Ab was conjugated with Cy-3 using a Cy-3 mAb labelling kit (GE Healthcare). 
The CXCL1 Ab was first dissolved such that the concentration was 1mg/ml and 100 µl of this 
diluted Ab solution was taken and added to 5 ml of coupling buffer from the kit (1 M Sodium 
Carbonate buffer). Then the entire volume was transferred to a vial containing the Cy3 dye and 
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mixed thoroughly. This was incubated at room temperature for 30 minutes with additional mixing 
every 10 minutes. The gel filtration column for the separation of labeled protein from non-
conjugated dye was mounted on a ring stand and 3 ml of fresh elution buffer (Phosphate buffered 
saline containing 0.1% Sodium azide as preservative) was allowed to flow through it. Then the Ab 
labeling mixture was transferred to the top of the column. 1.1 ml of elution buffer was added 
which moves through the column during which a fast moving pink band of labeled Ab will 
separate from the un-conjugated dye. Additional 1.1 ml of elution buffer was added to the column 
and the fast moving pink band of labeled Ab was collected in a clean tube as it elutes from the 
column. 
 
2.5.7  Serum analysis 
At the end of the experiment, approximately 500-700 µl of blood was taken in serum tubes 
(Sarstedt) and allowed to stand at room temperature for 2 hours. The tubes were centrifuged at 
2000 g for 20 minutes and the serum present in the supernatant was collected to measure the serum 
lipids and proteins. Serum cholesterol, C-reactive protein (CRP), alanine transaminase (ALT), 
triglycerides and creatinine levels were measured with an automatic analyser (Vitros 250, Johnson 
and Johnson). 
 
2.6  Molecular biology methods 
2.6.1  Quantification of RNA 
The RNA concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer (see also section 2.1). The absorbance at 280 nm was also measured to 
determine the RNA purity. RNA with an A260/A280 ratio of 1.8-2.0 was used. 
 
2.6.2  Quantitative real-time polymerase chain reaction (PCR) 
The differential regulation of the LPA receptors by vascular injury and hyperlipidemia was 
studied by quantitative real-time PCR. The PCR was performed using Quantitect SYBR green 
PCR kit (Qiagen) and commercially available primers for the LPA receptors (Quantitect primer 
assay, Qiagen). In order to quantify gene expression from small amounts of RNA, it is necessary to 
amplify the gene transcript. The RNA sample is first reverse-transcribed to cDNA with the enzyme 
reverse transcriptase and the cDNA is subjected to PCR amplification. SYBR green is a DNA 
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binding dye that binds to all double stranded DNA during PCR and results in fluorescence which 
can be measured. In this technique, the amplified cDNA is measured as the reaction progresses. 
During PCR, an increase in the DNA product leads to an increase in fluorescence intensity which 
can be measured at each cycle and hence the DNA concentration is quantified. This in turn can be 
used to calculate the expression of a target gene.  
RNA was isolated from carotid arteries, aorta or cultured macrophages using RNeasy micro kit 
(Qiagen, Hilden, Germany). In this procedure RNA was isolated by inducing the selective binding 
of RNA to the silica membrane of the RNeasy MinElute spin column. The binding of the RNA to 
the membrane is promoted by guanidine-thiocyanate which is present in the lysis buffer and 
ethanol which is added before transferring the sample to spin column. Traces of DNA that may be 
present were removed by treatment with DNaseΙ. The RNA concentration was determined (see 
also section 2.6.1) and up to 600 ng of total RNA was reverse transcribed using Quantitect reverse 
transcription kit (Qiagen). First the RNA was incubated with genomic DNA wipe out buffer at 42° 
C for 2 minutes to effectively remove any genomic DNA that may be present. Then, the RNA was 
incubated with the reverse transcription master mix at 42° C for 15 minutes and the reaction was 
stopped by incubation at 95° C for 3 minutes (refer to table 7 for more details). The cDNA was 
subjected to PCR amplification with primer sets specific for LPA1, LPA2 and LPA3 (Quantitect 
primer assay, Qiagen) in a real time cycler (Opticon, MJ Research) (refer to tables 8 and 9 for 
more details). GAPDH, -actin and rpl13a were used as the reference genes. The relative 
expression levels were calculated using multiple internal control genes [116], adjusted for 
differences in PCR efficiency (Qbase, Biogazelle) and logarithmically transformed. Expression of 
the housekeeping gene which is used to normalize the target gene expression should not vary 
among different samples used in the study. However, previous studies show that housekeeping 
gene expression can vary in different tissues, therefore the use of one housekeeping gene to 
normalize gene expression may lead to errors [116]. In order to obtain accurate measurement of 
gene expression, multiple internal control genes were used and the analysis was performed using 
the Qbase software. This software calculates the expression stability of the housekeeping genes in 
different samples. This is based on the principle that the ratio of two housekeeping gene expression 
is identical among all the samples [116]. An increasing variation in the ratio corresponds to 
decreasing expression stability of the housekeeping genes. In addition, the PCR efficiency was also 
determined for each primer and was included in the analysis. Determination of PCR efficiency is 
important for accurate quantification. The PCR efficiency was determined for the different primers 
(LPA1, LPA2, LPA3, RPL, GAPDH and -actin) used in the study by a serial dilution series. 
CDNA obtained from aorta of C57/BL6 mice were diluted to 40 ng, 20 ng, 10 ng, 5 ng and 1 ng. 
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PCR was performed for each primer with the different dilutions of cDNA. The Qbase software 
calculates the PCR efficiency E for each primer based on the formula E=10(-1/slope) and includes it 
in the analysis. The Q base software has the option of analysing the q-RT PCR results by including 
the PCR efficiency for each primer and taking into account multiple reference genes.  
 
Reverse transcription (RT,) table 7: 
SOLUTION VOLUME 
gDNA wipe out buffer, 7x 2µl 
quantiscript reverse transcriptase 1µl 
quantiscript RT buffer, 5x 4µl 
RT primer mix 1µl 
template RNA up to 600 ng 
RNase free water to make up to 20 µl 
 
Real time PCR, table 8: 
SOLUTION VOLUME 
cDNA or water 2 µl 
Quantitect SYBR Green PCR master mix, 2x 12.5 µl 
Quantitect primer assay (containing both 
forward and reverse primers), 10x 2.5 µl 
water 8 µl 
 
Real time PCR program, table 9: 
STEPS TEMPERATURE AND DURATION 
Initial activation 95° C, 15 min 
Denaturation 94° C, 15 sec 
Annealing 55° C, 30 sec 
Extension 72° C, 30 sec 
 
The gene expression of CXCL1, CCL2, CCL5 or CX3CL1 was studied using quantitative real-
time PCR. The PCR was performed in a 7900HT fast real-time PCR system (Applied Biosystems, 
40 
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Darmstadt, Germany). The taqman probe contains a reporter dye at the 5’ end and a nonfluorescent 
quencher at the 3’ end. During the PCR reaction, the probe is cleaved separating the reporter dye 
and the quencher dye. This increases the fluorescence of the reporter. The accumulation of the 
PCR products is detected by monitoring the increase in fluorescence of the reporter dye. 
Total RNA was isolated from PFA-fixed, paraffin embedded aortic root sections or from 
cultured endothelial cells (Recover all total nucleic acid isolation, Ambion and RNeasy micro kit, 
Qiagen, Hilden, Germany) and reverse transcribed (High capacity cDNA reverse transcription kit, 
Applied Biosystems, Foster city, CA) according to the manufacturer’s protocol (refer to table 10 
for more details). The RT reaction consists of the following four steps: 25°C for 10 min, 37°C for 
120 min, 85°C for 5 min and 4°C. Taqman Gene expression assays (Applied Biosystems) were 
performed to quantify CXCL1, CX3CL1, CCL5, or CCL2 expression. GAPDH was used as the 
reference gene (refer to tables 11 and 12 for more details). The relative expression levels were 
normalized to the reference gene and logarithmically transformed (Qbase, Biogazelle). 
 
Reverse transcription, table 10:  
SOLUTION VOLUME 
RT buffer, 10x 2 µl 
dNTP mix (100 mM), 25x 0.8 µl 
RT random primers, 10x 2 µl 
multiscribe reverse transcriptase 1 µl 
RNase inhibitor 1 µl 
nuclease free water 3.2 µl 
RNA (up to 500 ng) 10 µl 
 
Real time PCR, table 11:   
SOLUTION VOLUME 
taqman universal PCR master mix 5 µl 
taqman gene expression assay mix, 20x 0.5 µl 
cDNA diluted in RNase-free water 4.5 µl 
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Real time PCR program, table 12: 
STEPS TEMPERATURE AND DURATION 
UNG activation 
50° C, 2 min 
95° C, 10 min 
Denaturation 95° C, 15 sec 
Annealing/extension 60° C, 1 min 
 
Following transplantation of mice with BM cells expressing LacZ under a SMC-specific 
promoter, successful repopulation was confirmed after 4 weeks. This was performed by 
quantifying the peripheral blood cells for the SM22-LacZ genotype. DNA was isolated from the 
whole blood of the mice which were subjected to BM transplantation, a SM22-LacZ mouse and 
from a C57BL/6 mouse (BioSprint, Qiagen). A standard curve was made using DNA from the 
LacZ and C57BL/6 mice. The percentage of repopulation was quantified using the standard curve. 
The standards were made using LacZ and C57BL/6 mice DNA such that the total concentration of 
DNA used for the PCR was 40 ng. 
 The standards were the following: 
1) 40 ng of LacZ DNA 
2) 20 ng of LacZ DNA + 20 ng of C57BL/6 DNA 
3) 10 ng of LacZ DNA + 30 ng of C57BL/6 DNA 
4) 5 ng of LacZ DNA + 35 ng of C57BL/6 DNA 
5) 2.5 ng of LacZ DNA + 37.5 ng of C57BL/6 DNA 
6) 1 ng of LacZ DNA + 39 ng of C57BL/6 DNA 
Quantitative real-time PCR was performed using SYBR Green (Maxima SYBR Green qPCR 
master mix, Fermentas) in a real time cycler (Opticon, MJ Research) (refer to tables 13 and 14 for 
more details). The LacZ primers were purchased from Sigma-Aldrich. The percentage of LacZ 
genotype in the mice subjected to BM transplantation was calculated using the standard curve 
(Prism, GraphPad).  
 
 
 
 
 
 
40 
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Real time PCR, table 13:  
SOLUTION VOLUME 
SYBR Green master mix 12.5 µl 
nuclease free water 9.5 µl 
each forward and reverse primer 0.5 µl 
cDNA 2 µl 
 
Real time PCR program, table 14: 
STEPS TEMPERATURE AND DURATION 
Initial denaturation 95° C, 10 min 
Denaturation 95° C, 15 sec 
Annealing 63° C, 30 sec 
Extension 72° C, 30 sec 
 
LacZ forward primer - ACGGCAAGCCGTTGCTGATTCG 
LacZ reverse primer – AGCAGGATATCCTGCACCATCG 
 
2.7  Cell culture 
To culture Mono Mac 6 cells, the frozen cells were thawed and 1 ml of cell suspension was 
diluted to 10 ml with culture medium (RPMI 1640, Gibco, L-Glutamine 2 mM, Gibco Penicillin 
200 U/ml and Streptomycin 200 µg/ml, Gibco, non essential amino acids, Gibco, OPI supplement 
containing oxalacetic acid, sodium pyruvate and insulin, Sigma, 10% fetal bovine serum). The 
cells were centrifuged at 300 g for 5 minutes and resuspended in culture medium. Then 10*105 
cells were seeded in a 24 well cell culture plate and cultured overnight. Following this initial step, 
the cells were seeded at a density of 2*105 cells/ml with 2 ml per well in a 24 well plate and 
cultured at 37°C in an incubator with 5% CO2 for 3-4 days before they were used for experiments. 
All the solutions and medium were filter sterilised using a syringe filter (pore size 0.20 µm, 
Corning). 
To isolate endothelial cells (EC), aortas were harvested from C57BL/6 mice and the 
periadventitial fat and connective tissue removed under sterile conditions. The tissue was cut into 
1-2 mm2 sections and cultured in endothelial growth medium (Promocell, Heidelberg, Germany) 
40 
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for 7 days (37°C, 5% CO2) to allow the outgrowth of ECs [117]. Following outgrowth, the tissue 
was removed and the ECs were cultured in endothelial growth medium till the cells were 90% 
confluent. Then the cells were digested using accutase and passaged to new flasks. The medium 
was changed every 2 days. All the solutions and medium were filter sterilised using a syringe filter 
(pore size 0.20 µm, Corning). Lectin (Lycopersicon esculentum; Sigma, Munich, Germany) 
staining was performed to further confirm the EC phenotype. The staining was done by first 
dissolving the FITC-labelled lectin in endothelial growth medium such that the concentration was 
20 µg/ml and the cells were incubated with this for 20 hours. Following incubation, the cells were 
washed with PBS three times for three minutes each. Then the cells were fixed with 4% PFA for 
10 minutes and finally washed with PBS. Sub-confluent ECs (passages 3-5) were cultured in low 
serum medium (2%) and treated with LPA20:4 (10 µM), nLDL (200 µg/ml), or moxLDL (200 
µg/ml) for 1 h with or without Ki16425 (100 µM). 
To isolate BM cells, the femurs and tibias were aseptically removed from donor C57BL/6 mice 
and flushed with 5 ml of Dulbecco’s modified eagle medium (DMEM, PAA). Then the cells were 
disaggregated by pipetting the cells up and down. The cells were then passed through a cell 
strainer (BD falcon, 40 µm) and centrifuged at 300 g for 10 minutes. Then, the cells were counted 
and diluted to 18000 cells/ml in DMEM-F12/10% FCS/10% L929-conditioned medium. The 
mononuclear phagocytic progenitor cells require macrophage colony stimulating factor (M-CSF) 
to differentiate into macrophages. This M-CSF is secreted by L929 cells and hence L929 
conditioned medium was used to supply M-CSF to these cells. 2 ml of cells were seeded to each 
well of a 16 well plate and cultured at 37°C in an incubator for 3 days. Following 3 days, 1 ml of 
the medium was discarded and 1ml of fresh medium was added. On the 7th day the differentiated 
macrophages were harvested for experiments. To confirm the macrophage phenotype, F4/80 
(APC-labelled anti-mouse rat IgG2a, eBiosciences, Frankfurt, Germany) and CD11b (PerCP-
Cy™5.5-labelled anti-mouse rat IgG2b, BD Pharmingen, Heidelberg, Germany) expression was 
determined by flow cytometry (BD FACS Canto II). On the 7th day, the macrophages were 
digested with accutase (500 µl per well) and the cells were collected by centrifuging for 5 minutes 
at 300 g. Cells were incubated with the antibodies, F4/80 (1.5 µg) and CD11b (0.4 µg) for 30 
minutes in the dark on ice. Then they were washed with 3ml of Hanks complete solution (see also 
section 2.3) at 300 g for 5 minutes and the measurements were taken. Appropriate isotype matched 
IgG antibodies were used as negative controls (eBiosciences and BD Pharmingen). The gates were 
set based on the negative controls.  
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2.7.1  Quantification of ATX activity 
ECs were cultured in 24 well plates for 24 hours followed by incubation with a fluorescent 
ATX substrate, FS-3 (3 µM/HBSS, Echelon Biosciences, Salt Lake City, UT) for 3 hours at 37°C. 
FS-3 is a lysophosphatidylcholine analouge that is conjugated with a fluorophor and a quencher 
[118]. FS-3 incubated (3 µM/HBSS) without ECs was used as a control. The fluorescence intensity 
in the medium was detected with a microplate reader (see also section 2.1). All the treatment 
solutions were filter sterilised using a syringe filter (pore size 0.20 µm, Corning). 
 
2.7.2  Preparation of moxLDL 
Human nLDL (1 mg/ml, Calbiochem, Darmstadt, Germany) was mildly oxidised in the 
presence of 5 µM CuSO4 at 37°C for 4 hours. Oxidative modification of LDL was monitored by 
determining the formation of conjugated dienes. This was performed at an optical density of 234 
nm in semi continuous measurements (Nanodrop, see also section 2.1). Further oxidation of the 
moxLDL samples was stopped at the beginning of the propagation phase by the addition of 10 µM 
EDTA (final concentration) [119]. This was followed by washing the LDL with endothelial growth 
medium (serum free) or MOPS buffer (see also section 2.3) over a PD-10 desalting column (GE 
Healthcare, Uppsala, Sweden) [120]. The protein concentration was measured using DC protein 
assay kit (Bio-Rad, Munich, Germany) and the LDL was filtered (0.45 µm). This was stored at 4°C 
for no longer than 14 days. 
 
2.8  Data illustration and statistical analysis 
The data represent means ± SEMs. The data were compared with either an unpaired Student’s t-
test or 1- or 2- way ANOVA, followed by a Newman-Keuls or linear trend post-test when 
appropriate (Prism, GraphPad). The SAS 8.0 software (SAS Institute Inc., Cary, NC) was used to 
perform the ANOVA analysis for the randomized block design. A p-value <0.05 was considered 
significant.  
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3  Results 
3.1  LPA and vascular injury 
3.1.1  LPA receptor expression following vascular injury  
Short-term incubation of the carotid artery with unsaturated LPA induces neointima formation 
even in the absence of vascular injury [5, 105]. To further study the mechanism of LPA-induced 
neointima formation, the expression of the LPA receptors, LPA1 and LPA3 was analysed in 
uninjured and injured carotid arteries.  
 
 
 
Figure 15: Mouse vascular ECs express LPA1 and LPA3 
(A) To determine the specificity of the immunostaining for LPA1 or LPA3, carotid arteries of 
LPA1-/- and LPA3-/- mice were used as negative controls. (see chapter 2.5.5 for details). Scale bar: 
20 m. Nuclei were counterstained with DAPI. The arrows indicate the positive staining. (B) 
Double immunostaining for LPA1 (red) or LPA3 (red) with vWF (green) was performed in 
C57BL/6 mouse carotid arteries (see 2.5.5 for details). Scale bars: 20 m (LPA1) and 50 m 
(LPA3). The arrows indicate co-localisation of LPA1 or LPA3 with vWF.  
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LPA1 and LPA3 immunopositive staining was evident in wild-type mice, whereas no positive 
staining was seen in LPA1-/- and LPA3-/- mice respectively (Fig. 15A). This demonstrates the 
specificity of the LPA1 and LPA3 antibodies. Moreover, LPA1 and LPA3 protein is expressed in 
ECs of uninjured carotid arteries from C57BL/6 mice (Fig. 15A-B).  
 Immunostaining revealed that LPA1 and LPA3 are expressed in the media of uninjured carotid 
arteries in ApoE-/- mice (Fig. 16A-C). In contrast, expression of LPA1 and LPA3 1 week and 2 
weeks following vascular injury was predominantly detectable in the neointima (Fig. 16D-I). 
 
 
Figure 16: LPA receptor expression in uninjured and injured carotid arteries 
The expression of LPA1 (A) and LPA3 (B) was detected in the media of uninjured carotid 
arteries. Neointimal expression of LPA1 (D) and LPA3 (E) 1 week following injury was 
demonstrated by immunostaining (see chapter 2.5.5 for details). Neointimal expression of LPA1 
(G) and LPA3 (H) 2 weeks following vascular injury was demonstrated by immunostaining (see 
chapter 2.5.5 for details). The negative control shows negligible background staining (C, F, I). The 
nuclei are stained with DAPI in blue. Scale bars 100 m (A-F) and 50 m (G-I). 
 
The cells which express LPA1 and LPA3 in the neointima 2 weeks after injury were further 
analysed by double immunostaining for macrophage-specific (Mac-2) or EC (vWF)-specific 
markers and for the LPA receptors. LPA1 was evident in ECs (Fig. 17A), whereas LPA3 was 
primarily expressed in macrophage-derived foam cells (Fig. 17B). 
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 Figure 17: Cell-type specific expression of LPA receptors in the neointima  
(A) At 2 weeks following vascular injury, LPA1 (left) is predominantly co-localised with vWF 
(middle)-positive ECs as demonstrated by double immunostaining for vWF and LPA1 (right, 
overlay) (see chapter 2.5.5 for details). (B) LPA3 (left) is primarily co-localised with Mac-2 
positive (middle) macrophages as shown by double immunostaining for LPA3 and Mac-2 (overlay, 
right) (see chapter 2.5.5 for details). The inset shows an adjacent pentachrome-stained section (see 
chapter 2.5.4 for details). Arrowheads indicate the foam cells. Arrows indicate the neointima and 
stars delineate the lumen. Scale bars 100 m (A) and 50 m (B).  
 
To study the regulation of LPA receptor expression by vascular injury and hyperlipidemia, the 
mRNA expression of the different LPA receptors was quantified 1 and 2 weeks following vascular 
injury. In uninjured ApoE+/+ mice on regular diet (RD), the LPA1 mRNA expression is higher 
compared to both LPA2 and LPA3. The expression of LPA1 is 1.8-times and 2.4-times higher than 
the expression of LPA2 or LPA3, respectively (Fig. 18). Hyperlipidemia reduced the expression of 
LPA2 mRNA, whereas LPA1 and LPA3 mRNA expression was unaltered compared to mice fed a 
RD (Fig. 18). 1 week and 2 weeks following vascular injury, LPA1 mRNA was downregulated. In 
contrast, mRNA expression of LPA2 and LPA3 was up-regulated 1 week following injury (Fig. 18). 
These results show that LPA receptors are differentially regulated by vascular injury and 
hyperlipidemia. The LPA receptors LPA1 and LPA3 are both expressed in the arterial vessel walls 
after wire injury and during hyperlipidemia.  
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Figure 18: Regulation of LPA receptor expression by vascular injury and hyperlipidemia 
The mRNA expression of LPA1, LPA2 and LPA3 in uninjured carotid arteries of ApoE+/+ mice on 
RD is shown in the upper left panel. The effect of HFD and vascular injury on mRNA expression 
of LPA1 (upper right), LPA2 (lower left) and LPA3 (lower right) was studied by quantitative real 
time RT-PCR (see 2.6.2 for details). ‡P<0.05 versus LPA1; *P<0.05 versus ApoE-/- uninjured 
group; **P<0.05 versus both uninjured groups; ¶P<0.05 versus ApoE+/+ uninjured; #P<0.001 
versus both uninjured and 2 week groups; §P<0.001 versus 1 week group. n=3-4 mice. 
 
3.1.2  Blocking LPA1 and LPA3 inhibits the neointimal accumulation of SMCs 
and macrophages 
It has previously been shown that blocking of LPA1 and LPA3 using Ki16425 significantly 
reduces neointima formation following vascular injury in ApoE-/- mice [121]. We further studied 
the effect of Ki16425 on the cellular composition of the neointima following carotid wire injury. 
The mice were injected (IP) daily with Ki16425 (5 mg/kg/day) or control buffer (10% DMSO 
dissolved in PBS) for 3 weeks following injury. The arteries were harvested 1 week after the last 
injection of Ki16425. Treatment with Ki16425 reduced the SMC content in the neointima 
compared to vehicle-treated group, as demonstrated by the reduced -SMA-, SM22- and calponin-
immunopositive area in the neointima (Fig. 19A). In addition, Ki16425 diminished the neointimal 
Mac-2 positive area by 49%, whereas the CD3+ T-cell number was unaltered compared to the 
vehicle-treated group (Fig. 19B-C).  
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Figure 19: Effect of Ki16425 on the cellular composition of the neointima 
(A) Ki16425 reduced the SMC content in the neointima as demonstrated by reduced -SMA, 
SM22 and calponin staining (see chapter 2.5.5 for details). n=4-6 mice. (B) The CD3+ T-cell 
content of the neointima was unaltered by treatment with Ki16425 (see chapter 2.5.5 for details). 
n=4-5 mice. Immunostaining for Mac-2 in control buffer- (C, left) and Ki16425-treated (C, 
middle) mice revealed that Ki16425 significantly reduced the Mac-2-positive area in the neointima 
(C, right) (see chapter 2.5.5 for details). Scale bars: 100 m. *P<0.05. Arrows delineate the 
neointima. n=5-6 mice 
 
Almost complete re-endothelialisation of the injured artery was observed in control buffer- and 
Ki16425-treated mice 28 days following injury as shown by immunostaining for vWF (Fig. 20). 
Therefore, a role of LPA receptors in endothelial recovery is unlikely. In addition, vWF-positive 
cells were absent in the neointima (Fig. 20), indicating that lesional neovascularisation is not 
affected by Ki16425. 
A 
C 
B 
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Figure 20: Effect of Ki16425 on endothelial recovery following vascular injury 
Almost complete re-endothelialisation was evident in both the control buffer- (A, D) and the 
Ki16425-treated (B, E) group, as shown by immunostaining for vWF (see chapter 2.5.5 for 
details). The nuclei were stained with DAPI (D-F) Negligible background fluorescence was seen in 
the negative controls (C). Scale bars: 50 m. The arrows delineate the neointima.  
 
Studies have shown that blocking LPA1 and LPA3 following vascular injury reduces the 
neointimal expression of the transcription factor HIF-1 and of the chemokine CXCL12 [121]. 
HIF-1is upregulated following injury and regulates the neointimal expression of CXCL12 [104]. 
Moreover, the CXCL12/CXCR4 axis plays an important role in neointima formation by inducing 
stem cell-mediated vascular repair following vascular injury [97, 98]. Blocking LPA1 and LPA3 by 
Ki16425 inhibits the injury-induced mobilisation of Sca-1+/lin- SPCs into the circulation [121]. To 
study the role of LPA receptors in neointimal SPC accumulation, we quantified Sca-1/-SMA 
immunopositive cells in the neointima following treatment with Ki16425. We found that blocking 
LPA1 and LPA3 reduced the neointimal accumulation of Sca-1+/-SMA+ cells by 46% (Fig. 21). 
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Figure 21: Role of Ki16425 in the neointimal accumulation of Sca-1+/-SMA+ cells 
(A) The neointimal accumulation of Sca-1+/-SMA+ cells was reduced by treatment with Ki16425 
as determined by double immunostaining for Sca-1 and -SMA (see chapter 2.5.5 for details). 
Representative merged images for Sca-1 (green) and -SMA (red) double staining from control 
buffer (B) and Ki16425 (C) treated mice are shown. The negative control staining shows negligible 
background staining (D). §P<0.05 versus PBS. Scale bars: 50 m. The arrows delineate the 
neointima. n=4-5 mice. 
 
Of note, Ki16425 did not affect serum cholesterol, triglycerides, ALT, and creatinine levels 
(Table.15). 
 
 
 
 
 
 
 
 
 
 
 
Table 15: Serum biochemistry of ApoE-/- mice treated with Ki16425 or vehicle (see chapter 
2.5.7 for details). 
 PBS Ki16425 P value 
Cholesterol 
mmol/L 
13.6 ± 1.1 
N=6 
11.6 ± 1.7 
N=9 
P=0.417 
Triglyceride 
mmol/L 
0.89 ± 0.33 
N=6 
0.82 ± 0.13 
N=9 
P=0.813 
ALT 
U/L 
32.6 ± 8 
N=6 
33.3 ± 7 
N=9 
P=0.951 
Creatinine 
mol/L 
25.1 ± 2.5 
N=6 
22.2 ± 2.4 
N=9 
P=0.434 
A 
B C D 
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Since blocking LPA1 and LPA3 following vascular injury reduced the neointimal accumulation 
of macrophages, the role of LPA in arterial monocyte recruitment was further studied in ex vivo 
perfused carotid arteries using monocytic MM6 cells. Pre-perfusion of the carotid arteries with 
LPA20:4 (40 µM) for 4 h increased the adhesion of monocytes to the endothelium implying a 
direct role of LPA20:4 in atherogenic monocyte recruitment (Fig. 22). Moreover, pre-treatment of 
the MM6 cells with either a blocking CXCR2 or CXCR4 antibody diminished the LPA20:4-
induced monocyte adhesion (Fig. 22). Taken together, these results indicate that blocking LPA1 
and LPA3 following vascular injury may reduce the neointimal accumulation of macrophages via 
impaired monocyte adhesion to the vessel wall. 
 
 
Figure 22: Role of LPA in monocyte adhesion 
The carotid arteries were pre-perfused ex vivo with LPA20:4 (40 M, 3 hours) followed by 
perfusion with MM6 cells. LPA20:4-treatment significantly increased MM6 cell adhesion to the 
vessel wall compared to untreated arteries. This LPA-induced adhesion was inhibited when the 
MM6 cells were pre-treated with blocking antibodies against CXCR4 or CXCR2 prior to perfusion 
(see chapter 2.4.9 for details). *P<0.05, #P<0.05. n=3 mice. 
 
3.1.3  LPA20:4 induces the expression of CXCL12 and HIF-  
The molecular mechanisms of LPA-induced neointima formation were studied after 
endoluminal incubation of carotid arteries from C57BL/6 mice with unsaturated LPA20:4. The 
HIF-1 and CXCL12 protein expression in the vessel wall was quantified by Western analysis or 
ELISA, respectively. Right carotid arteries without LPA incubation were used as controls. HIF-1 
was upregulated as early as 1 day following incubation and remained elevated until day 28 as 
compared to control (Fig. 23A). In addition, CXCL12 was increased in the vessel wall 1 day, 9 
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days, and 28 days after LPA20:4-incubation compared with control (Fig. 23B). Taken together, 
these data suggest that unsaturated LPA20:4 induces prolonged upregulation of HIF-1 and 
CXCL12 in the vessel wall. 
 
 
              
 Figure 23: LPA-induced HIF-1 and CXCL12 expression  
(A) Western blot was performed to quantify HIF-1and the band intensity was normalized to the 
GAPDH signal (representative western blot from 3 independent experiments is shown) (see 
chapter 2.5.3 for details). The numbers represent the ratio of band intensity for each time point. (B) 
The CXCL12 protein in the carotid arteries was quantified by ELISA following endoluminal 
incubation with LPA20:4 (see chapter 2.5.2 for details). *P<0.05 versus control. n=3-5 mice. 
 
To obtain additional evidence for a HIF-1-dependent regulation of CXCL12 expression 
following LPA incubation [104], we studied whether HIF-1 and CXCL12 were expressed in the 
same neointimal cells by double immunostaining. CXCL12 was predominantly expressed in 
neointimal cells with nuclear localisation of HIF-1, indicating increased transcriptional activity of 
HIF-1 in cells that express CXCL12 (Fig. 24).  
 
Figure 24: Cellular co-localisation of HIF-1 and CXCL12 
(A) CXCL12 immunopositive area was evident primarily in the neointimal cells (green). HIF-1 
(B) was detectable in the nucleus of both neointimal and medial cells (red). Overlay shows the 
cellular co-localisation of nuclear HIF-1 and CXCL12 in the neointimal cells (C) (see chapter 
2.5.5 for details). DAPI was used to stain the nuclei. Scale bars: 25 m. Arrows indicate the 
positive staining.  
 
To study the role of LPA-induced CXCL12 expression in the vessel wall on SPC mobilisation, 
CXCL12 was silenced by perivascular application of siRNA during LPA-incubation. Silencing of 
C B 
A B 
A 
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CXCL12 blocked the LPA20:4-induced SPC mobilisation after 24 h and the neointima formation 
after 28 days compared to non-targeting control siRNA (Fig. 25A-B). The arterial expression of 
CXCL12 is essential for LPA20:4-induced SPC mobilisation and neointima formation.  
 
 
 
 
 
Figure 25: Arterial CXCL12 is important for LPA20:4-induced neointima formation 
(A) LPA20:4-induced mobilisation of SPCs 24 hours was blocked by CXCL12-specific siRNA 
(siCXCL12) but not with the non-targeting siRNA (siNT) as shown by flow cytometry (see 
chapter 2.5.1 for details). Control = before LPA20:4 incubation. *P<0.05 versus all other groups. 
n=3-5 mice. (B) Treatment with siCXCL12 reduced the LPA20:4-induced neointima formation as 
compared to siNT treatment. *P<0.05. n=3 mice. 
 
3.1.4  Unsaturated LPA induces SPC mobilisation via LPA1 and/or LPA3  
To study whether LPA1 and LPA3 are involved in LPA-induced mobilisation of SPCs, 
circulating Sca-1+/lin- cells were quantified by flow cytometry after co-incubation of the carotid 
artery with LPA and Ki16425. Endoluminal incubation of the carotid artery with LPA20:4 
increased the mobilisation of SPCs at 1 day compared to PBS (Fig. 26). Co-incubation with the 
LPA1 and LPA3 antagonist Ki16425 prevented the LPA20:4-induced SPC mobilisation (Fig. 26). 
Therefore, LPA20:4 acts via LPA1 and/or LPA3 to induce the mobilisation of SPCs.  
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Figure 26: LPA20:4 acts via LPA1 and LPA3 to induce SPC mobilisation 
Endoluminal incubation of the carotid artery with LPA20:4 induced the mobilisation of Sca-1+/lin- 
cells following 1 day and this was blocked by co-incubation with Ki16425 as shown by flow 
cytometry (see chapter 2.5.1 for details). Control = before LPA20:4 incubation. *P<0.05 versus all 
other groups. n=3-5 mice. 
 
In contrast to LPA20:4, 1AGP18:1 is known to mobilise SPCs 9 days after incubation of the 
carotid artery, suggesting delayed upregulation of HIF-1 and CXCL12. Co-incubation of 
1AGP18:1 with Ki16425 also inhibited the increase of SPCs after 1AGP18:1 treatment (Fig. 27). 
Therefore, the difference between the time courses of the SPC mobilisation following LPA20:4 
and 1AGP18:1 treatment is not due to activation of different LPA receptors. 
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Figure 27: 1AGP18:1 acts via LPA1 and LPA3 to induce SPC mobilisation  
Endoluminal incubation of the carotid artery with 1AGP18:1 induced mobilisation of Sca-1+/lin- 
cells after 9 days. Co-incubation with Ki16425 blocked the 1AGP18:1-induced SPC mobilisation 
after 9 days as determined by flow cytometry (see chapter 2.5.1 for details). Control = before 
1AGP18:1 incubation. *P<0.05 versus all other groups. n=4-5 mice. 
 
3.1.5  LPA induces neointima formation by the recruitment of SPCs 
LPA-induced neointima formation was studied 28 days following incubation. In contrast to 
PBS, LPA20:4 and 1AGP18:1 induced neointima formation in the carotid artery after short-term 
incubation (Fig. 28). This LPA-induced neointima formation was blocked by co-incubation with 
Ki16425 (Fig. 28), indicating that LPA20:4- and 1AGP18:1-induced neointima formation is 
mediated by LPA1 and/or LPA3. 
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Figure 28: LPA20:4 and 1AGP18:1 induce neointima formation via LPA1 and LPA3 
Endoluminal incubation of the carotid artery only with 1AGP18:1 and LPA20:4 induced neointima 
formation following 28 days and this was blocked by co-incubation with Ki16425 (see chapter 
2.5.4 for details). Control = PBS incubation. *P<0.05 versus all other groups. n=4-5 mice. 
 
To study whether LPA-induced neointima formation is associated with recruitment of SPCs, 
whole body irradiated C57BL/6 mice were transplanted with SM22-LacZ+ BM cells. The carotid 
artery was incubated with LPA20:4 and 4 weeks later, neointimal LacZ+ cells were studied by 
TPLSM. Following LPA20:4 incubation, BM-derived LacZ+ SPCs were detected in the neointima, 
whereas co-incubation with Ki16425 greatly reduced neointimal LacZ+ SPCs (Fig. 29A-B). In 
mice with wild-type BM, only negligible background fluorescence was observed in the carotid 
artery (Fig. 29C).  
 
 
 
 
Figure 29: The role of BM-derived SPCs in LPA-induced neointima formation 
(A) 3-D reconstruction of the carotid artery imaged by TPLSM shows LacZ+ cells (green) in 
LPA20:4-induced neointima of mice transplanted with SM22-LacZ BM cells (see chapter 2.5.6 for 
details). (B) The LacZ+ neointimal cells were greatly reduced following co-incubation of LPA20:4 
with Ki16425. (C) Negligible background fluorescence was seen in the untreated carotid artery. 
Blue, second harmonic generation signal of collagen; aquamarine, auto fluorescence of elastin 
bands. Control = PBS. 
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In addition, immunostaining for -galactosidase was performed in chimeric mice with SM22-
LacZ+ BM cells, following LPA20:4-incubation with or without Ki16425. After 4 weeks, -
galactosidase positive cells were detectable in the neointima of LPA20:4-treated arteries (Fig. 
30A). In contrast, no -galactosidase positive cells were detectable in carotid arteries that were 
incubated with LPA20:4 and Ki16425 (Fig. 30B). Negligible background was observed in carotid 
artery sections stained with a non-specific control antibody (Fig. 30C). These results suggest that 
LPA20:4 induces neointima formation by recruiting SPCs from the BM via activation of LPA1 
or/and LPA3 in the vessel wall. 
 
 
Figure 30: LPA20:4-induced recruitment of BM-derived SPCs  
(A) Immunostaining for -galactosidase showed recruitment of BM-derived SPCs to the neointima 
28 days following endoluminal incubation of the carotid artery with LPA20:4. (B) After combined 
incubation with LPA20:4 and Ki16425, no -galactosidase positive cells were detectable in the 
neointima. (C) No specific immunostaining was found using a non-specific control antibody (see 
chapter 2.5.5 for details). The arrows indicate the luminal side of the artery. Scale bars: 25 µm.  
 
3.1.6  LPA20:4-induced SPC mobilisation and neointima formation requires 
LPA1 and LPA3  
To identify which LPA receptor is involved in the LPA-induced SPC mobilisation and 
neointima formation, LPA1 and LPA3 were silenced in the carotid arteries by perivascular 
application of siRNA. Treatment with 4 nmol of LPA1- or 3 nmol of LPA3-specific siRNA reduced 
the LPA1 mRNA expression by 83.9% (n=2-3 mice, P<0.05) and LPA3 mRNA expression by 84% 
(n=2-3 mice, P<0.05) respectively compared to treatment with non-targeting siRNA after 4 days. 
Therefore, 3 nmol of LPA3-specific and 4 nmol of LPA1-, LPA2-specific or of non-targeting 
siRNA was used. Treatment with LPA1- or LPA3-specific siRNA blocked the LPA20:4-induced 
mobilisation of Sca-1+/lin- cells 1 day following incubation compared to non-targeting siRNA 
treatment (Fig. 31A). Following LPA20:4-incubation, the neointimal area was also reduced in the 
LPA1- or LPA3-siRNA treated compared to non-targeting siRNA-treated mice (Fig. 31B). Taken 
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together, these results imply that LPA1 and LPA3 are independently involved in LPA20:4-induced 
neointima formation. 
 
 
 
Figure 31: Role of LPA1 and LPA3 in LPA20:4-induced neointima formation 
(A) Mobilisation of SPCs at 1 day after LPA20:4 incubation was blocked by treatment with LPA1- 
(siLPA1) or LPA3 (siLPA3)-specific siRNA but not with the non-targeting siRNA (siNT) as shown 
by flow cytometry (see chapter 2.5.1 for details). Control = before LPA20:4 incubation. *P<0.05 
versus all other groups. n=4-5 mice. (B) Treatment with siLPA1 or siLPA3 reduced the neointima 
formation 28 d after LPA20:4 incubation as compared to siNT treatment. *P<0.05 versus all other 
groups. n=4-5 mice. 
 
3.2  LPA and atherosclerosis 
3.2.1  MoxLDL-induced monocyte recruitment is mediated by LPA  
We studied the role of LPA in moxLDL-induced monocyte adhesion, because LPA is produced 
following mild oxidation of LDL and triggers monocyte recruitment (section 3.1.2) [10]. In 
contrast to native LDL, pre-treatment of ex vivo perfused carotid arteries with moxLDL increased 
the rolling and adhesion of monocytic MM6 cells to the vessel wall (Fig. 32A-B). Blocking of 
CXCR2 on monocytes or CXCL1 in the vessel wall using neutralizing antibodies reduced the 
moxLDL-induced monocyte rolling and adhesion (Fig. 32A-B). Moreover, blocking the LPA1 and 
LPA3 receptors which are expressed on ECs (as shown in Fig.15) using Ki16425 during moxLDL 
perfusion completely blocked rolling and adhesion of monocytes (Fig. 32A-B). These results 
indicate that moxLDL activates LPA receptors in the vessel wall and releases CXCL1, which 
triggers the rolling and adhesion of monocytes via CXCR2. 
LDL oxidation results in the synthesis of LPC [122] which is a physiological substrate for ATX, 
the enzyme which converts LPC into LPA [1]. To study whether vessel-wall-derived ATX is 
involved in moxLDL-induced monocyte recruitment, carotid arteries were pre-treated with the 
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ATX inhibitor S32826 in addition to moxLDL. S32826 significantly reduced moxLDL-induced 
rolling and adhesion of monocytes (Fig. 32A-B), indicating that ATX generates LPA from 
moxLDL-derived LPC and is essential in moxLDL-induced monocyte recruitment.  
 
 
 
Figure 32: MoxLDL-induced rolling and arrest of monocytic MM6 cell requires CXCL1 and 
the LPA receptors on. 
(A) Mouse carotid arteries were perfused ex vivo with nLDL or moxLDL for 1 h followed by 
perfusion with MM6 cells (see chapter 2.4.9 for details). The rolling of MM6 cells was quantified 
during 10 min of perfusion. *P<0.05 versus moxLDL with or without control Ab, #P<0.05 versus 
vehicle and nLDL. n= 3-4 mice. (B) Mouse carotid arteries were perfused ex vivo with nLDL or 
moxLDL for 1 h followed by perfusion with MM6 cells (see chapter 2.4.9 for details). The 
adhesion of MM6 cells to the vessel wall was quantified during 10 min of perfusion. *P<0.05 
versus moxLDL with or without control Ab, #P<0.05 versus vehicle and nLDL. n= 3-4 mice. 
 
To investigate the role of LPA in moxLDL-induced monocyte adhesion via the CXCL1/CXCR2 
axis, carotid arteries were perfused with LPA20:4 and the monocyte adhesion and rolling were 
studied. Similar to previous results which show that treatment with LPA20:4 (40 M) for 3 h 
induces monocyte arrest in a CXCR2-dependent manner (Fig. 22), treatment with LPA20:4 (10 
M) for 1 h also significantly increased monocyte rolling and adhesion to the vessel wall (Fig. 
33A-B). This reduced concentration of LPA20:4 mimics more closely the LPA levels during 
atherogenesis, whereas wire injury may result in much higher LPA concentrations in the vessel 
wall due to the activation of platelets. The LPA20:4-induced rolling and adhesion of MM6 cells 
was inhibited by blocking either CXCR2 on monocytes or CXCL1 in the vessel wall (Fig. 33A-B). 
LPA20:4 induces monocyte rolling and adhesion to the endothelium via the CXCL1/CXCR2 axis.  
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Figure 33: LPA20:4-induced monocyte rolling and adhesion requires CXCL1 
(A) Mouse carotid arteries were perfused ex vivo with LPA20:4 (10 m) for 1 h followed by 
perfusion with MM6 cells (see chapter 2.4.9 for details). The rolling of MM6 cells was quantified. 
*P<0.05 versus LPA20:4 with or without control Ab, #P<0.05 versus vehicle. n= 2-3 mice. (B) 
Mouse carotid arteries were perfused ex vivo with LPA20:4 (10 m) for 1 h followed by perfusion 
with MM6 cells (see chapter 2.4.9 for details). The adhesion of MM6 cells was quantified. 
*P<0.05 versus LPA20:4 with or without control Ab, #P<0.05 versus vehicle. n=3-4 mice. 
 
Collectively, these results suggest that LPA mediates moxLDL-induced monocyte adhesion and 
rolling via endothelial LPA receptor-mediated release of CXCL1. 
 
3.2.2  LPA20:4 induces the release of endothelial CXCL1  
The mechanism of moxLDL-induced release of CXCL1 from ECs was studied in vitro. 
Blocking the LPA receptors inhibited the secretion and surface immobilisation of CXCL1 
triggered by moxLDL as determined by ELISA (Fig. 34A-B). Therefore, LPA is involved in 
moxLDL-induced secretion and surface deposition of endothelial cell-derived CXCL1. 
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Figure 34: Role of LPA in moxLDL-induced release of CXCL1 from ECs 
(A) Surface deposition of CXCL1 on ECs after stimulation with nLDL (200 μg/ml) or mox-LDL 
(200 μg/ml) was quantified by surface ELISA (see chapter 2.5.2 for details). #P<0.05 versus nLDL 
or vehicle; *P<0.05 versus moxLDL. n=4. (B) Endothelial CXCL1 secretion after stimulation with 
nLDL (200 μg/ml) or moxLDL (200 μg/ml) was quantified in the medium by ELISA (see chapter 
2.5.2 for details). #P<0.01 versus nLDL or vehicle; *P<0.01 versus moxLDL. n=4. 
 
Furthermore, treatment of ECs in vitro with LPA20:4, but not with LPA18:0, upregulated 
CXCL1 mRNA expression after 60 minutes (Fig. 35). This LPA-induced CXCL1 mRNA 
expression was reduced by blocking LPA receptors using Ki16425 (Fig. 35), demonstrating that 
LPA receptors are involved in LPA20:4-mediated upregulation of CXCL1. Taken together, these 
results imply that unsaturated LPA triggers both the acute release of preformed CXCL1 and the 
transcriptional upregulation of CXCL1 resulting in a bi-phasic response of endothelial CXCL1. 
 
 
Figure 35: Unsaturated LPA induces CXCL1 expression 
The CXCL1 mRNA expression was determined by qRT-PCR (see chapter 2.6.2 for details) in 
treated ECs that were treated for 30 or 60 min with LPA20:4 or LPA18:0 (10 μM). In addition, the 
effect of LPA20:4 on endothelial CXCL1 expression was studied in the presence of the LPA 
receptor antagonist Ki16425 (100 μM). #P<0.05 versus LPA18:0; *P<0.05 versus LPA20:4. n=4.  
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To study whether CXCL1 is stored in arterial endothelial cells in vivo, double immunostaining 
for vWF and CXCL1 was performed in normal mouse carotid arteries. Indeed, CXCL1-specific 
immunostaining was evident in vWF-positive ECs (Fig. 36A).  
Chemokines need to be immobilised on the cell surface to effectively induce monocyte 
adhesion [63]. Therefore, the endothelial surface deposition of CXCL1 in carotid arteries upon 
treatment with LPA was studied in vivo using two-photon microscopy. Following perfusion of 
carotid arteries for 1 h with LPA20:4, CXCL1 was detectable by a fluorescently-labelled CXCL1 
Ab on the surface of the ECs (Fig. 36B). In contrast, CXCL1-specific immunostaining on the 
endothelial surface was absent after treatment with control buffer (Fig. 36B). 
 
 
 
 
 
Figure 36: LPA induces deposition of preformed CXCL1 on endothelial surface 
(A) Double immunostaining for CXCL1 and vWF shows the presence of CXCL1 protein in the 
ECs of normal mouse carotid arteries (see chapter 2.5.5 for details). Scale bars: 20 µm. (B) Two-
photon microscopy was performed in mouse carotid arteries, which were perfused ex vivo with 
control buffer or LPA20:4 (10 µM). Using a fluorescently-labelled Ab (red), CXCL1 was detected 
in 3-D reconstructions of the z-stack images (see chapter 2.5.6 for details). Green; elastic laminae, 
blue; collagen. 
 
3.2.3  Expression of LPA1 and LPA3 in atherosclerotic plaques  
The expression of LPA1 mRNA in normal mouse arteries is almost twice as high as LPA2 and 
LPA3 (Fig.18). QRT PCR was performed to study the differential regulation of the LPA receptors 
by hyperlipidemia. Following two months of a HFD, the LPA2 mRNA expression was reduced by 
A 
B 
3 Results 
 
 83
38% in the aorta of ApoE-/- mice as compared to a normal diet (Fig. 37). In contrast, LPA3 
expression increased between 1 month and 2 months of a HFD, whereas the LPA1 mRNA 
expression remained unchanged (Fig. 37). These results demonstrate that the expression of LPA1 
and LPA3 predominate in the aortic wall during hyperlipidemia. 
 
Figure 37: Regulation of LPA receptor expression during hyperlipidemia 
LPA1, LPA2 and LPA3 mRNA expression in the aortas of ApoE-/- mice that were fed a 
normal diet or a HFD for 1 or 2 months was analysed by qRT PCR (see chapter 2.6.2 for 
details). *P<0.05 versus normal diet; #P<0.05 versus 1 month HFD; §P<0.001 for linear 
trend. n=3-4 mice. 
 
To identify the cell types in atherosclerotic plaques that express LPA receptors, double 
immunofluorescence staining was performed. In aortic root lesions of ApoE-/- mice that 
were fed a HFD for 3 months, both Mac-2-positive macrophages and vWF-positive ECs 
expressed LPA1 as well as LPA3 (Fig. 38A-B).  
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Figure 38: Expression of LPA1 and LPA3 in mouse atherosclerotic plaques 
(A) Double immunostaining for Mac-2 and for either LPA1 or LPA3 was performed in aortic root 
sections from ApoE-/- mice on a HFD for 3 months (see chapter 2.5.5 for details). Scale bars: 50 
µm. (B) Double immunostaining for vWF and for either LPA1 or LPA3 was performed in aortic 
root plaques of ApoE-/- mice (see chapter 2.5.5 for details). Scale bars: 20 µm. 
 
To compare the cellular LPA receptor expression between mouse and human atherosclerotic 
plaques, double immunostaining for vWF and either LPA1 or LPA3 was performed in sections 
from human carotid artery plaques (Fig. 39). LPA1 and LPA3 were expressed in vWF-positive 
endothelial cells of human plaques. Moreover, additional cell types in the lesions also expressed 
LPA1 and LPA3. This demonstrates that the LPA receptor expression in lesional endothelial cells is 
similar in mice and humans. 
 
 
 
3 Results 
 
 85
            
 
Figure 39: Expression of LPA1 and LPA3 in human atherosclerotic plaques 
Double immunostaining for vWF and either LPA1 or LPA3 was performed in sections of human 
atherosclerotic plaques from carotid arteries (see chapter 2.5.5 for details). Scale bars: 100 µm. 
Stars indicate the lumen. 
 
3.2.4  LPA induces arterial recruitment of leukocytes via LPA1 and LPA3  
Hyperlipidemia-induced arterial leukocyte adhesion in ApoE-/- mice is inhibited by treatment 
with Ki16425 [123], which preferentially blocks LPA1 and LPA3 [106]. To identify the roles of 
LPA1 and LPA3 in hyperlipidemia-induced leukocyte adhesion independently, LPA receptors were 
silenced. LPA receptor-specific siRNA was applied locally to the carotid artery of ApoE-/- mice 
that were fed a HFD for 4 weeks. The leukocyte adhesion to the carotid artery was analysed 4 d 
after treatment with non-targeting siRNA, LPA1-, LPA2- or LPA3-specific siRNA by intravital 
microscopy. In contrast to the treatment with LPA2-specific siRNA, LPA1- or LPA3-specific 
siRNA reduced the hyperlipidemia-induced leukocyte adhesion to the arterial wall (Fig. 40A). The 
leukocyte adhesion to the vessel wall fully recovered 14 days following LPA1- or LPA3-specific 
siRNA treatment (Fig. 40B). Taken together, these results demonstrate that both LPA1 and LPA3 
mediate independently hyperlipidemia-induced arterial leukocyte adhesion in vivo. 
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Figure 40: LPA1 and LPA3 independently mediate hyperlipidemia-induced leukocyte 
adhesion 
(A) IVM was performed to study leukocyte adhesion to carotid arteries in ApoE-/- mice 4 days 
following treatment with non-targeting siRNA (siNT), LPA1-, LPA2- or LPA3-specific siRNA (see 
chapter 2.4.8 for details). *P<0.05 versus siNT and LPA2-siRNA. n=3-4 mice. (B) Leukocyte 
adhesion in ApoE-/- mice was studied by IVM 14 days after treatment with LPA1-, siNT- or LPA3-
specific siRNA (see chapter 2.4.8 for details). n=3-4 mice.  
 
3.2.5  Unsaturated LPA promotes the progression of atherosclerosis 
The effect of LPA on the progression of atherosclerosis was studied in ApoE-/- mice that were 
fed a HFD by systemic administration of LPA20:4, LPA18:0 or vehicle for 4 weeks. No significant 
differences in the lipid levels were detectable between the three groups (Table.16). Treatment with 
LPA20:4 increased the lipid deposition in the aorta and the plaque area in the aortic root compared 
to vehicle (Fig. 41A-B). This atherogenic effect is most likely due to enhanced recruitment of 
monocytes, since LPA20:4-treatment increased the lesional macrophage number as well as the 
Mac-2-immunopositive area (Fig. 41C). In contrast, LPA18:0 did neither affect the lipid 
deposition, the plaque area nor the plaque macrophage content (Fig. 41A-C). Therefore, only 
unsaturated LPAs, such as LPA20:4, enhance atherogenesis. 
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Figure 41: LPA20:4 induces progression of atherosclerosis 
ApoE-/- mice on a HFD were treated with LPA20:4, LPA18:0 (both 2 nmol/mouse, twice weekly, 
IP) or vehicle (PBS, IP) for 4 weeks. (A) The lipid deposition in the aorta was quantified by Oil 
red O staining (see chapter 2.5.4 for details). *P<0.05 versus all other groups. n=5-6 mice. (B) The 
plaque area in the aortic valve was quantified by EVG staining (see chapter 2.5.4 for details). Scale 
bars: 500 µm. *P<0.05 versus all other groups. n=4-6 mice. (C) The Mac-2-immunopositive area 
and the Mac-2 positive cell number were quantified (see chapter 2.5.5 for details). Scale bars: 100 
µm. *P<0.05 versus all other groups. n=5-7 mice. 
 
 
Table 16: Serum biochemistry of ApoE-/-mice treated with LPA20:4, LPA18:0 or vehicle (see 
chapter 2.5.7 for details). 
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Oxidation of LDL primarily occurs in the vessel wall and not in the circulation [28, 124]. 
Therefore, the local effect of LPA inside the arterial wall on atherogenesis was studied. 
Accelerated plaque formation was induced locally by partial carotid ligation, which acutely 
reduces blood flow velocity and shear stress. In hyperlipidemic mice, partial carotid ligation leads 
to formation of atherosclerotic plaques in the CCA within 6 weeks [107]. 2 weeks after partial 
ligation, carotid arteries were treated with LPA20:4 by weekly perivascular application of pluronic 
gel. This treatment with LPA20:4 increased the plaque size in the carotid artery 4 weeks after 
partial ligation as compared to vehicle (Fig. 42A). This enhanced plaque formation by local 
LPA20:4 applications were associated with increased accumulation of macrophages compared 
with vehicle-treated carotid arteries (Fig. 42B).  
This demonstrates that in addition to circulating LPA, increased levels of unsaturated LPA in 
the vessel wall also promote atherosclerotic plaque progression and the accumulation of 
macrophages. 
 
 
 
 
Figure 42: Increased LPA20:4 in the vessel wall results in increased plaque progression 
Carotid arteries of ApoE-/- mice were treated weekly with LPA20:4 (2 nmol/mouse) or vehicle 
(PBS) by perivascular application following 2 weeks after partial ligation. (A) The plaque area was 
quantified by EVG staining 4 weeks after partial carotid ligation (see chapter 2.5.4 for details). 
*P<0.05. n=3-4 mice. (B) The neointimal Mac-2 immunopositive area was determined 4 weeks 
after partial carotid ligation (see chapter 2.5.5 for details). *P<0.05. n=3-4 mice. 
 
3.2.6  Diet-induced atherosclerosis is suppressed by blocking LPA1 and LPA3 
The role of LPA receptors in diet-induced atherosclerosis was studied by treating ApoE-/- mice 
on HFD with Ki16425 for 3 months by daily injections. Serum biochemistry parameters were 
determined after 3 months of Ki16425 treatment to determine potential adverse effects on renal 
function. The creatinine levels in the serum were not significantly different from vehicle-treated 
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mice (Table.17). Furthermore, chronic Ki16425 application did not affect the cholesterol, 
triglyceride and CRP levels in ApoE-/- mice (Table.17). 
 
Table 17: Serum biochemistry of ApoE-/- mice treated with Ki16425 or vehicle for 3 months 
(see chapter 2.5.7 for details).  
 
Atherosclerosis was quantified in ApoE-/- mice by Oil red O staining of the en face prepared 
thoracoabdominal aorta and in sections of the aortic root by planimetry. Treatment with Ki16425 
reduced the lipid deposition in the aorta by 38% compared to control buffer-treated mice (Fig. 
43A). Accordingly, the plaque area in the aortic root was reduced by 35% in the Ki16425-treated 
mice (Fig. 43B). 
 
 Vehicle Ki16425 P value 
Cholesterol 
(mmol/L) 
18.77±0.80 (n=4) 17.58±1.13 (n=3) 0.41 
Triglycerides 
(mmol/L) 
0.46±0.06 (n=4) 0.48±0.06 (n=3) 0.88 
Creatinine 
(mol/L) 
16.00±1.47 (n=4) 18.00±2.19 (n=4) 0.47 
CRP (mg/L) 1.50±0.86 (n=4) 1.25±1.25 (n=4) 0.87 
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Figure 43: Effect of Ki16425 on diet-induced plaque formation 
ApoE-/- mice on HFD were treated with Ki16425 (5 mg/Kg/day) or vehicle (10% DMSO in PBS) 
for 3 months by daily injections (IP) (see 2.4.3 for details). (A) The lipid deposition in the aorta 
was quantified in the en face prepared thoracoabdominal aorta by Oil red O staining (see chapter 
2.5.4 for details). *P<0.05. n=4 mice. (B) The plaque size in the aortic root was determined in 
sections that were stained with Movats’ pentachrome or EVG (see chapter 2.5.4 for details). 
*P<0.05. Scale bars: 500 µm. n=3 mice. 
 
The effect of Ki16425 on the cellular composition of the atherosclerotic plaques was studied by 
cell-specific immunostainings of aortic root sections. The diminished plaque size in the aortic root 
was associated with a reduced macrophage accumulation in Ki16425-treated as compared to 
vehicle-treated mice, as detected by Mac-2 immunostaining (Fig. 44A). Moreover, the Mac-2-
positive cell number in the plaque was reduced by Ki16425 treatment, indicating impaired 
recruitment of monocytes (Fig. 44A). In contrast, the SMC content of the plaque was unaltered in 
Ki16425-treated as compared to vehicle-treated mice (Fig. 44B).  
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Figure 44: Effect of Ki16425 on macrophage and SMC accumulation in atherosclerotic 
plaques 
ApoE-/- mice on a HFD were treated with Ki16425 (5 mg/Kg/day) or vehicle (10% DMSO in PBS) 
for 3 months by daily injections (IP) (see chapter 2.4.3 for details). (A) The macrophage content in 
the plaque was studied by analysing the Mac-2 immunopositive area and the Mac-2 positive cell 
number (see chapter 2.5.5 for details). Scale bar: 200 µm. *P<0.05. n=3-4 mice. (B) The SMC 
content in the plaque was studied by immunostaining for -SMA (see chapter 2.5.5 for details). 
Scale bar: 200 µm. P=NS. n=4 mice.  
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To study the effect of Ki16425 on CXCL1 expression in atherosclerotic lesions, 
immunostaining for CXCL1 was performed. In Ki16425-treated mice, the CXCL1-
immunopositive area per plaque area was reduced by 35% compared to control buffer-treated mice 
(Fig. 45). 
 
 
 
 
Figure 45: Role of LPA receptors on CXCL1 expression in atherosclerotic plaque 
ApoE-/- mice on a HFD were treated with Ki16425 (5 mg/Kg/day) or vehicle (10% DMSO in PBS) 
for 3 months by daily injections (IP) (see chapter 2.4.3 for details). Immunostaining for CXCL1 
(red) was performed in aortic root sections. The CXCL1-immunopositive area per plaque area was 
quantified (see chapter 2.5.5 for details). Scale bar: 100 µm. n=2-4 mice. *P<0.05.  
 
To assess the effect of Ki16425 on the expression of other chemokines which are known to play 
a role in atherosclerosis, such as CCL2, CCL5, and CX3CL1, quantitative real time RT-PCR was 
performed in plaque samples obtained from ApoE-/- mice on HFD for 3 months. Treatment with 
Ki16425 did not affect the expression of CCL2, CCL5 or CX3CL1 in atherosclerotic lesions 
compared to vehicle (Fig. 46). This indicates that the inhibitory effect of Ki16425 on CXCL1 
expression is rather specific for this chemokine. 
 
Figure 46: Effect of Ki16425 on chemokine expression 
ApoE-/- mice on HFD were treated with Ki16425 (5 mg/Kg/day) or vehicle (10% DMSO in PBS) 
for 3 months by daily injections (IP) (see chapter 2.4.3 for details). The expression of CCL2, 
CCL5 and CX3CL1 in the plaque was studied by qRT-PCR (see chapter 2.6.2 for details). P=NS. 
n=4. 
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To further verify that CXCL1 mediates the pro-atherogenic effects of LPA receptors, the role of 
Ki16425 on atherosclerosis was studied in ApoE-/- mice on HFD in which CXCL1 was inhibited 
by blocking antibody. In mice treated with CXCL1 Ab, the plaque size and the lesional 
macrophage accumulation was not decreased by treatment with Ki16425 as compared to vehicle 
(Fig. 47). This strongly suggests that the anti-atherogenic effects of Ki16425 are mediated by an 
impaired function of CXCL1.  
 
 
 
Figure 47: Effect of Ki16425 on atherosclerotic plaques 
ApoE-/- mice on HFD were treated with CXCL1 Ab (50 g/mouse/twice weekly) with or without 
Ki16425 (5 mg/Kg/day, see chapter 2.4.3 for details). After 4 weeks, the plaque size in the aortic 
root and the lesional macrophage accumulation were studied by EVG staining and Mac-2 
immunostaining, respectively (see chapter 2.5.4 and 2.5.5 for details). n=4-6. P=NS. 
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4.  Discussion 
4.1  LPA receptors: Differential regulation in vascular diseases 
LPA exerts its functions via 7 G protein-coupled receptors [1, 3, 4], of which LPA1, LPA2, and 
LPA3 belong to the EDG family of receptors [7]. LPA1 is highly expressed in rat carotid arteries, 
whereas LPA2 and LPA3 mRNA are not detectable [5]. In contrast to the LPA receptor expression 
profile in rats, we found that the uninjured carotid arteries of C57BL/6 mice express LPA1, LPA2, 
and LPA3 mRNA. Cheng and co-workers reported that the expression of LPA1 mRNA in the 
carotid arteries of C57BL/6 mice is significantly higher than that of LPA2 and LPA3 [6]. Similar to 
this study, we found that LPA1 mRNA expression in the murine carotid artery is approximately 2 
times higher than LPA2 and LPA3 expression. Following carotid ligation, Panchatcharam and co-
workers found that LPA1 and LPA2 are upregulated, and LPA3 remains unaltered [125]. However, 
we found that LPA1 mRNA expression was downregulated and that of LPA2 and LPA3 were 
upregulated 1 week after wire-induced carotid injury. The difference in the injury models used and 
the time point at which the LPA receptor expression was studied could explain the contrasting 
results between our study and the study by Panchatcharam and colleagues [125]. We found 
predominant expression of LPA1 in the endothelial cells and of LPA3 in the macrophages of the 
neointima. The substantial loss of endothelial cells following wire-induced carotid injury could 
explain the reduction of LPA1 mRNA 1 week following injury. Cultured macrophages exhibit high 
expression of LPA2 and LPA3 mRNA [123]. The increase in LPA2 and LPA3 mRNA at 1 week 
after vessel injury might have been due to the macrophage accumulation in the neointima. As 
compared to the expression of LPA1 and LPA2 mRNA 1 week after injury, that at 2 weeks after 
injury was downregulated. 
Previous studies demonstrate that monocytes and macrophages express LPA1, LPA2, and LPA3 
mRNA [123, 126], whereas human umbilical ECs (HUVECS) produce mainly LPA1 and LPA3 
[12]. We detected LPA1 and LPA3 protein expression in the ECs and macrophages of 
atherosclerotic plaques from hyperlipidemic mice. LPA1 and LPA3 proteins were also detected in 
the ECs of human atherosclerotic plaques. In the vessel wall, hyperlipidemia induced 
downregulation of LPA2 mRNA expression, upregulation of LPA3 mRNA expression and no 
change in LPA1 mRNA expression. 
 Regulation of the various LPA receptors in the vessel wall differed between wire-induced 
endothelial denudation, atherosclerosis, hyperlipidemia, and carotid ligation. Our results indicate 
that LPA1 and LPA3 are prominently expressed in the vessel wall in murine atherosclerosis and 
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vascular injury models. The cell-specific expression of LPA receptors in atherosclerotic plaques 
between mice and humans is similar. 
 
4.2   LPA-induced neointima formation via CXCL12 
4.2.1  Role of LPA receptors in neointima formation 
Several reports have shown that uninjured carotid arteries incubated with unsaturated LPA such 
as LPA18:1 or LPA20:4 develop neointimal lesions [5, 105]. Similar to these previous results, we 
found that incubation of mouse carotid arteries with unsaturated LPA20:4 and the LPA analogue 
1-AGP18:1 resulted in neointima formation. This LPA-induced neointima formation was blocked 
by local pharmacological inhibition of LPA1 and LPA3 in the vessel wall. In contrast, neointima 
formation after carotid ligation was increased in LPA1-/- mice [125]. However, this was associated 
with an enhanced migratory activity of LPA1-/- SMCs due to the compensatory upregulation of 
LPA3 [125]. Therefore, increased LPA3 expression might cause aggravated neointimal hyperplasia 
in LPA1-/- mice. 
A further study in LPA1-/- mice showed that treatment of the carotid artery with 1-AGP induces 
neointima formation similar to that of wild-type mice [6]. We found that LPA1 and LPA3 
independently mediated LPA-induced neointima formation, as demonstrated by the silencing of 
LPA1 and LPA3 in the carotid artery. Thus, we avoided the problem of using LPA1-/- mice, which 
overexpress LPA3, and were able to study the effects of LPA1 and LPA3 on neointima formation 
independently.  
Furthermore, LPA receptor knockout mice, except LPA2-/- mice, display phenotypic changes 
which may affect neointima formation [3, 8]. Approximately 50% of LPA1 knockout mice die 
perinatally, and the surviving mice are characterised by reduced body size, reduced brain mass, a 
suckling defect, and craniofacial dysmorphism [3]. The genetic deletion of LPA3 results in delayed 
embryo implantation, altered embryo spacing, and reduced litter size [3, 8]. Although LPA2 
knockout mice do not exhibit any obvious phenotypic changes, a reduction of LPA-induced 
phospholipase C (PLC) activation and Ca2+ mobilisation is evident in embryonic fibroblasts from 
LPA2-/- mice [8]. Therefore, other methods of studying the function of LPA receptors, such as 
pharmacological inhibitors or RNA interference, might be more reliable than involving the use of 
knockout mice. In addition to LPA receptor subtype-specific siRNA, we applied the 
pharmacological inhibitor Ki16425, which selectively inhibits LPA1 and LPA3 with a Ki value of 
0.34 µM and 0.93 µM, respectively [106]. To a lesser extent, Ki16425 also inhibits LPA2 with a Ki 
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value of 6.5 µM [106]. Since LPA1, LPA2, and LPA3 are also expressed on macrophages, the 
effect of Ki16425 on macrophage LPA receptors cannot be excluded [123]. Ki16425 does not alter 
the actions of other receptor agonists such as sphingosine-1-phosphate, 
sphingosylphosphorylcholine, psychosine, 2-arachidonoylglycerol, PAF, lysophosphatidylcholine, 
A1 adenosine receptor agonist, bradykinin, epidermal growth factor, and platelet-derived growth 
factor [106]. Although Ki16425 has a high selectivity towards LPA1 and LPA3, the possibility of it 
binding to other receptors cannot be completely excluded. Ki16425 has been used in previous 
studies for in vivo experiments [127, 128], and our results demonstrated no toxic effects in mice 
treated with Ki16425. Therefore, there is substantial evidence that renders Ki16425 acceptable for 
in vivo experiments.  
Dioctylglycerol pyrophosphate (DGPP) is an LPA receptor antagonist that blocks 
predominantly LPA3 but also LPA1 [129]. In line with our results, LPA-induced neointima 
formation in rats lackingLPA3 expression in the vessel wall is partially blocked by treatment with 
DGPP, indicating that LPA1 is involved in neointima formation [5]. The reason for the partial 
inhibition of neointima formation could be explained by the incomplete inhibition of LPA1 through 
DGPP.  
PPAR- is a nuclear receptor belonging to the nuclear hormone receptor superfamily and 
regulates genes that control cellular differentiation, development, and energy metabolism [130]. 
PPAR- is an intracellular receptor for LPA [130]. In rats, LPA-induced neointima formation is 
blocked by co-incubation with the PPAR antagonist GW9662 [5]. Moreover, 1-AGP-induced 
neointima formation is completely inhibited in conditional PPAR-knockout mice [6]. 
Conversely, treatment of carotid arteries with the PPAR- agonist rosiglitazone causes neointima 
formation similar to that caused by unsaturated LPA [5]. LPA20:4-induced activation of PPAR- 
is partially inhibited by the LPA1/3 antagonist DGPP, suggesting that LPA1/3 may be involved in 
activating PPAR- [5]. Moreover, HIF-1-induced activation of PPAR- is described in cardiac 
hypertrophy, indicating that LPA activates PPAR- by LPA receptor-mediated upregulation of 
HIF-1[131]. Interestingly, treatment with rosiglitazone following balloon injury of carotid 
arteries in rats reduces neointima formation in contrast to 1-AGP [6]. Rosiglitazone has opposite 
effects on neointima formation in uninjured and injured carotid arteries, indicating that the role of 
PPAR- is not directly related to LPA [6]. 
In summary, our results clearly demonstrate that both LPA1 and LPA3 independently mediate 
LPA-induced neointima formation and that pharmacological inhibition of LPA receptors might be 
of therapeutic value in the prevention of neointimal hyperplasia. 
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4.2.2  LPA in neointima formation: Role of SPCs 
BM-derived progenitor cells characterised by the expression of the stem cell marker Sca-1 and 
absence of lineage (lin) markers are increased in the circulation following vascular injury [98]. 
These progenitor cells are recruited to the neointima and differentiate into SMMHC-expressing 
SMCs after systemic injection into mice with carotid injury, suggesting that this population of Sca-
1+/lin- progenitor cells contain SPCs [98]. In a study using mice that were transplanted with BM 
cells that express LacZ, -galactosidase-positive SMCs were detected in the neointima, indicating 
that endogenous SPCs reside in the BM [132]. Following vascular injury, blocking LPA1 and 
LPA3 using Ki16425 inhibits the neointimal expression of CXCL12 and HIF-1, the mobilisation 
of SPCs, and neointima formation [121]. However, it is unclear whether the LPA receptor-
mediated SPC mobilisation leads to SMC accumulation in the neointima. We found that blocking 
LPA1 and LPA3 following vascular injury reduced the neointimal accumulation of SMCs and 
macrophages. Moreover, this SMC population expresses Sca-1, indicating that LPA receptors 
mediate the recruitment of SPCs to the neointima. However, these results do not directly 
demonstrate the role of LPA1 and LPA3 in the recruitment of BM-derived SPCs to the neointima. 
Intraluminal incubation of the carotid artery with LPA20:4 or 1-AGP induced the mobilisation of 
Sca-1+/lin- cells into the circulation and neointima formation via LPA1 and LPA3. Thus, BM-
derived SPCs are recruited to the neointima and differentiate into SMCs. LPA induces SPC 
mobilisation and neointima formation via LPA1 and LPA3.  
 
4.2.3  Role of SPCs in vascular diseases 
The role of SPCs in vascular diseases is a controversial issue. Following mechanical vascular 
injury in female mice transplanted with male BM cells, 44% of the neointimal SMCs were derived 
from the BM [133]. In another study, wire-induced injury of the femoral artery was performed in 
mice that were subjected to BM transplantation with cells that express the LacZ gene. Double 
immunostaining for LacZ and -SMA shows that BM-derived SPCs are recruited to the neointima 
following injury [132].  
The type of vascular injury, for example wire-induced injury, ligation injury, or cuff placement, 
determines the extent of BM-derived SPC recruitment to the neointima. The percentage of 
neointimal cells derived from the BM is the highest following wire-induced vascular injury [134]. 
Conversely, following vascular ligation or cuff placement, only a small number of BM-derived 
SPCs are detected in the neointima [134]. These differences in the extent of neointimal SPC 
recruitment correlates with the degree of injury-induced apoptosis of vascular cells [134]. 
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Furthermore, lesional recruitment of SPCs appears to be infrequent in diet-induced atherosclerosis, 
which might be explained by the low rate of apoptosis in plaque cells as compared to medial cells 
after vascular injury [132, 135]. However, inducing apoptosis of endogenous SPCs that have been 
recruited to atherosclerotic lesions reduces plaque size, indicating that SPCs also play a role in 
diet-induced atherosclerosis [136].  
Several studies also show that neointimal SMCs are not derived from circulating SPCs after 
vascular injury [137-139]. The inability to detect SPC-derived SMCs in the neointima may be due 
to methodological difficulties. Detection of LacZ expression by X-gal staining, for instance, is 
performed in fixed tissues and requires the enzymatic cleavage of X-gal. Overfixation of the tissue 
with paraformaldehyde can result in the inactivity of -galactosidase and thus lead to false-
negative results. We developed a new method to detect BM-derived SMCs in vital, ex vivo-
perfused carotid arteries by TPLSM, which is highly sensitive and reliable. We transplanted BM 
cells from mice that express LacZ under the control of a SMC-specific promoter into wild-type 
mice and studied the -galactosidase activity in the carotid artery 4 weeks after LPA incubation 
using a fluorescent substrate. This technique enables the investigation of -galactosidase activity in 
live, BM-derived SMCs in the vessel wall and avoids false-negative results due to overfixation. 
Moreover, this method avoids the problems related to immunostaining, which might not be 
sufficiently sensitive if the SMC marker expression is low. Thus, we were able to clearly 
demonstrate SMC-specific LacZ activity in BM-derived cells of the LPA-treated vessel wall, i.e. in 
SPCs. This SMC-specific LacZ activity is almost absent if the LPA receptors are blocked, 
demonstrating that LPA treatment induces the neointimal recruitment of SPCs via LPA1 and LPA3. 
Therefore, the extent of neointimal SPC recruitment depends on the type of vascular injury and 
is correlated with the degree of apoptotic vascular cells. Studying the reporter gene expression 
under a SMC-specific promoter is currently the most advanced technique to identify the 
recruitment of SPCs to the neointima. We have convincingly demonstrated that LPA induces the 
recruitment of BM-derived SPCs to the neointima via LPA1 and LPA3.  
 
4.2.4  LPA-induced HIF-1/CXCL12 axis in vascular injury 
The transcription factor HIF-1 is upregulated following vascular injury and regulates the 
expression of CXCL12 in the vessel wall [104]. CXCL12 induces the mobilisation and recruitment 
of BM-derived SPCs to the site of injury, where the SPCs contribute to neointima formation [97, 
98]. HIF-1 silencing following vascular injury reduces the neointimal expression of CXCL12 and 
blocks SPC mobilisation and neointima formation [104]. HIF-1 upregulates CXCL12, which 
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promotes SPC-mediated neointima formation following vascular injury. However, the trigger for 
HIF-1activation following injury is unknown. In this context, 2 separate studies have shown that 
carotid artery incubation with unsaturated LPA induces neointimal hyperplasia containing mostly 
SMCs [5, 105]. Moreover, blocking the LPA receptors LPA1 and LPA3 following vascular injury 
inhibits neointima formation, SPC mobilisation, and neointimal expression of HIF-1 and 
CXCL12, suggesting that LPA may activate the HIF-1/CXCL12 axis following vascular injury, 
resulting in neointima formation [121]. Moreover, the neointimal expression of HIF-1 and 
CXCL12 is elevated 4 weeks following intraluminal incubation of the carotid artery with LPA20:4 
or 1AGP18:1 [121]. However, HIF-1 and CXCL12 need to be upregulated at earlier time points 
in order to induce the recruitment of SPCs to the neointima. Our findings demonstrated that HIF-
1 and CXCL12 were elevated as early as 1 day following intraluminal incubation with LPA20:4. 
Subsequently, the levels of HIF-1 and CXCL12 in the vessel wall remained elevated throughout 
neointima formation. Moreover, we demonstrated that HIF-1 and CXCL12 were co-localised 
within the same neointimal cell, indicating that HIF-1 regulates the expression of CXCL12. 
These results are in line with previous studies and support the concept that LPA activates HIF-1 
to induce CXCL12-mediated SPC recruitment, leading to neointima formation. Mechanistically, 
we showed that the increased CXCL12 expression in the LPA20:4-treated vessel wall was 
responsible for SPC mobilisation and neointima formation, because silencing of CXCL12 in the 
vessel wall prevented the effects of LPA. Furthermore, blocking LPA1 and LPA3 during LPA 
incubation inhibited CXCL12-mediated SPC mobilisation and neointima formation.  
Heterodimer formation of LPA receptors has been shown, including LPA1 with LPA3 [140]. We 
found that selective knockdown of either LPA1 or LPA3 in the vessel wall is sufficient to prevent 
LPA20:4-induced SPC mobilisation and neointima formation, which can be explained by the 
functional interaction of LPA1 with LPA3, for example, as heterodimers [140]. Therefore, blocking 
either one of these LPA receptors is sufficient to inhibit the effects induced by LPA. Moreover, 
activation of a particular receptor heterodimer may lead to a specific signalling pathway compared 
to the activation of monomers. Taken together, LPA acts independently via LPA1 and LPA3 to 
activate the HIF-1/CXCL12 axis that induces the mobilisation and recruitment of SPCs and 
results in neointimal hyperplasia (Fig. 48). 
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Figure 48: LPA-induced HIF-1/CXCL12 axis in neointima formation 
Following vascular injury, unsaturated LPA acts via LPA1 and LPA3 to induce HIF-1-mediated 
CXLC12 expression in medial SMCs. CXCL12 induces the mobilisation of Sca1+/lin- SPCs to the 
circulation and these SPCs are subsequently recruited to the site of injury via the CXCL12 
receptor, CXCR4 (modified according to Schober 2008). 
 
4.2.5  Sources of LPA following vascular injury 
Following vascular injury, LPA can be produced in a number of ways such as from activated 
platelets or apoptotic cells [1, 141, 142]. Soon after vessel injury, platelets bind to the injured 
surface via the platelet-specific receptor glycoprotein 1b and its ligand vWF and are activated 
[143]. LPA is generated in a 2-step process after platelet activation. First, membrane phospholipids 
of the activated platelets are converted to LPLs by the enzymes secretory-type PL-A2 and PS-
specific PLA1 and then, these LPLs are converted to LPA by ATX [1, 142]. In particular, activated 
platelets are an important source of LPA20:4 precursors [144] and may substantially increase the 
concentration of unsaturated LPA in the vessel wall immediately after endothelial denudation. 
Apoptosis leads to the release of microvesicles, which are characterised by the translocation of 
LPA precursors such as PS or PA from the inner to the outer leaflet of the plasma membrane [141, 
145]. This translocation of LPA precursors makes them accessible to enzymes involved in LPA 
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synthesis [141, 145]. For example, PA can be further converted to LPA by PLA1 or PLA2-type 
enzymes [1].  
Following vascular injury, a large proportion of the medial SMCs become apoptotic, and 
apoptotic bodies produced from injured SMCs induce CXCL12 expression in uninjured SMCs 
[97]. Moreover, blocking the apoptosis of medial SMCs after vascular injury reduced the CXCL12 
expression in vivo [97]. Apoptotic microvesicles from medial SMCs might play an important role 
in generating LPA, which in turn mediates the upregulation of CXCL12 by apoptotic SMCs.  
Neointima formation induced by vessel ligation upregulates ATX [125]. ATX hydrolyses LPLs 
to generate LPA and is a major LPA-producing enzyme in the blood [1]. The combined 
upregulation of precursors for LPA and ATX may lead to enhanced LPA generation following 
vascular injury. 
 
4.3  LPA-induced monocyte recruitment via CXCL1 
4.3.1  MoxLDL-derived LPA in monocyte adhesion 
Although LDL plays an essential role in cholesterol transport in the blood, increased levels of 
circulating LDL cholesterol are associated with an increased risk for atherosclerotic cardiovascular 
disease [28, 32, 34]. LDL consists of a core made up of esterified cholesterol and triglycerides that 
are surrounded by a shell of phospholipids, free cholesterol, and apolipoprotein B100 (ApoB100) 
[28]. Accumulation of circulating LDL in the intima via binding of ApoB100 to extracellular 
matrix-derived proteoglycans [146, 147] is important in the initiation of atherogenesis [148]. In the 
sub-endothelium, LDL can be oxidatively modified by myeloperoxidase, lipoxygenases, or 
reactive oxygen species such as HOCl, phenoxyl radical intermediates, or peroxynitrite, which are 
generated in the intima during inflammation [28, 34, 42]. Depending on the degree of oxidation, 
oxidised LDL can be functionally divided into minimally modified LDL (mmLDL)/mildly 
oxidised LDL (moxLDL), and profoundly oxidised LDL (oxLDL) [149]. In addition to oxidation, 
products of other processes such as glycation or desialylation are also called mmLDL [149]. 
Therefore, the effects of mmLDL may differ from that of moxLDL. Similar to LDL, mmLDL and 
moxLDL are recognised by the LDL receptor but not by most of the scavenger receptors [149]. In 
contrast, oxLDL is not recognised by the LDL receptor due to extensive oxidation of the ApoB 
component. However, oxLDL is a ligand for various scavenger receptors, which leads to 
uncontrolled uptake of oxLDL by macrophages [149]. Modified LDL induces the expression of 
various adhesion molecules and cytokines in ECs, which mediates the recruitment of circulating 
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monocytes to the sub-endothelial space [32, 34, 35], a crucial step in early atherogenesis [34, 35]. 
Moreover, LPA is produced during mild oxidation of LDL [5, 10] and has been shown to induce 
monocyte adhesion to the endothelium under static conditions in vitro by increasing the endothelial 
expression of adhesion molecules and chemokines [12, 13].  
According to our results, moxLDL-induced monocyte rolling and adhesion requires endothelial 
LPA receptors and ATX activity, indicating that moxLDL-derived LPA induces monocyte 
adhesion to the endothelium (Fig. 49). Moreover, the presence of ATX activity in the medium of 
cultured endothelial cells has been demonstrated, further suggesting that ATX derived from 
endothelial cells generates LPA from moxLDL [123]. In contrast to blocking the endothelial LPA 
receptors, inhibiting ATX activity did not completely prevent monocyte adhesion, which could be 
due to an insufficient dose of the ATX inhibitor or to LPA derived from a source that does not 
require endothelial ATX activity. Similar to moxLDL, LPA20:4 also promotes monocyte rolling 
and adhesion to the endothelium. In contrast to LPA20:4, LPA18:0 does not promote monocyte 
rolling or adhesion, suggesting that the type of fatty acid chain determines the functional 
differences of LPA species in monocyte adhesion [123].  
CXCL1 is the main chemokine for the VCAM-1-mediated adhesion of monocytes to the 
endothelium of atherosclerotic arteries [61, 150]. Here, we show that the CXCL1/CXCR2 axis 
plays an essential role in monocyte recruitment induced by moxLDL, because blocking endothelial 
CXCL1 or monocyte-specific CXCR2 inhibits moxLDL-induced monocyte rolling and adhesion in 
carotid arteries perfused ex vivo (Fig. 49). Similar to our results, a previous study showed that 
CXCL1 mediates mmLDL-induced monocyte adhesion to cultured endothelial cells under static 
conditions [62]. Our finding that blocking the LPA receptors completely inhibits moxLDL-induced 
monocyte adhesion suggests that the moxLDL-dependent activation of LPA receptors is closely 
linked to the effects of CXCL1 as an adhesion chemokine. Moreover, LPA20:4-induced monocyte 
adhesion is exclusively mediated via the CXCL1/CXCR2 axis, implying that LPA20:4 is crucial 
for moxLDL to induce CXCL1-dependent monocyte arrest. However, the contribution of other 
LPA species such as 1AGP18:1 in inducing CXCL1-mediated monocyte arrest following moxLDL 
treatment cannot be excluded [123]. Other LPA species may promote moxLDL-induced monocyte 
adhesion in a CXCL1-independent manner since blocking CXCL1, in contrast to the inhibition of 
LPA receptors, reduces the monocyte adhesion following moxLDL treatment by only 50%.  
Furthermore, we demonstrated that hyperlipidemia-induced leukocyte adhesion in ApoE-/-mice 
is also mediated by LPA1 and LPA3 expressed in the vessel wall. These findings confirm the 
crucial role of these LPA receptors in monocyte adhesion in a mouse model of atherosclerosis and 
imply that LPA is involved in hyperlipidemia-induced monocyte recruitment. Notably, 
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hyperlipidemia results in enhanced LPA formation likely due to upregulation of ATX [14, 151]. 
Similar to humans, lipoprotein oxidation, especially minimally oxidised LDL, has been 
demonstrated in ApoE-/- mice and causally linked to atherogenesis [152, 153]. Although it is 
unclear whether oxidised LDL is instrumental in hyperlipidemia-induced leukocyte adhesion in 
ApoE-/- mice, our results are compatible with the concept that LPA derived from lipoprotein 
oxidation also determines atherogenic leukocyte recruitment in this mouse model. However, we 
cannot exclude the possibility that other mechanisms of LPA synthesis play a role in 
hyperlipidemia-induced leukocyte adhesion, e.g. increased ATX expression and activity [14, 151]. 
Notably, inhibition of either LPA1 or LPA3 signalling is sufficient to block hyperlipidemia-induced 
leukocyte adhesion, which could be due to the formation of heterodimers between LPA1 and LPA3 
(see section 4.2.4 for details). 
Surface immobilisation via glycosaminoglycans of CXCL1 released from endothelial cells is a 
prerequisite for the efficient adhesion of monocytes [62, 63]. We provide the first evidence for a 
secretagogue effect of LPA on endothelial CXCL1, because blocking the LPA receptors inhibited 
the moxLDL-induced release of CXCL1 from endothelial cells and its subsequent deposition on 
the endothelial surface (Fig. 49). The finding that LPA20:4 induces CXCL1 secretion from 
endothelial cells indicates that LPA20:4 might be involved in moxLDL-induced release of CXCL1 
[123]. Moreover, we demonstrated that LPA20:4 promotes the surface deposition of CXCL1 in 
carotid arteries, which might be due to its enhanced release from endothelial cells. In addition to 
the release of CXCL1 [123], LPA20:4, but not LPA18:0, upregulates CXCL1 mRNA expression 
in endothelial cells. In contrast to the ROCK signalling pathway that mediates only the release of 
CXCL1, activation of NF-B by LPA20:4 induces the expression of CXCL1 in endothelial cells 
[123]. In addition to our results, LPA18:1 has been shown to release pentraxin-3 from endothelial 
cells, resulting in enhanced monocyte migration; however, a role for pentraxin-3 in inducing 
monocyte adhesion has not been reported [154]. 
Although CXCL1 appears to play an essential role in moxLDL-induced monocyte adhesion, 
blocking monocytic CXCR2 results in a more pronounced reduction of monocyte adhesion than 
inhibition of endothelial cell-derived CXCL1, suggesting that other CXCR2 ligands such as 
macrophage migration inhibitory factor (MIF) may also be involved in this process. A role of MIF 
in oxLDL-induced monocyte adhesion to endothelial cells has been described in vitro [155] and 
MIF mediates monocyte adhesion via CXCR2 in ex vivo-perfused carotid arteries of 
hyperlipidemic ApoE-/- mice [156]. Thus, our results would be in agreement with a role of MIF in 
LPA-mediated leukocyte adhesion, because inhibition or silencing of LPA1 and LPA3 completely 
prevented the moxLDL- and hyperlipidemia-induced monocyte adhesion. LPA20:4-induced 
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monocyte adhesion was solely due to the effects of CXCL1 (at least at a low dose of 10 µM), 
indicating that a different LPA species derived from the oxidation of LDL might affect MIF. 
However, currently, there is no evidence to prove a functional interaction of MIF with any LPA 
species. Notably, prolonged treatment (3 h) of carotid arteries with a high dose of LPA20:4 (40 
µM) induces monocyte adhesion also via CXCR4 in addition to CXCR2. This CXCR4-dependent 
monocyte adhesion may be mediated by MIF, since MIF can trigger leukocyte adhesion via 
CXCR4 and CXCR2 [156]. However, such high LPA20:4 concentrations (40 µM) have not been 
observed in vivo during hyperlipidemia, thus it is unlikely that there is a dose-dependent effect of 
this LPA species on MIF-dependent leukocyte adhesion in vivo.  
 
 
 
Figure 49: LPA-induced monocyte recruitment via CXCL1 
LPA generated during mild oxidation of LDL via endothelial cell-derived ATX activates LPA1 and 
LPA3 on ECs. This activation of LPA1 and LPA3 induces the transcriptional upregulation of 
CXCL1 and the release of preformed CXCL1 from the endothelium resulting in monocyte 
adhesion [123]. LPA-lysophosphatidic acid, LPC- lysophosphatidylcholine, moxLDL-mildly 
oxidised LDL. 
 
4.3.2  LPA effects on CXCL1: A 2-phase model 
Our results demonstrate that moxLDL induces CXCL1-dependent monocyte adhesion to the 
endothelium via LPA receptors following short-term treatment (1 h) of the carotid arteries, 
indicating that LPA-dependent release of endothelial CXCL1 may account for moxLDL-induced 
monocyte adhesion. Similarly, LPA20:4 enhances monocyte rolling and adhesion to the 
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endothelium following short-term treatment in a CXCL1-dependent manner [123]. In contrast to 
LPA20:4, monocyte rolling and adhesion is absent following treatment with LPA18:0, indicating 
that only particular LPA species mediate this effect [123]. The presence of pre-formed CXCL1 
protein in endothelial cells could be deduced because short-term treatment (1 h) with LPA20:4 was 
sufficient to induce monocyte adhesion. Accordingly, we detected CXCL1 expression in the ECs 
of normal mouse carotid arteries. Notably, it has been shown that pre-formed CXCL1 is stored in 
non Weibel-Palade body (WPB) secretory vesicles in the ECs [157, 158]. Further evidence for the 
release of endothelial CXCL1 by LPA was obtained from in vitro experiments: both LPA20:4 
[123] and moxLDL induced the release of CXCL1 via LPA1 and LPA3 from cultured endothelial 
cells following short-term treatment. Furthermore, we clearly demonstrated the endothelial surface 
deposition of CXCL1 following stimulation of the carotid artery with LPA20:4. Therefore, this 
LPA20:4-induced release of CXCL1 accounts for an immediate response of the endothelial cells, 
resulting in monocyte adhesion.  
In addition to releasing pre-formed CXCL1, LPA can also upregulate CXCL1 mRNA 
expression. We showed that treatment of cultured ECs with LPA20:4 induced CXCL1 mRNA 
expression in a LPA1- and LPA3-dependent manner, whereas LPA18:0 did not affectCXCL1 
mRNA expression. Furthermore, a sustained effect of LPA20:4 on CXCL1-mediated leukocyte 
adhesion was observed in vivo even 3 days following treatment, although plasma LPA levels were 
not increased at this time, indicating that a transient rise in LPA20:4 after injection triggers a long-
term response, for instance by enhancing CXCL1 mRNA expression [123]. Moreover, reduced 
expression of CXCL1 in the plaque following LPA receptor antagonist treatment may be due to 
impaired CXCL1 transcription. Therefore, we postulate that LPA exerts a 2-phase response of 
CXCL1, including the acute release of pre-formed CXCL1 and a more chronic upregulation of 
CXCL1 mRNA expression. This 2-phase model might explain the profound and long-lasting effect 
of even trace amounts of LPA in inducing monocyte recruitment.  
 
4.3.3  Role of LPA and LPA receptors in atherosclerosis 
Via G protein-coupled LPA receptors, LPA promotes various biological processes associated 
with atherosclerosis [159]. For example, LPA induces the expression of chemoattractants and 
adhesion molecules such as CCL2, IL8, ICAM-1, VCAM-1, and E-selectin in cultured endothelial 
cells, resulting in enhanced monocyte adhesion under static conditions [12, 13, 160, 161]. In 
SMCs, LPA mediates moxLDL-induced CCL20 expression, which is increased in the circulation 
of patients with atherosclerosis [162] and induces a synthetic phenotype characterised by reduced 
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expression of contractile proteins and an increased proliferation rate [163]. Furthermore, LPA is 
responsible for the activation of monocytes, platelets, and endothelial cells by modified LDL [10, 
164]. Despite these atherogenic properties in vitro, the role of LPA and LPA receptors in 
atherosclerotic plaque development has not been studied. 
To our knowledge, this is the first report providing evidence for the role of LPA receptors in 
atherosclerosis. According to our results, pharmacological inhibition of LPA1 and LPA3 reduces 
hyperlipidemia-induced plaque formation. This effect of the LPA receptor antagonist, which is 
highly specific for LPA1 and LPA3, suggests that these 2 LPA receptors play an important role in 
plaque formation [106]. In contrast to diet-induced atherosclerosis, enhanced plaque formation was 
observed after carotid ligation in LPA1-/- mice [125]. Furthermore, combined LPA1 and LPA2 
deficiency partially prevented ligation-induced lesion development, whereas genetic deletion of 
only LPA2 was ineffective [125]. Carotid ligation is primarily characterised by vascular 
remodelling due to the response of SMCs to the cessation of flow but not by macrophage 
accumulation as in diet-induced atherosclerosis [165]. Therefore, the underlying mechanisms of 
lesion formation are fundamentally different between these 2 animal models, and the effects of 
targeting LPA receptors cannot be compared. Accordingly, increased lesion formation in LPA1-
deficient mice has been attributed to the enhanced migration of SMCs due to the overexpression of 
LPA3 [125]. Our finding that the LPA receptor antagonist reduced the macrophage cell number in 
the plaque likely accounts for the diminished plaque size. The plaque macrophage content is 
primarily determined by the recruitment of circulating monocytes [166]. Our finding that 
endothelial LPA1 and LPA3 are crucial for atherogenic monocyte adhesion (See Section 4.3.1 for 
details), the first step in the recruitment of monocytes, implies that blocking LPA receptors reduces 
atherosclerosis via diminished monocyte recruitment. LPA receptor-mediated monocyte adhesion 
depends on the release of CXCL1 from the endothelium (See section 4.3.1 for details). In 
agreement with a prominent role of LPA receptor-mediated monocyte adhesion in plaque 
formation, we found that inhibiting LPA receptors reduced CXCL1 expression in the plaque and 
blocking CXCL1 offset the effect of the LPA receptor antagonist in atherogenesis. Moreover, the 
expression of other chemokines such as CX3CL1, CCL2, and CCL5, known to be involved in 
monocyte accumulation in plaques, was not affected by blocking LPA1 and LPA3. Of note, we 
demonstrate LPA1 and LPA3 expression in endothelial cells of mouse and human atherosclerotic 
plaques indicating that LPA receptor-mediated atherogenic monocyte recruitment also occurs in 
humans. In contrast, we have no evidence for a crucial role for endothelial LPA2 in atherosclerosis 
because suppression of LPA2 in the vessel wall does not affect atherogenic leukocyte adhesion, 
and hyperlipidemia downregulates LPA2 in the aorta. However, we cannot exclude the possibility 
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that LPA2, which is highly expressed in macrophages, also contributes to plaque development 
[123]. In addition to establishing an important role of LPA1 and LPA3, the effects of the LPA 
receptor antagonist on atherosclerosis also implies that LPA generated during hyperlipidemia 
promotes plaque formation.  
Further evidence for the role of LPA in plaque development was obtained by LPA treatment. In 
line with the results of the LPA receptor antagonist, LPA20:4 enhanced plaque formation and 
monocyte recruitment. However, LPA18:0 did not affect atherosclerosis, demonstrating that pro-
atherogenic effects depend on the LPA species. Similar to the effects of LPA receptors, treatment 
with LPA20:4 induces leukocyte adhesion to the endothelium in a CXCL1-dependent manner, 
indicating that LPA-dependent monocyte recruitment is also instrumental in LPA20:4-induced 
plaque formation [123]. Although the endothelium appearsto be the main source of CXCL1 in 
LPA-induced monocyte recruitment following LPA injection, activated platelets may be an 
additional source of CXCL1 contributing to plaque formation [167, 168]. We showed that 
enhanced monocyte recruitment plays a prominent role in LPA-induced plaque formation. 
Alternatively, LPA inhibits reverse transendothelial migration of monocyte-derived cells in vitro, 
indicating that LPA enhances macrophage retention within the plaque [169]. However, the role of 
macrophage emigration in lesion regression is under debate [169, 170]. 
LPA accumulates in atherosclerotic plaques and progressively increases during lesion 
development, suggesting that vessel-derived LPA plays an important role in atherogenesis [10, 
171]. Similar to the results obtained after LPA injection, treatment of the carotid artery with 
LPA20:4 promoted atherosclerotic lesion development by enhanced macrophage accumulation, 
indicating that LPA directly acts on the vessel wall cells to enhance atherogenesis. The mechanism 
of macrophage accumulation induced by vessel wall-derived LPA appears to be similar to that 
induced by circulating LPA, because local treatment with LPA20:4, like injection of LPA20:4, 
promotes leukocyte adhesion to the endothelium in a CXCL1-dependent manner [123]. Thus, we 
could prove the pro-atherogenic function of vessel wall-derived LPA. However, the 
atherosclerosis-promoting effect of increased circulating LPA levels observed following systemic 
LPA injection might also be involved in human atherogenesis, as plasma LPA levels are elevated 
during hypercholesterolemia (Dohi, Miyauchi et al. 2012). Moreover, the formation of LPA 
through LDL oxidation may also occur in the circulation because plasma concentrations of oxLDL 
are elevated during atherosclerosis [172]. Taken together, we showed that both vessel wall-derived 
and circulating LPAs can be pro-atherogenic; however, further studies are required to determine 
the relative contribution of LPA from different origins to atherosclerosis.  
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4.3.4  The sources of LPA in atherosclerosis 
Various studies from different groups have demonstrated that LPA is generated during mild 
oxidation of LDL [5, 10]. Initially, it was reported that the total LPA level increases after copper-
mediated (640 µmol/L, 20 h copper treatment) or spontaneous oxidation of LDL and mediates 
moxLDL-induced platelet activation [10]. A following study demonstrated that the alkyl ether 
analogues of LPA but not the acyl LPA species are selectively increased in moxLDL compared to 
nLDL [5]. In contrast, very mild oxidation of LDL (100 µmol/L, 4 h copper treatment) does not 
result in LPA generation but increases the LPC content [123]. Although these differences might be 
explained by a varying degree of LDL oxidation, the precise mechanism by which LPA is 
produced during oxidation of LDL is unclear. LDL oxidation generates oxidised 
phosphatidylcholine, which is effectively converted by the lipoprotein-associated phospholipase 
A2 into LPC [122]. LDL-derived ATX activity may be postulated from the above mentioned 
finding that LPA is generated during LDL oxidation in the absence of exogenous ATX activity [5, 
10]. Our data strongly suggest that moxLDL-derived LPC can also be converted to LPA, for 
example, via ATX derived from endothelial cells because moxLDL-induced monocyte adhesion 
was inhibited by blocking the endothelial ATX activity in carotid arteries perfused ex vivo. In 
agreement, LPC-induced lymphocyte adhesion to ECs requires the expression and secretion of 
ATX, indicating that LPA mediates the effects of LPC on lymphocyte adhesion [173]. 
Furthermore, endothelial cell-derived ATX has been linked to lymphocyte homing to lymph nodes 
[174]. 
Therefore, we propose a 2-step process of LPA generation from oxidised LDL, where PLA2 
produces LPC which is further converted to LPA by ATX. This mechanism of LPA synthesis from 
oxidised LDL might be a significant source of LPA during atherogenesis. Hyperlipidemia 
increases the plasma LPC levels, followed by its accumulation in the aorta and serum ATX activity 
[14, 175]. The accumulation of LPC during plaque formation precedes the increase of LPA [171]. 
In addition, ATX is expressed in vascular lesions and may convert LPC to LPA in developing 
atherosclerotic plaques [125]. 
Although LDL is believed to be protected from oxidation in the plasma, owing to the presence 
of antioxidants, several animal and human studies describe increased plasma concentrations of 
oxLDL during atherosclerosis, indicating that LDL is either oxidised in the circulation or that 
oxLDL generated in the vessel wall leaks into the circulation [172, 176, 177]. In humans, plasma 
LPA levels are positively correlated with LPC, ATX, and LDL levels, indicating that LPA may 
also be generated from oxidised LDL in the circulation [178]. LPA levels in the circulation are 
further elevated in patients with acute coronary syndrome, which may be due to the activation of 
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platelets [178]. Platelets play an important role in atherogenesis, and activated platelets are a 
source for LPA; therefore, activated platelets may additionally contribute to LPA generation 
during atherosclerosis [1]. However, the role of platelet-derived LPA in plaque formation remains 
to be determined.  
 
4.3.5  Role of CXCL1 in atherosclerosis 
Chemokines play an important role in leukocyte recruitment during atherogenesis [179]. This 
monocyte recruitment is crucial for the accumulation of lesional macrophages through different 
stages of atheroma formation [170, 180].  
Studies have shown that genetic deletion of the CC chemokine CCL2 or its receptor CCR2 
reduces atherosclerosis due to reduced macrophage accumulation, suggesting that the CCL2/CCR2 
axis may induce monocyte recruitment during atherosclerosis [181-183]. In addition, CCL2 and 
CCR2 are increased in SMCs and monocytes during hyperlipidemia [184, 185]. Moreover, CCL2 
and CXCL1 work together in promoting monocyte recruitment via an inflamed endothelium [63]. 
CXCL1 is immobilised on the endothelial surface and induces monocyte adhesion via CXCR2, 
whereas CCL2 is secreted in a soluble form and contributes to monocyte shape change, spreading, 
and trans-endothelial migration via CCR2 [63]. In addition, the CCL2/CCR2 axis is involved in 
monocyte homeostasis and hyperlipidemia-induced monocytosis, as demonstrated in CCR2 and 
CCL2-deficient mice [186]. Therefore, the pro-atherogenic role of the CCL2/CCR2 axis can be 
addressed both to monocyte mobilisation during hyperlipidemia and to increased monocyte 
recruitment. 
Genetic deletion of the CCL5 receptor CCR5 impairs atherosclerotic plaque formation and 
produces a more stable plaque phenotype with reduced macrophages/T cells and increased SMC 
accumulation [187]. Platelet-derived CCL5 and CXCL4 can be deposited and immobilised on the 
activated endothelium or lesions, resulting in enhanced monocyte recruitment [188, 189]. 
However, the effects of platelet-derived chemokines such as CCL5 and CXCL4 may not be 
functional during the initial stages of plaque development, where platelet activation is sparse. 
Moreover, blocking CCL5 using an antagonist inhibits the progression of established 
atherosclerotic lesions by blocking the recruitment of leukocytes to the plaque [190].  
Furthermore, genetic deletion of the CX3CL1 receptor CX3CR1 inhibits atherosclerotic lesion 
development [191]. CX3CL1 induces monocyte and T cell arrest to the endothelium via CX3CR1 
in an integrin-dependent manner [192]. Most importantly, the CX3CL1/CX3CR1 interaction is 
essential for the survival of monocytes and macrophages within the plaque [193]. In humans, 
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polymorphisms in the CX3CR1 gene have been identified as a risk factor for coronary artery 
disease and atherosclerosis [194, 195].  
Combined inhibition of CCL2, CX3CR1, and CCR5 almost completely inhibits atherosclerosis 
in ApoE-/- mice, which is attributed to declined levels of circulating monocytes [196]. In contrast 
to CCL2 deficiency, which reduces the levels of both the Ly6Chi (inflammatory subtype) and 
Ly6Clo (non-inflammatory subtype) monocyte subsets in the circulation, the absence of CX3CR1 
only reduces the Ly6Clo subset, suggesting that CCL2 and CX3CR1 limit plaque formation by 
reducing different monocyte subsets in the circulation [196]. Alternatively, increased apoptosis of 
plaque cells due to the absence of CX3CR1 signalling may also account for the reduced plaque size 
in CX3CR1-deficient mice [193]. Moreover, the combined inhibition of CCL2, CX3CR1, and 
CCR5 axes results in an even more profound reduction of Ly6Chi and Ly6Clo monocyte subsets 
than in CCL2 and CX3CR1-deficient mice, further suggesting that the reduced plaque size is due to 
the declined number of circulating monocytes [196]. Of note, Ly6Chi monocytes require CCR2 and 
CX3CR1 whereas the Ly6Clo monocytes require CCR5 for plaque entry, indicating that reduced 
monocyte entry into the plaque may additionally account for the abrogated atherosclerotic lesion 
development in CCL2/CX3CR1-deficient mice treated with a CCR5 antagonist [197]. Therefore, 
the study by Combadiere and co-workers demonstrates an additive effect on the inhibition of 
atherosclerosis compared to the studies where only one of the chemokine axes is blocked, 
suggesting that the contribution of each chemokine to plaque formation is distinct and not 
redundant [181, 187, 191]. Although combined inhibition of the CCL2, CX3CR1, and CCR5 axes 
almost completely abolishes plaque formation, the essential role of CXCL1, which induces 
leukocyte arrest to the endothelium, in atherogenesis cannot be overlooked [61, 196]. It is possible 
to envision that CXCL1-induced monocyte adhesion is no longer essential for plaque development 
if circulating monocytes are greatly reduced, as seen in CCL2/CX3CR1-deficient mice treated with 
a CCR5 antagonist [196]. We showed that CXCL1 is crucial for LPA-induced plaque development 
because blocking CXCL1 abolished the atheroprotective effect of the LPA receptor antagonist. 
Furthermore, pharmacological inhibition of LPA1 and LPA3 did not only impair plaque formation 
but also reduced, in contrast to CCL2, CCL5, and CX3CL1, the lesional expression of CXCL1. 
The pro-atherogenic effect of CXCL1 appears to be more important in early atherosclerosis, 
because inhibition of CXCL1 in mice with advanced lesion formation was not associated with a 
regression of atherosclerosis, although there was a tendency towards impaired lesion progression 
[156]. 
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4.4  Saturated versus unsaturated LPA in vascular diseases 
Hypercholesterolemia is associated with increased serum levels of LPC and ATX activity [14]. 
ATX exhibits a substrate specificity for unsaturated over saturated LPC in hypercholesterolemic 
rabbits [14]. In contrast to saturated LPA, incubation of carotid arteries with unsaturated LPA 
induces neointima formation even in the absence of injury [5, 105]. Among a variety of 
unsaturated LPAs, LPA20:4 and 1AGP18:1 are most effective in stimulating neointimal growth 
[5]. Moreover, unsaturated LPA but not saturated LPA switches the phenotype of VSMCs from a 
differentiated to a dedifferentiated state, which is involved in atherosclerosis [163], and induces the 
activation of atheroprotective PPAR- in vitro [5].  
Taken together, these studies suggest that only unsaturated LPA plays an important role in 
vascular diseases. We found that preferentially unsaturated LPA20:4 and 1AGP18:1 induced the 
HIF-1-mediated CXCL12/CXCR4 axis, resulting in SPC mobilisation and neointima formation. 
However, this HIF-1-mediated SPC recruitment was not observed when the arteries were treated 
with saturated LPA18:0 [121]. In contrast to LPA18:0, LPA20:4 induces monocyte adhesion and 
rolling via the CXCL1/CXCR2 axis [123]. Moreover, treatment of hyperlipidemic mice with 
LPA20:4 induced the progression of atherosclerosis, whereas LPA18:0 did not have any effect on 
plaque progression.  
One reason for the differential effects of the various LPA species may be due to differences in 
receptor specificity towards unsaturated and saturated LPA [198]. For instance, LPA3 shows a 
higher affinity towards unsaturated LPA than saturated LPA, whereas LPA1 and LPA2 have broad 
ligand specificity [198]. However, our finding that both LPA1 and LPA3 mediate LPA-induced 
neointima formation and monocyte adhesion makes LPA receptor specificity towards different 
LPA species an unlikely explanation for the exclusive effects of unsaturated LPA. Compared to 
saturated fatty acids, unsaturated fatty acid chains are more susceptible to oxidation, and this may 
influence the receptor-binding properties of various LPA species. Unfortunately, the level of 
oxidation in saturated and unsaturated LPA is currently unknown. Further studies are required to 
accurately determine the underlying cause for the atherogenic properties of unsaturated LPA. 
 
4.5  Dual roles of LPA in vascular diseases 
The current study demonstrates that LPA plays a crucial role in 2 distinct disease mechanisms 
of vascular lesion formation. In neointima formation, which is characterised by the accumulation 
of SMCs, LPA induces SPC recruitment by upregulating CXCL12 in SMCs. However, in 
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macrophage-rich atherosclerotic lesion formation, LPA recruits monocytes via endothelial 
CXCL1.  
Our results suggest that the concentration of LPA shapes the type of vascular response because, 
in contrast to high LPA concentrations (40 µM), low levels of LPA (10 µM) did not affect SMC 
accumulation in vascular lesions. Both platelet activation and apoptosis of SMCs after vascular 
injury may transiently lead to an exceptionally high local LPA concentration in the vessel wall that 
triggers the CXCL12-induced SPC mobilisation, similar to incubation of the carotid artery with 40 
µM LPA. However, high as well as low LPA levels increase the adhesion of monocytes in arteries 
perfused ex vivo, indicating that high LPA concentrations can also promote monocyte recruitment.  
Alternatively, cell type-specific effects on endothelial cells and SMCs may underlie the dual 
role of LPA in vascular diseases. During carotid incubation, LPA has been shown to enter the 
vessel wall and to localise in the media [105]. In addition, endothelial denudation after vascular 
injury allows direct access of LPA to medial SMCs. Therefore, LPA may induce a SMC-specific 
response after vascular injury that is characterised by CXCL12-mediated recruitment of SPCs. 
During atherogenesis, our results showed that LPA mediates adhesion of monocytes via CXCL1, 
which is stored in endothelial cells [157].  
Of note, the differential effects of LPA in the vasculature are not because of the activation of 
different LPA receptors. In fact, we found that the effects of LPA on both CXCL12-mediated SPC 
recruitment and CXCL1-dependent atherogenesis can be prevented by silencing LPA1 or LPA3. 
Therefore, drugs that inhibit either LPA1 or LPA3 might be a promising for the treatment and 
prevention of both atherosclerosis and restenosis. The LPA1 antagonist AM152 has been tested in 
phase 1/2 clinical trials for the treatment of idiopathic pulmonary fibrosis; unfortunately, no results 
of these trials are available [199]. In principle, drugs targeting the LPA receptors can be 
administered via drug-eluting stents, to inhibit restenosis or systemically to treat atherosclerosis. 
Additionally, the enzymes critically involved in LPA synthesis are attractive therapeutic targets in 
vascular diseases. Currently, the lipoprotein-associated phospholipase A2 inhibitor darapladib is 
being investigated in phase 3 trials for its effect in atherosclerotic cardiovascular disease [200]. 
Further studies are required to establish the clinical value of drugs that target LPA receptors or 
LPA synthesis in the treatment of cardiovascular diseases.  
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5  Summary  
LPA and vascular diseases 
The CXCL12/CXCR4 axis directs the SPC mediated vascular repair following injury [97-99]. 
The mechanism that induces CXCL12 following vessel injury and thus leads to neointima 
formation through SPC recruitment was unknown. Of note, short-term incubation of uninjured 
carotid arteries with unsaturated LPA, which is produced upon platelet activation, results in intimal 
SMC accumulation [5, 105, 201]. Furthermore, unsaturated LPA induces CXCL12 expression in a 
LPA1- and LPA3-dependent manner in vitro [15]. Following vascular injury, blocking LPA1 and 
LPA3 inhibits the mobilisation of SPC, neointima formation and neointimal expression of HIF-1 
and CXCL12 [121]. Moreover, blocking CXCR4 suppressed LPA-induced neointima formation 
[121]. LPA may activate the CXCL12/CXCR4 axis resulting in SPC-mediated neointima 
formation. However, there is no direct evidence which shows that LPA induces neointima 
formation by the recruitment of BM-derived SPCs. In addition, it is not known whether LPA1 and 
LPA3 have differential functions in LPA-induced neointima formation.  
LPA receptor expression was differentially regulated following vascular injury. LPA1, which 
was primarily detectable in ECs, was reduced, whereas LPA2 and LPA3 were transiently increased, 
e.g. macrophages. Blocking LPA1 and LPA3 following injury reduced the neointimal SMCs, which 
express the stem cell marker Sca-1 and macrophage content with no difference in the T-cell 
content and re-endothelialisation. This suggests that LPA promotes neointima formation by the 
recruitment of SPCs. Of note short-term incubation with unsaturated LPA induces a sustained 
upregulation of HIF-1 together with CXCL12 in neointimal cells. Knockdown of LPA-induced 
CXCL12 expression in the vessel wall blocked the SPC mobilisation and neointima formation. 
This indicates that LPA activates the HIF-1/CXCL12 axis and thus SPC-mediated vascular 
repair. Furthermore, the mobilisation of SPCs and the neointima formation following incubation 
with unsaturated LPA was inhibited by blocking LPA1 and LPA3. This provides additional 
evidence that the effect of blocking LPA1 and LPA3 on neointima formation after vascular injury is 
due to a reduced SPC recruitment. In mice, which express a SMC-specific reporter gene only in 
BM cells, reporter gene activity was found in neointimal cells following LPA incubation. Blocking 
LPA1 and LPA3 during LPA incubation inhibited the recruitment of BM-derived cells which 
express the SMC-specific reporter gene. This clearly demonstrates that LPA via LPA1 and/or LPA3 
promotes neointima formation by the recruitment of BM-derived SPCs. Silencing of each of the 
LPA receptors, LPA1 and LPA3, in the vessel wall blocked LPA-induced SPC mobilisation and 
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neointima formation. LPA-induced SPC recruitment and neointima formation can be mediated 
independently by either LPA1 or LPA3. Although the LPA-mediated recruitment of SPCs explains 
the reduced neointimal SMC content after blocking LPA1 and LPA3, it remains unclear how LPA 
is involved in the accumulation of macrophages.  
Lesional macrophages are derived from circulating monocytes, which are recruited into the 
vessel wall via activated ECs. LDL that is modified in the sub-endothelial space plays a central 
role in the proatherogenic activation of ECs by inducing CXCL1 [34, 62]. Noteworthy, mild 
oxidation of LDL leads to the synthesis of LPA and high concentrations of LPA is present in the 
core of the atherosclerotic lesions [10]. Moreover, LPA induces the adhesion of monocytes to ECs 
by increasing the expression of endothelial chemokines and adhesion molecules [12, 13]. 
Therefore, LPA1 and LPA3 may mediate monocyte recruitment that is induced by modified LDL-
derived LPA. We studied the role of LPA in modified LDL-induced monocyte recruitment and 
atherosclerosis.  
Ex vivo perfusion experiments of the carotid artery revealed that moxLDL increases monocyte 
adhesion to the endothelium via CXCL1, which is mediated by endothelial LPA1 and LPA3 and 
requires the release of ATX from ECs. Accordingly, the moxLDL-induced surface expression and 
secretion of CXCL1 from ECs is mediated by LPA1 and LPA3. This indicates that LPA is of 
crucial importance in the moxLDL-induced monocyte adhesion. Treatment with LPA20:4, indeed, 
increased the adhesion of monocytes to the endothelium via CXCL1. In the endothelium of murine 
carotid arteries, pre-formed CXCL1 was found which was released and immobilised on the cell 
surface following LPA20:4-stimulation. Moreover, unsaturated LPA20:4 but not saturated 
LPA18:0 increased the CXCL1 mRNA expression in ECs in a LPA1- and LPA3-dependent 
manner. MoxLDL-derived LPA induces monocyte adhesion to ECs by stimulating the release and 
transcription of CXCL1.  
Hyperlipidemia induces differential regulation of LPA receptor expression in the aorta of ApoE-
/- mice characterised by a reduced LPA2 expression, an increased LPA3 expression and an 
unchanged LPA1 expression. Immunofluorescence staining demonstrates that both LPA1 and LPA3 
are expressed in macrophages and ECs of mouse atherosclerotic plaques. In addition, LPA1 and 
LPA3 are also present in ECs of human atherosclerotic plaques. LPA1 and LPA3 are predominantly 
expressed during atherosclerosis which indicates that they may play an important role in 
atherogenesis. Accordingly, silencing of either LPA1 or LPA3 in the artery blocked the 
hyperlipidemia-induced leukocyte adhesion to the endothelium. However, knockdown of LPA2 did 
not have any effect on leukocyte adhesion. LPA1 and LPA3 independently play a role in 
hyperlipidemia-induced leukocyte adhesion. Systemic or local treatment of hyperlipidemic mice 
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with LPA20:4 increased the plaque size due to enhanced macrophage accumulation whereas 
systemic treatment with LPA18:0 had no effect on the progression of atherosclerosis. Conversely, 
pharmacological inhibition of LPA1 and LPA3 by Ki16425 in hyperlipidemic mice reduced the 
plaque size due to diminished macrophage accumulation. This effect was absent in mice that were 
treated with a blocking CXCL1 Ab in addition to Ki16425. Moreover, the expression of CXCL1, 
but not of CCL2, CCL5 and CX3CL1, was reduced in the plaque after treatment with the LPA 
receptor antagonist. Endogenous LPA induces macrophage accumulation and atherosclerosis via 
CXCL1 in hyperlipidemic mice.  
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